{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "f26c0cfa-bb16-4004-be57-eadd8ed8bbe3",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Requirement already satisfied: transformers in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (4.46.2)\n",
      "Requirement already satisfied: datasets in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (3.2.0)\n",
      "Requirement already satisfied: accelerate in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (1.2.1)\n",
      "Requirement already satisfied: peft in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (0.15.2)\n",
      "Requirement already satisfied: torch in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (2.5.1)\n",
      "Requirement already satisfied: rouge-score in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (0.1.2)\n",
      "Requirement already satisfied: bert-score in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (0.3.13)\n",
      "Requirement already satisfied: nltk in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (3.9.1)\n",
      "Requirement already satisfied: pandas in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (2.2.3)\n",
      "Requirement already satisfied: scikit-learn in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (1.5.2)\n",
      "Requirement already satisfied: bitsandbytes in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (0.45.0)\n",
      "Requirement already satisfied: shap in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (0.46.0)\n",
      "Requirement already satisfied: auto-gptq in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (0.3.1)\n",
      "Requirement already satisfied: opacus in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (1.5.2)\n",
      "Requirement already satisfied: filelock in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from transformers) (3.13.1)\n",
      "Requirement already satisfied: huggingface-hub<1.0,>=0.23.2 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from transformers) (0.26.2)\n",
      "Requirement already satisfied: numpy>=1.17 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from transformers) (1.26.4)\n",
      "Requirement already satisfied: packaging>=20.0 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from transformers) (24.1)\n",
      "Requirement already satisfied: pyyaml>=5.1 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from transformers) (6.0.2)\n",
      "Requirement already satisfied: regex!=2019.12.17 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from transformers) (2024.11.6)\n",
      "Requirement already satisfied: requests in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from transformers) (2.32.3)\n",
      "Requirement already satisfied: safetensors>=0.4.1 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from transformers) (0.4.5)\n",
      "Requirement already satisfied: tokenizers<0.21,>=0.20 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from transformers) (0.20.3)\n",
      "Requirement already satisfied: tqdm>=4.27 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from transformers) (4.67.0)\n",
      "Requirement already satisfied: pyarrow>=15.0.0 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from datasets) (18.1.0)\n",
      "Requirement already satisfied: dill<0.3.9,>=0.3.0 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from datasets) (0.3.8)\n",
      "Requirement already satisfied: xxhash in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from datasets) (3.5.0)\n",
      "Requirement already satisfied: multiprocess<0.70.17 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from datasets) (0.70.16)\n",
      "Requirement already satisfied: fsspec<=2024.9.0,>=2023.1.0 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from fsspec[http]<=2024.9.0,>=2023.1.0->datasets) (2024.9.0)\n",
      "Requirement already satisfied: aiohttp in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from datasets) (3.11.10)\n",
      "Requirement already satisfied: psutil in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from accelerate) (5.9.0)\n",
      "Requirement already satisfied: typing-extensions>=4.8.0 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from torch) (4.11.0)\n",
      "Requirement already satisfied: setuptools in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from torch) (75.1.0)\n",
      "Requirement already satisfied: sympy==1.13.1 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from torch) (1.13.1)\n",
      "Requirement already satisfied: networkx in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from torch) (3.2.1)\n",
      "Requirement already satisfied: jinja2 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from torch) (3.1.4)\n",
      "Requirement already satisfied: mpmath<1.4,>=1.1.0 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from sympy==1.13.1->torch) (1.3.0)\n",
      "Requirement already satisfied: absl-py in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from rouge-score) (2.1.0)\n",
      "Requirement already satisfied: six>=1.14.0 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from rouge-score) (1.16.0)\n",
      "Requirement already satisfied: matplotlib in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from bert-score) (3.9.3)\n",
      "Requirement already satisfied: click in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from nltk) (8.1.7)\n",
      "Requirement already satisfied: joblib in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from nltk) (1.4.2)\n",
      "Requirement already satisfied: python-dateutil>=2.8.2 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from pandas) (2.9.0.post0)\n",
      "Requirement already satisfied: pytz>=2020.1 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from pandas) (2024.1)\n",
      "Requirement already satisfied: tzdata>=2022.7 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from pandas) (2024.2)\n",
      "Requirement already satisfied: scipy>=1.6.0 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from scikit-learn) (1.14.1)\n",
      "Requirement already satisfied: threadpoolctl>=3.1.0 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from scikit-learn) (3.5.0)\n",
      "Requirement already satisfied: slicer==0.0.8 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from shap) (0.0.8)\n",
      "Requirement already satisfied: numba in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from shap) (0.60.0)\n",
      "Requirement already satisfied: cloudpickle in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from shap) (3.1.0)\n",
      "Requirement already satisfied: rouge in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from auto-gptq) (1.0.1)\n",
      "Requirement already satisfied: opt-einsum>=3.3.0 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from opacus) (3.4.0)\n",
      "Requirement already satisfied: aiohappyeyeballs>=2.3.0 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from aiohttp->datasets) (2.4.4)\n",
      "Requirement already satisfied: aiosignal>=1.1.2 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from aiohttp->datasets) (1.3.2)\n",
      "Requirement already satisfied: attrs>=17.3.0 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from aiohttp->datasets) (24.2.0)\n",
      "Requirement already satisfied: frozenlist>=1.1.1 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from aiohttp->datasets) (1.5.0)\n",
      "Requirement already satisfied: multidict<7.0,>=4.5 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from aiohttp->datasets) (6.1.0)\n",
      "Requirement already satisfied: propcache>=0.2.0 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from aiohttp->datasets) (0.2.1)\n",
      "Requirement already satisfied: yarl<2.0,>=1.17.0 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from aiohttp->datasets) (1.18.3)\n",
      "Requirement already satisfied: charset-normalizer<4,>=2 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from requests->transformers) (3.3.2)\n",
      "Requirement already satisfied: idna<4,>=2.5 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from requests->transformers) (3.7)\n",
      "Requirement already satisfied: urllib3<3,>=1.21.1 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from requests->transformers) (2.2.3)\n",
      "Requirement already satisfied: certifi>=2017.4.17 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from requests->transformers) (2025.1.31)\n",
      "Requirement already satisfied: colorama in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from tqdm>=4.27->transformers) (0.4.6)\n",
      "Requirement already satisfied: MarkupSafe>=2.0 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from jinja2->torch) (2.1.3)\n",
      "Requirement already satisfied: contourpy>=1.0.1 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from matplotlib->bert-score) (1.3.1)\n",
      "Requirement already satisfied: cycler>=0.10 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from matplotlib->bert-score) (0.12.1)\n",
      "Requirement already satisfied: fonttools>=4.22.0 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from matplotlib->bert-score) (4.55.2)\n",
      "Requirement already satisfied: kiwisolver>=1.3.1 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from matplotlib->bert-score) (1.4.7)\n",
      "Requirement already satisfied: pillow>=8 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from matplotlib->bert-score) (10.4.0)\n",
      "Requirement already satisfied: pyparsing>=2.3.1 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from matplotlib->bert-score) (3.2.0)\n",
      "Requirement already satisfied: llvmlite<0.44,>=0.43.0dev0 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from numba->shap) (0.43.0)\n",
      "Requirement already satisfied: peft in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (0.15.2)\n",
      "Requirement already satisfied: numpy>=1.17 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from peft) (1.26.4)\n",
      "Requirement already satisfied: packaging>=20.0 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from peft) (24.1)\n",
      "Requirement already satisfied: psutil in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from peft) (5.9.0)\n",
      "Requirement already satisfied: pyyaml in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from peft) (6.0.2)\n",
      "Requirement already satisfied: torch>=1.13.0 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from peft) (2.5.1)\n",
      "Requirement already satisfied: transformers in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from peft) (4.46.2)\n",
      "Requirement already satisfied: tqdm in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from peft) (4.67.0)\n",
      "Requirement already satisfied: accelerate>=0.21.0 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from peft) (1.2.1)\n",
      "Requirement already satisfied: safetensors in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from peft) (0.4.5)\n",
      "Requirement already satisfied: huggingface_hub>=0.25.0 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from peft) (0.26.2)\n",
      "Requirement already satisfied: filelock in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from huggingface_hub>=0.25.0->peft) (3.13.1)\n",
      "Requirement already satisfied: fsspec>=2023.5.0 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from huggingface_hub>=0.25.0->peft) (2024.9.0)\n",
      "Requirement already satisfied: requests in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from huggingface_hub>=0.25.0->peft) (2.32.3)\n",
      "Requirement already satisfied: typing-extensions>=3.7.4.3 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from huggingface_hub>=0.25.0->peft) (4.11.0)\n",
      "Requirement already satisfied: setuptools in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from torch>=1.13.0->peft) (75.1.0)\n",
      "Requirement already satisfied: sympy==1.13.1 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from torch>=1.13.0->peft) (1.13.1)\n",
      "Requirement already satisfied: networkx in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from torch>=1.13.0->peft) (3.2.1)\n",
      "Requirement already satisfied: jinja2 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from torch>=1.13.0->peft) (3.1.4)\n",
      "Requirement already satisfied: mpmath<1.4,>=1.1.0 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from sympy==1.13.1->torch>=1.13.0->peft) (1.3.0)\n",
      "Requirement already satisfied: colorama in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from tqdm->peft) (0.4.6)\n",
      "Requirement already satisfied: regex!=2019.12.17 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from transformers->peft) (2024.11.6)\n",
      "Requirement already satisfied: tokenizers<0.21,>=0.20 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from transformers->peft) (0.20.3)\n",
      "Requirement already satisfied: MarkupSafe>=2.0 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from jinja2->torch>=1.13.0->peft) (2.1.3)\n",
      "Requirement already satisfied: charset-normalizer<4,>=2 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from requests->huggingface_hub>=0.25.0->peft) (3.3.2)\n",
      "Requirement already satisfied: idna<4,>=2.5 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from requests->huggingface_hub>=0.25.0->peft) (3.7)\n",
      "Requirement already satisfied: urllib3<3,>=1.21.1 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from requests->huggingface_hub>=0.25.0->peft) (2.2.3)\n",
      "Requirement already satisfied: certifi>=2017.4.17 in c:\\users\\my pc\\.ai-navigator\\micromamba\\envs\\cuda\\lib\\site-packages (from requests->huggingface_hub>=0.25.0->peft) (2025.1.31)\n"
     ]
    }
   ],
   "source": [
    "!pip install transformers datasets accelerate peft torch rouge-score bert-score nltk pandas scikit-learn bitsandbytes shap auto-gptq opacus\n",
    "!pip install --upgrade peft"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "c2111eed-96ae-4511-86a5-4ed40987b992",
   "metadata": {},
   "outputs": [],
   "source": [
    "import nltk\n",
    "from transformers import BitsAndBytesConfig, FbgemmFp8Config\n",
    "from peft import LoraConfig, get_peft_model, prepare_model_for_kbit_training\n",
    "from transformers import AutoTokenizer, AutoModelForCausalLM, GPTQConfig\n",
    "from auto_gptq import AutoGPTQForCausalLM\n",
    "from transformers import pipeline\n",
    "from transformers import DataCollatorForLanguageModeling\n",
    "from transformers import Trainer, TrainingArguments\n",
    "import torch\n",
    "import bitsandbytes as bnb\n",
    "from transformers import TrainingArguments, Trainer\n",
    "from opacus import PrivacyEngine\n",
    "from torch import nn, optim\n",
    "from datasets import load_dataset\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "from transformers import AutoConfig\n",
    "from torch.utils.data import DataLoader\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "b002e972-909e-4598-ac3a-903d34ffe3f7",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "[nltk_data] Downloading package wordnet to C:\\Users\\my pc/nltk_data...\n",
      "[nltk_data]   Package wordnet is already up-to-date!\n"
     ]
    }
   ],
   "source": [
    "from transformers import DataCollatorForLanguageModeling\n",
    "\n",
    "device = torch.device(\"cuda:0\" if torch.cuda.is_available() else \"cpu\")\n",
    "\n",
    "nltk.download('wordnet')\n",
    "# Load medical abstract dataset\n",
    "train_data = load_dataset('csv', data_files='medical_tc_train.csv', split='train')\n",
    "test_data = load_dataset('csv', data_files='medical_tc_test.csv', split='train')\n",
    "# Load Model & Tokenizer\n",
    "model_name = \"meta-llama/Llama-3.2-1B\"\n",
    "tokenizer = AutoTokenizer.from_pretrained(model_name, trust_remote_code=True)\n",
    "tokenizer.pad_token = tokenizer.eos_token  # Add padding token if necessary\n",
    "def tokenize_function(examples):\n",
    "    return tokenizer(\n",
    "        examples['medical_abstract'], truncation=True, padding='max_length', max_length=128\n",
    "    )\n",
    "    return tokenized\n",
    "data_collator = DataCollatorForLanguageModeling(tokenizer=tokenizer, mlm=False)\n",
    "\n",
    "# Tokenize dataset\n",
    "train_data = train_data.map(tokenize_function, batched=True)\n",
    "test_data = test_data.map(tokenize_function, batched=True)\n",
    "\n",
    "# Set format for PyTorch\n",
    "train_data.set_format(type=\"torch\", columns=[\"input_ids\", \"attention_mask\"])\n",
    "test_data.set_format(type=\"torch\", columns=[\"input_ids\", \"attention_mask\"])\n",
    "# DataLoader\n",
    "train_dataloader = DataLoader(train_data, batch_size=8, shuffle=True, collate_fn=data_collator)\n",
    "test_dataloader = DataLoader(test_data, batch_size=8, collate_fn=data_collator)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "9ed40711-afe7-4844-adcc-3ca5467bf253",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "LlamaForCausalLM(\n",
       "  (model): LlamaModel(\n",
       "    (embed_tokens): Embedding(128256, 2048)\n",
       "    (layers): ModuleList(\n",
       "      (0-15): 16 x LlamaDecoderLayer(\n",
       "        (self_attn): LlamaSdpaAttention(\n",
       "          (q_proj): Linear(in_features=2048, out_features=2048, bias=False)\n",
       "          (k_proj): Linear(in_features=2048, out_features=512, bias=False)\n",
       "          (v_proj): Linear(in_features=2048, out_features=512, bias=False)\n",
       "          (o_proj): Linear(in_features=2048, out_features=2048, bias=False)\n",
       "          (rotary_emb): LlamaRotaryEmbedding()\n",
       "        )\n",
       "        (mlp): LlamaMLP(\n",
       "          (gate_proj): Linear(in_features=2048, out_features=8192, bias=False)\n",
       "          (up_proj): Linear(in_features=2048, out_features=8192, bias=False)\n",
       "          (down_proj): Linear(in_features=8192, out_features=2048, bias=False)\n",
       "          (act_fn): SiLU()\n",
       "        )\n",
       "        (input_layernorm): LlamaRMSNorm((2048,), eps=1e-05)\n",
       "        (post_attention_layernorm): LlamaRMSNorm((2048,), eps=1e-05)\n",
       "      )\n",
       "    )\n",
       "    (norm): LlamaRMSNorm((2048,), eps=1e-05)\n",
       "    (rotary_emb): LlamaRotaryEmbedding()\n",
       "  )\n",
       "  (lm_head): Linear(in_features=2048, out_features=128256, bias=False)\n",
       ")"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#model_name = \"deepseek-ai/deepseek-coder-1.3b-base\"\n",
    "#model_name = \"deepseek-ai/deepseek-V2.5-1210\"\n",
    "#model_name = \"meta-llama/Llama-3.1-8B\"\n",
    "model_name = \"meta-llama/Llama-3.2-1B\"\n",
    "#config = AutoConfig.from_pretrained(model_name, trust_remote_code=True)\n",
    "config = AutoConfig.from_pretrained(model_name)\n",
    "model = AutoModelForCausalLM.from_pretrained(model_name)\n",
    "model.to(device)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "c4c10d96-b0bd-4396-b854-0e0abfe1d7cf",
   "metadata": {},
   "outputs": [],
   "source": [
    "torch.cuda.empty_cache()\n",
    "# Define LoRA Configuration\n",
    "lora_config = LoraConfig(\n",
    "    r=8,               # LoRA rank\n",
    "    lora_alpha=16,      # Scaling factor\n",
    "    lora_dropout=0.3,   # Dropout rate\n",
    "    target_modules=[\"q_proj\", \"v_proj\"]  # Apply LoRA to attention layers\n",
    ")\n",
    "model = prepare_model_for_kbit_training(model)\n",
    "model = get_peft_model(model, lora_config)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "164628e6-a1c7-4cd8-818f-42d2cd8cd8be",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/home/dgxuser49/.local/lib/python3.8/site-packages/opacus/privacy_engine.py:95: UserWarning: Secure RNG turned off. This is perfectly fine for experimentation as it allows for much faster training performance, but remember to turn it on and retrain one last time before production with ``secure_mode`` turned on.\n",
      "  warnings.warn(\n",
      "/home/dgxuser49/.local/lib/python3.8/site-packages/opacus/accountants/analysis/rdp.py:332: UserWarning: Optimal order is the largest alpha. Please consider expanding the range of alphas to get a tighter privacy bound.\n",
      "  warnings.warn(\n"
     ]
    }
   ],
   "source": [
    "torch.cuda.empty_cache()\n",
    "model.to(device)\n",
    "# Optimizer\n",
    "optimizer = optim.AdamW(model.parameters(), lr=1e-4)\n",
    "privacy_engine = PrivacyEngine()\n",
    "sample_rate = 8 / len(train_data)  # Batch size / dataset size\n",
    "model, optimizer, dataloader = privacy_engine.make_private_with_epsilon(\n",
    "    module=model,\n",
    "    optimizer=optimizer,\n",
    "    data_loader=train_dataloader,\n",
    "    target_epsilon=10.0,\n",
    "    target_delta=1e-5,    \n",
    "    epochs=3,\n",
    "    max_grad_norm=1.0,\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "f9cd2a84-260c-4626-aa39-8229a054b09b",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/home/dgxuser49/.local/lib/python3.8/site-packages/torch/nn/modules/module.py:1373: UserWarning: Using a non-full backward hook when the forward contains multiple autograd Nodes is deprecated and will be removed in future versions. This hook will be missing some grad_input. Please use register_full_backward_hook to get the documented behavior.\n",
      "  warnings.warn(\"Using a non-full backward hook when the forward contains multiple autograd Nodes \"\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Epoch [1/3], Step [0], Loss: 2.0311\n",
      "Epoch [1/3], Step [10], Loss: 2.1246\n",
      "Epoch [1/3], Step [20], Loss: 3.6974\n",
      "Epoch [1/3], Step [30], Loss: 2.9864\n",
      "Epoch [1/3], Step [40], Loss: 2.0909\n",
      "Epoch [1/3], Step [50], Loss: 2.1139\n",
      "Epoch [1/3], Step [60], Loss: 2.7050\n",
      "Epoch [1/3], Step [70], Loss: 3.7664\n",
      "Epoch [1/3], Step [80], Loss: 2.2889\n",
      "Epoch [1/3], Step [90], Loss: 3.0982\n",
      "Epoch [1/3], Step [100], Loss: 2.7449\n",
      "Epoch [1/3], Step [110], Loss: 2.1457\n",
      "Epoch [1/3], Step [120], Loss: 2.1331\n",
      "Epoch [1/3], Step [130], Loss: 2.2121\n",
      "Epoch [1/3], Step [140], Loss: 2.2859\n",
      "Epoch [1/3], Step [150], Loss: 2.4775\n",
      "Epoch [1/3], Step [160], Loss: 2.0575\n",
      "Epoch [1/3], Step [170], Loss: 2.3504\n",
      "Epoch [1/3], Step [180], Loss: 2.3841\n",
      "Epoch [1/3], Step [190], Loss: 3.1464\n",
      "Epoch [1/3], Step [200], Loss: 2.2561\n",
      "Epoch [1/3], Step [210], Loss: 1.9975\n",
      "Epoch [1/3], Step [220], Loss: 2.3221\n",
      "Epoch [1/3], Step [230], Loss: 3.2456\n",
      "Epoch [1/3], Step [240], Loss: 2.2504\n",
      "Epoch [1/3], Step [250], Loss: 2.5120\n",
      "Epoch [1/3], Step [260], Loss: 2.3258\n",
      "Epoch [1/3], Step [270], Loss: 2.1556\n",
      "Epoch [1/3], Step [280], Loss: 2.3673\n",
      "Epoch [1/3], Step [290], Loss: 2.3045\n",
      "Epoch [1/3], Step [300], Loss: 2.8514\n",
      "Epoch [1/3], Step [310], Loss: 1.9058\n",
      "Epoch [1/3], Step [320], Loss: 3.2051\n",
      "Epoch [1/3], Step [330], Loss: 2.3649\n",
      "Epoch [1/3], Step [340], Loss: 2.6006\n",
      "Epoch [1/3], Step [350], Loss: 2.0832\n",
      "Epoch [1/3], Step [360], Loss: 2.3548\n",
      "Epoch [1/3], Step [370], Loss: 2.4696\n",
      "Epoch [1/3], Step [380], Loss: 2.8349\n",
      "Epoch [1/3], Step [390], Loss: 2.2850\n",
      "Epoch [1/3], Step [400], Loss: 2.0078\n",
      "Epoch [1/3], Step [410], Loss: 3.0541\n",
      "Epoch [1/3], Step [420], Loss: 1.8547\n",
      "Epoch [1/3], Step [430], Loss: 2.1398\n",
      "Epoch [1/3], Step [440], Loss: 2.4691\n",
      "Epoch [1/3], Step [450], Loss: 2.7360\n",
      "Epoch [1/3], Step [460], Loss: 2.2688\n",
      "Epoch [1/3], Step [470], Loss: 2.7413\n",
      "Epoch [1/3], Step [480], Loss: 2.6710\n",
      "Epoch [1/3], Step [490], Loss: 2.2504\n",
      "Epoch [1/3], Step [500], Loss: 2.4806\n",
      "Epoch [1/3], Step [510], Loss: 2.1900\n",
      "Epoch [1/3], Step [520], Loss: 2.5306\n",
      "Epoch [1/3], Step [530], Loss: 2.1046\n",
      "Epoch [1/3], Step [540], Loss: 2.3232\n",
      "Epoch [1/3], Step [550], Loss: 2.1013\n",
      "Epoch [1/3], Step [560], Loss: 2.5621\n",
      "Epoch [1/3], Step [570], Loss: 2.5930\n",
      "Epoch [1/3], Step [580], Loss: 2.6728\n",
      "Epoch [1/3], Step [590], Loss: 2.1758\n",
      "Epoch [1/3], Step [600], Loss: 2.4868\n",
      "Epoch [1/3], Step [610], Loss: 2.2759\n",
      "Epoch [1/3], Step [620], Loss: 2.8626\n",
      "Epoch [1/3], Step [630], Loss: 1.9410\n",
      "Epoch [1/3], Step [640], Loss: 3.0910\n",
      "Epoch [1/3], Step [650], Loss: 2.3805\n",
      "Epoch [1/3], Step [660], Loss: 2.8596\n",
      "Epoch [1/3], Step [670], Loss: 2.2896\n",
      "Epoch [1/3], Step [680], Loss: 2.1997\n",
      "Epoch [1/3], Step [690], Loss: 2.2752\n",
      "Epoch [1/3], Step [700], Loss: 2.2140\n",
      "Epoch [1/3], Step [710], Loss: 2.4746\n",
      "Epoch [1/3], Step [720], Loss: 2.6274\n",
      "Epoch [1/3], Step [730], Loss: 2.2436\n",
      "Epoch [1/3], Step [740], Loss: 2.2082\n",
      "Epoch [1/3], Step [750], Loss: 2.6507\n",
      "Epoch [1/3], Step [760], Loss: 2.1173\n",
      "Epoch [1/3], Step [770], Loss: 2.1188\n",
      "Epoch [1/3], Step [780], Loss: 2.2161\n",
      "Epoch [1/3], Step [790], Loss: 2.1884\n",
      "Epoch [1/3], Step [800], Loss: 2.1061\n",
      "Epoch [1/3], Step [810], Loss: 2.3741\n",
      "Epoch [1/3], Step [820], Loss: 2.4333\n",
      "Epoch [1/3], Step [830], Loss: 2.3990\n",
      "Epoch [1/3], Step [840], Loss: 1.7559\n",
      "Epoch [1/3], Step [850], Loss: 2.0792\n",
      "Epoch [1/3], Step [860], Loss: 2.1238\n",
      "Epoch [1/3], Step [870], Loss: 2.1396\n",
      "Epoch [1/3], Step [880], Loss: 2.2011\n",
      "Epoch [1/3], Step [890], Loss: 2.3851\n",
      "Epoch [1/3], Step [900], Loss: 2.0573\n",
      "Epoch [1/3], Step [910], Loss: 2.3941\n",
      "Epoch [1/3], Step [920], Loss: 2.1200\n",
      "Epoch [1/3], Step [930], Loss: 2.2070\n",
      "Epoch [1/3], Step [940], Loss: 2.0001\n",
      "Epoch [1/3], Step [950], Loss: 2.3277\n",
      "Epoch [1/3], Step [960], Loss: 2.5447\n",
      "Epoch [1/3], Step [970], Loss: 2.4460\n",
      "Epoch [1/3], Step [980], Loss: 2.3558\n",
      "Epoch [1/3], Step [990], Loss: 2.2847\n",
      "Epoch [1/3], Step [1000], Loss: 2.3782\n",
      "Epoch [1/3], Step [1010], Loss: 2.1118\n",
      "Epoch [1/3], Step [1020], Loss: 2.2922\n",
      "Epoch [1/3], Step [1030], Loss: 2.4294\n",
      "Epoch [1/3], Step [1040], Loss: 2.2143\n",
      "Epoch [1/3], Step [1050], Loss: 2.4116\n",
      "Epoch [1/3], Step [1060], Loss: 2.1279\n",
      "Epoch [1/3], Step [1070], Loss: 2.2031\n",
      "Epoch [1/3], Step [1080], Loss: 2.1456\n",
      "Epoch [1/3], Step [1090], Loss: 1.9744\n",
      "Epoch [1/3], Step [1100], Loss: 2.3482\n",
      "Epoch [1/3], Step [1110], Loss: 2.3400\n",
      "Epoch [1/3], Step [1120], Loss: 2.1142\n",
      "Epoch [1/3], Step [1130], Loss: 2.1241\n",
      "Epoch [1/3], Step [1140], Loss: 2.0685\n",
      "Epoch [1/3], Step [1150], Loss: 2.2108\n",
      "Epoch [1/3], Step [1160], Loss: 2.3689\n",
      "Epoch [1/3], Step [1170], Loss: 2.0975\n",
      "Epoch [1/3], Step [1180], Loss: 2.1363\n",
      "Epoch [1/3], Step [1190], Loss: 2.2535\n",
      "Epoch [1/3], Step [1200], Loss: 2.2258\n",
      "Epoch [1/3], Step [1210], Loss: 2.0063\n",
      "Epoch [1/3], Step [1220], Loss: 2.2612\n",
      "Epoch [1/3], Step [1230], Loss: 1.9898\n",
      "Epoch [1/3], Step [1240], Loss: 2.1213\n",
      "Epoch [1/3], Step [1250], Loss: 2.0090\n",
      "Epoch [1/3], Step [1260], Loss: 2.0957\n",
      "Epoch [1/3], Step [1270], Loss: 2.1901\n",
      "Epoch [1/3], Step [1280], Loss: 2.0906\n",
      "Epoch [1/3], Step [1290], Loss: 1.9756\n",
      "Epoch [1/3], Step [1300], Loss: 2.2311\n",
      "Epoch [1/3], Step [1310], Loss: 2.2427\n",
      "Epoch [1/3], Step [1320], Loss: 2.0933\n",
      "Epoch [1/3], Step [1330], Loss: 2.0356\n",
      "Epoch [1/3], Step [1340], Loss: 1.9675\n",
      "Epoch [1/3], Step [1350], Loss: 2.2783\n",
      "Epoch [1/3], Step [1360], Loss: 1.9738\n",
      "Epoch [1/3], Step [1370], Loss: 2.1973\n",
      "Epoch [1/3], Step [1380], Loss: 2.2958\n",
      "Epoch [1/3], Step [1390], Loss: 1.9939\n",
      "Epoch [1/3], Step [1400], Loss: 2.1381\n",
      "Epoch [1/3], Step [1410], Loss: 2.0146\n",
      "Epoch [1/3], Step [1420], Loss: 2.1950\n",
      "Epoch [1/3], Step [1430], Loss: 2.2781\n",
      "Epoch [1/3], Step [1440], Loss: 2.1463\n",
      "Epoch [2/3], Step [0], Loss: 2.0289\n",
      "Epoch [2/3], Step [10], Loss: 2.1801\n",
      "Epoch [2/3], Step [20], Loss: 2.0555\n",
      "Epoch [2/3], Step [30], Loss: 1.9300\n",
      "Epoch [2/3], Step [40], Loss: 2.0302\n",
      "Epoch [2/3], Step [50], Loss: 2.0716\n",
      "Epoch [2/3], Step [60], Loss: 2.0719\n",
      "Epoch [2/3], Step [70], Loss: 2.1005\n",
      "Epoch [2/3], Step [80], Loss: 1.9086\n",
      "Epoch [2/3], Step [90], Loss: 2.0789\n",
      "Epoch [2/3], Step [100], Loss: 2.0840\n",
      "Epoch [2/3], Step [110], Loss: 1.9660\n",
      "Epoch [2/3], Step [120], Loss: 2.0344\n",
      "Epoch [2/3], Step [130], Loss: 2.0148\n",
      "Epoch [2/3], Step [140], Loss: 2.1157\n",
      "Epoch [2/3], Step [150], Loss: 2.0368\n",
      "Epoch [2/3], Step [160], Loss: 2.0423\n",
      "Epoch [2/3], Step [170], Loss: 2.0975\n",
      "Epoch [2/3], Step [180], Loss: 2.0924\n",
      "Epoch [2/3], Step [190], Loss: 2.0671\n",
      "Epoch [2/3], Step [200], Loss: 1.9831\n",
      "Epoch [2/3], Step [210], Loss: 1.9897\n",
      "Epoch [2/3], Step [220], Loss: 2.0970\n",
      "Epoch [2/3], Step [230], Loss: 2.1945\n",
      "Epoch [2/3], Step [240], Loss: 2.4191\n",
      "Epoch [2/3], Step [250], Loss: 2.3267\n",
      "Epoch [2/3], Step [260], Loss: 2.1842\n",
      "Epoch [2/3], Step [270], Loss: 1.8485\n",
      "Epoch [2/3], Step [280], Loss: 2.1421\n",
      "Epoch [2/3], Step [290], Loss: 2.1446\n",
      "Epoch [2/3], Step [300], Loss: 1.9695\n",
      "Epoch [2/3], Step [310], Loss: 2.4010\n",
      "Epoch [2/3], Step [320], Loss: 2.1787\n",
      "Epoch [2/3], Step [330], Loss: 1.8768\n",
      "Epoch [2/3], Step [340], Loss: 2.2057\n",
      "Epoch [2/3], Step [350], Loss: 2.0301\n",
      "Epoch [2/3], Step [360], Loss: 1.8487\n",
      "Epoch [2/3], Step [370], Loss: 2.1953\n",
      "Epoch [2/3], Step [380], Loss: 2.0057\n",
      "Epoch [2/3], Step [390], Loss: 2.1460\n",
      "Epoch [2/3], Step [400], Loss: 2.0040\n",
      "Epoch [2/3], Step [410], Loss: 2.2038\n",
      "Epoch [2/3], Step [420], Loss: 2.0054\n",
      "Epoch [2/3], Step [430], Loss: 2.1611\n",
      "Epoch [2/3], Step [440], Loss: 2.2171\n",
      "Epoch [2/3], Step [450], Loss: 2.3546\n",
      "Epoch [2/3], Step [460], Loss: 2.0198\n",
      "Epoch [2/3], Step [470], Loss: 2.0166\n",
      "Epoch [2/3], Step [480], Loss: 2.0194\n",
      "Epoch [2/3], Step [490], Loss: 2.0153\n",
      "Epoch [2/3], Step [500], Loss: 1.9528\n",
      "Epoch [2/3], Step [510], Loss: 2.0180\n",
      "Epoch [2/3], Step [520], Loss: 2.0147\n",
      "Epoch [2/3], Step [530], Loss: 1.9897\n",
      "Epoch [2/3], Step [540], Loss: 1.9936\n",
      "Epoch [2/3], Step [550], Loss: 2.0083\n",
      "Epoch [2/3], Step [560], Loss: 1.9448\n",
      "Epoch [2/3], Step [570], Loss: 1.8632\n",
      "Epoch [2/3], Step [580], Loss: 2.0255\n",
      "Epoch [2/3], Step [590], Loss: 2.2094\n",
      "Epoch [2/3], Step [600], Loss: 2.0107\n",
      "Epoch [2/3], Step [610], Loss: 2.2521\n",
      "Epoch [2/3], Step [620], Loss: 2.2140\n",
      "Epoch [2/3], Step [630], Loss: 2.1444\n",
      "Epoch [2/3], Step [640], Loss: 2.0629\n",
      "Epoch [2/3], Step [650], Loss: 2.2860\n",
      "Epoch [2/3], Step [660], Loss: 2.0494\n",
      "Epoch [2/3], Step [670], Loss: 1.9578\n",
      "Epoch [2/3], Step [680], Loss: 1.9059\n",
      "Epoch [2/3], Step [690], Loss: 2.0824\n",
      "Epoch [2/3], Step [700], Loss: 2.0766\n",
      "Epoch [2/3], Step [710], Loss: 1.9384\n",
      "Epoch [2/3], Step [720], Loss: 1.9944\n",
      "Epoch [2/3], Step [730], Loss: 2.0607\n",
      "Epoch [2/3], Step [740], Loss: 1.9588\n",
      "Epoch [2/3], Step [750], Loss: 1.8361\n",
      "Epoch [2/3], Step [760], Loss: 2.2749\n",
      "Epoch [2/3], Step [770], Loss: 1.9172\n",
      "Epoch [2/3], Step [780], Loss: 1.7424\n",
      "Epoch [2/3], Step [790], Loss: 2.0932\n",
      "Epoch [2/3], Step [800], Loss: 1.9557\n",
      "Epoch [2/3], Step [810], Loss: 1.8545\n",
      "Epoch [2/3], Step [820], Loss: 2.1078\n",
      "Epoch [2/3], Step [830], Loss: 1.8449\n",
      "Epoch [2/3], Step [840], Loss: 2.0736\n",
      "Epoch [2/3], Step [850], Loss: 1.9492\n",
      "Epoch [2/3], Step [860], Loss: 1.9753\n",
      "Epoch [2/3], Step [870], Loss: 2.1120\n",
      "Epoch [2/3], Step [880], Loss: 2.1040\n",
      "Epoch [2/3], Step [890], Loss: 2.0596\n",
      "Epoch [2/3], Step [900], Loss: 2.3062\n",
      "Epoch [2/3], Step [910], Loss: 1.8248\n",
      "Epoch [2/3], Step [920], Loss: 2.0872\n",
      "Epoch [2/3], Step [930], Loss: 2.0905\n",
      "Epoch [2/3], Step [940], Loss: 2.1075\n",
      "Epoch [2/3], Step [950], Loss: 1.8325\n",
      "Epoch [2/3], Step [960], Loss: 1.8799\n",
      "Epoch [2/3], Step [970], Loss: 2.1188\n",
      "Epoch [2/3], Step [980], Loss: 2.0954\n",
      "Epoch [2/3], Step [990], Loss: 2.0473\n",
      "Epoch [2/3], Step [1000], Loss: 2.1183\n",
      "Epoch [2/3], Step [1010], Loss: 2.0412\n",
      "Epoch [2/3], Step [1020], Loss: 2.2292\n",
      "Epoch [2/3], Step [1030], Loss: 1.9272\n",
      "Epoch [2/3], Step [1040], Loss: 2.0492\n",
      "Epoch [2/3], Step [1050], Loss: 2.0039\n",
      "Epoch [2/3], Step [1060], Loss: 2.1656\n",
      "Epoch [2/3], Step [1070], Loss: 2.1213\n",
      "Epoch [2/3], Step [1080], Loss: 2.1362\n",
      "Epoch [2/3], Step [1090], Loss: 2.1730\n",
      "Epoch [2/3], Step [1100], Loss: 1.9725\n",
      "Epoch [2/3], Step [1110], Loss: 2.0129\n",
      "Epoch [2/3], Step [1120], Loss: 1.6514\n",
      "Epoch [2/3], Step [1130], Loss: 2.1659\n",
      "Epoch [2/3], Step [1140], Loss: 2.1957\n",
      "Epoch [2/3], Step [1150], Loss: 2.1469\n",
      "Epoch [2/3], Step [1160], Loss: 2.0078\n",
      "Epoch [2/3], Step [1170], Loss: 2.0758\n",
      "Epoch [2/3], Step [1180], Loss: 1.7071\n",
      "Epoch [2/3], Step [1190], Loss: 1.8110\n",
      "Epoch [2/3], Step [1200], Loss: 2.0629\n",
      "Epoch [2/3], Step [1210], Loss: 2.1210\n",
      "Epoch [2/3], Step [1220], Loss: 2.0295\n",
      "Epoch [2/3], Step [1230], Loss: 1.9159\n",
      "Epoch [2/3], Step [1240], Loss: 1.9616\n",
      "Epoch [2/3], Step [1250], Loss: 1.9311\n",
      "Epoch [2/3], Step [1260], Loss: 2.1273\n",
      "Epoch [2/3], Step [1270], Loss: 2.0367\n",
      "Epoch [2/3], Step [1280], Loss: 2.0584\n",
      "Epoch [2/3], Step [1290], Loss: 2.1289\n",
      "Epoch [2/3], Step [1300], Loss: 2.0513\n",
      "Epoch [2/3], Step [1310], Loss: 1.7877\n",
      "Epoch [2/3], Step [1320], Loss: 2.1601\n",
      "Epoch [2/3], Step [1330], Loss: 2.0890\n",
      "Epoch [2/3], Step [1340], Loss: 1.8915\n",
      "Epoch [2/3], Step [1350], Loss: 1.9991\n",
      "Epoch [2/3], Step [1360], Loss: 1.9652\n",
      "Epoch [2/3], Step [1370], Loss: 1.9196\n",
      "Epoch [2/3], Step [1380], Loss: 1.9783\n",
      "Epoch [2/3], Step [1390], Loss: 2.0509\n",
      "Epoch [2/3], Step [1400], Loss: 2.0897\n",
      "Epoch [2/3], Step [1410], Loss: 1.9026\n",
      "Epoch [2/3], Step [1420], Loss: 2.1340\n",
      "Epoch [2/3], Step [1430], Loss: 2.1607\n",
      "Epoch [2/3], Step [1440], Loss: 2.0502\n",
      "Epoch [3/3], Step [0], Loss: 2.0158\n",
      "Epoch [3/3], Step [10], Loss: 1.7918\n",
      "Epoch [3/3], Step [20], Loss: 1.8946\n",
      "Epoch [3/3], Step [30], Loss: 2.1402\n",
      "Epoch [3/3], Step [40], Loss: 2.0420\n",
      "Epoch [3/3], Step [50], Loss: 2.1073\n",
      "Epoch [3/3], Step [60], Loss: 2.2790\n",
      "Epoch [3/3], Step [70], Loss: 2.2456\n",
      "Epoch [3/3], Step [80], Loss: 2.1143\n",
      "Epoch [3/3], Step [90], Loss: 2.0794\n",
      "Epoch [3/3], Step [100], Loss: 2.1056\n",
      "Epoch [3/3], Step [110], Loss: 1.9036\n",
      "Epoch [3/3], Step [120], Loss: 2.0249\n",
      "Epoch [3/3], Step [130], Loss: 2.0325\n",
      "Epoch [3/3], Step [140], Loss: 1.9082\n",
      "Epoch [3/3], Step [150], Loss: 2.0291\n",
      "Epoch [3/3], Step [160], Loss: 2.0271\n",
      "Epoch [3/3], Step [170], Loss: 1.9336\n",
      "Epoch [3/3], Step [180], Loss: 1.9673\n",
      "Epoch [3/3], Step [190], Loss: 1.7855\n",
      "Epoch [3/3], Step [200], Loss: 1.9663\n",
      "Epoch [3/3], Step [210], Loss: 1.8279\n",
      "Epoch [3/3], Step [220], Loss: 1.9642\n",
      "Epoch [3/3], Step [230], Loss: 2.3332\n",
      "Epoch [3/3], Step [240], Loss: 2.0325\n",
      "Epoch [3/3], Step [250], Loss: 1.9370\n",
      "Epoch [3/3], Step [260], Loss: 1.9661\n",
      "Epoch [3/3], Step [270], Loss: 2.0784\n",
      "Epoch [3/3], Step [280], Loss: 1.8736\n",
      "Epoch [3/3], Step [290], Loss: 2.0514\n",
      "Epoch [3/3], Step [300], Loss: 2.0545\n",
      "Epoch [3/3], Step [310], Loss: 2.0315\n",
      "Epoch [3/3], Step [320], Loss: 1.8503\n",
      "Epoch [3/3], Step [330], Loss: 2.0726\n",
      "Epoch [3/3], Step [340], Loss: 2.1961\n",
      "Epoch [3/3], Step [350], Loss: 2.0986\n",
      "Epoch [3/3], Step [360], Loss: 1.9491\n",
      "Epoch [3/3], Step [370], Loss: 1.8790\n",
      "Epoch [3/3], Step [380], Loss: 2.2392\n",
      "Epoch [3/3], Step [390], Loss: 2.1325\n",
      "Epoch [3/3], Step [400], Loss: 2.2490\n",
      "Epoch [3/3], Step [410], Loss: 2.2145\n",
      "Epoch [3/3], Step [420], Loss: 1.9112\n",
      "Epoch [3/3], Step [430], Loss: 2.0318\n",
      "Epoch [3/3], Step [440], Loss: 1.8975\n",
      "Epoch [3/3], Step [450], Loss: 1.8447\n",
      "Epoch [3/3], Step [460], Loss: 1.9115\n",
      "Epoch [3/3], Step [470], Loss: 2.1485\n",
      "Epoch [3/3], Step [480], Loss: 2.0238\n",
      "Epoch [3/3], Step [490], Loss: 2.1443\n",
      "Epoch [3/3], Step [500], Loss: 1.9180\n",
      "Epoch [3/3], Step [510], Loss: 2.0507\n",
      "Epoch [3/3], Step [520], Loss: 2.3244\n",
      "Epoch [3/3], Step [530], Loss: 1.8929\n",
      "Epoch [3/3], Step [540], Loss: 2.1788\n",
      "Epoch [3/3], Step [550], Loss: 2.0285\n",
      "Epoch [3/3], Step [560], Loss: 1.9253\n",
      "Epoch [3/3], Step [570], Loss: 1.9367\n",
      "Epoch [3/3], Step [580], Loss: 2.0594\n",
      "Epoch [3/3], Step [590], Loss: 2.1367\n",
      "Epoch [3/3], Step [600], Loss: 1.7306\n",
      "Epoch [3/3], Step [610], Loss: 1.9175\n",
      "Epoch [3/3], Step [620], Loss: 1.9481\n",
      "Epoch [3/3], Step [630], Loss: 1.7699\n",
      "Epoch [3/3], Step [640], Loss: 2.0002\n",
      "Epoch [3/3], Step [650], Loss: 1.8696\n",
      "Epoch [3/3], Step [660], Loss: 2.0093\n",
      "Epoch [3/3], Step [670], Loss: 1.8844\n",
      "Epoch [3/3], Step [680], Loss: 2.0726\n",
      "Epoch [3/3], Step [690], Loss: 2.0981\n",
      "Epoch [3/3], Step [700], Loss: 1.7264\n",
      "Epoch [3/3], Step [710], Loss: 1.8025\n",
      "Epoch [3/3], Step [720], Loss: 2.1417\n",
      "Epoch [3/3], Step [730], Loss: 1.9332\n",
      "Epoch [3/3], Step [740], Loss: 2.0470\n",
      "Epoch [3/3], Step [750], Loss: 1.8437\n",
      "Epoch [3/3], Step [760], Loss: 2.1315\n",
      "Epoch [3/3], Step [770], Loss: 2.0573\n",
      "Epoch [3/3], Step [780], Loss: 1.9430\n",
      "Epoch [3/3], Step [790], Loss: 1.8829\n",
      "Epoch [3/3], Step [800], Loss: 2.2575\n",
      "Epoch [3/3], Step [810], Loss: 1.9255\n",
      "Epoch [3/3], Step [820], Loss: 1.9052\n",
      "Epoch [3/3], Step [830], Loss: 2.2037\n",
      "Epoch [3/3], Step [840], Loss: 2.0120\n",
      "Epoch [3/3], Step [850], Loss: 2.1922\n",
      "Epoch [3/3], Step [860], Loss: 1.9777\n",
      "Epoch [3/3], Step [870], Loss: 1.8115\n",
      "Epoch [3/3], Step [880], Loss: 2.1115\n",
      "Epoch [3/3], Step [890], Loss: 2.0822\n",
      "Epoch [3/3], Step [900], Loss: 1.9671\n",
      "Epoch [3/3], Step [910], Loss: 2.3877\n",
      "Epoch [3/3], Step [920], Loss: 2.1405\n",
      "Epoch [3/3], Step [930], Loss: 2.0648\n",
      "Epoch [3/3], Step [940], Loss: 2.2363\n",
      "Epoch [3/3], Step [950], Loss: 2.0777\n",
      "Epoch [3/3], Step [960], Loss: 2.4815\n",
      "Epoch [3/3], Step [970], Loss: 1.6893\n",
      "Epoch [3/3], Step [980], Loss: 1.9989\n",
      "Epoch [3/3], Step [990], Loss: 2.1733\n",
      "Epoch [3/3], Step [1000], Loss: 1.9070\n",
      "Epoch [3/3], Step [1010], Loss: 1.8872\n",
      "Epoch [3/3], Step [1020], Loss: 2.2323\n",
      "Epoch [3/3], Step [1030], Loss: 1.9753\n",
      "Epoch [3/3], Step [1040], Loss: 2.0343\n",
      "Epoch [3/3], Step [1050], Loss: 1.7522\n",
      "Epoch [3/3], Step [1060], Loss: 1.8353\n",
      "Epoch [3/3], Step [1070], Loss: 1.9137\n",
      "Epoch [3/3], Step [1080], Loss: 2.0049\n",
      "Epoch [3/3], Step [1090], Loss: 1.8798\n",
      "Epoch [3/3], Step [1100], Loss: 1.9339\n",
      "Epoch [3/3], Step [1110], Loss: 1.8524\n",
      "Epoch [3/3], Step [1120], Loss: 1.7935\n",
      "Epoch [3/3], Step [1130], Loss: 2.2432\n",
      "Epoch [3/3], Step [1140], Loss: 1.9310\n",
      "Epoch [3/3], Step [1150], Loss: 2.0508\n",
      "Epoch [3/3], Step [1160], Loss: 2.0988\n",
      "Epoch [3/3], Step [1170], Loss: 2.0377\n",
      "Epoch [3/3], Step [1180], Loss: 2.1371\n",
      "Epoch [3/3], Step [1190], Loss: 2.1199\n",
      "Epoch [3/3], Step [1200], Loss: 1.9273\n",
      "Epoch [3/3], Step [1210], Loss: 2.1240\n",
      "Epoch [3/3], Step [1220], Loss: 1.7459\n",
      "Epoch [3/3], Step [1230], Loss: 2.0141\n",
      "Epoch [3/3], Step [1240], Loss: 1.8178\n",
      "Epoch [3/3], Step [1250], Loss: 1.8232\n",
      "Epoch [3/3], Step [1260], Loss: 2.0111\n",
      "Epoch [3/3], Step [1270], Loss: 1.9278\n",
      "Epoch [3/3], Step [1280], Loss: 1.7559\n",
      "Epoch [3/3], Step [1290], Loss: 2.2350\n",
      "Epoch [3/3], Step [1300], Loss: 2.2049\n",
      "Epoch [3/3], Step [1310], Loss: 1.9426\n",
      "Epoch [3/3], Step [1320], Loss: 2.0966\n",
      "Epoch [3/3], Step [1330], Loss: 2.0175\n",
      "Epoch [3/3], Step [1340], Loss: 1.8857\n",
      "Epoch [3/3], Step [1350], Loss: 1.9803\n",
      "Epoch [3/3], Step [1360], Loss: 2.2866\n",
      "Epoch [3/3], Step [1370], Loss: 1.9382\n",
      "Epoch [3/3], Step [1380], Loss: 2.1189\n",
      "Epoch [3/3], Step [1390], Loss: 1.9911\n",
      "Epoch [3/3], Step [1400], Loss: 1.9950\n",
      "Epoch [3/3], Step [1410], Loss: 1.8187\n",
      "Epoch [3/3], Step [1420], Loss: 2.3719\n",
      "Epoch [3/3], Step [1430], Loss: 1.8162\n",
      "Epoch [3/3], Step [1440], Loss: 2.0607\n"
     ]
    }
   ],
   "source": [
    "torch.cuda.empty_cache()\n",
    "model.to(device)\n",
    "epochs = 3\n",
    "for epoch in range(epochs):\n",
    "    total_loss = 0.0\n",
    "    for step, batch in enumerate(train_dataloader):\n",
    "        input_ids = batch['input_ids'].to(device)\n",
    "        model.train()\n",
    "        optimizer.zero_grad()        \n",
    "        outputs = model(input_ids=input_ids, labels=input_ids)\n",
    "        loss = outputs.loss        \n",
    "        loss.backward()\n",
    "        optimizer.step()      \n",
    "        total_loss += loss.item()\n",
    "        if step % 10 == 0:\n",
    "            print(f\"Epoch [{epoch+1}/{epochs}], Step [{step}], Loss: {loss.item():.4f}\")  \n",
    "        torch.cuda.empty_cache()    \n",
    "    torch.cuda.empty_cache()\n",
    "torch.cuda.empty_cache()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "faec77df-e571-4580-a014-7995cbaf1851",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Model saved to lora_dp_medical_llama328.pth\n"
     ]
    }
   ],
   "source": [
    "# Save the LoRA-adapted model\n",
    "def save_model(model, epoch, filename='lora_dp_medical_llama328.pth'):\n",
    "    state_dict = {\n",
    "        'epoch': epoch,\n",
    "        'model_state_dict': model.state_dict()\n",
    "    }\n",
    "    torch.save(state_dict, filename)\n",
    "    print(f\"Model saved to {filename}\")  \n",
    "model = model._module\n",
    "save_model(model, epoch)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "5cc5974f-09a8-4929-8d37-c579822db4f9",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\my pc\\AppData\\Local\\Temp\\ipykernel_6764\\1202912694.py:4: FutureWarning: You are using `torch.load` with `weights_only=False` (the current default value), which uses the default pickle module implicitly. It is possible to construct malicious pickle data which will execute arbitrary code during unpickling (See https://github.com/pytorch/pytorch/blob/main/SECURITY.md#untrusted-models for more details). In a future release, the default value for `weights_only` will be flipped to `True`. This limits the functions that could be executed during unpickling. Arbitrary objects will no longer be allowed to be loaded via this mode unless they are explicitly allowlisted by the user via `torch.serialization.add_safe_globals`. We recommend you start setting `weights_only=True` for any use case where you don't have full control of the loaded file. Please open an issue on GitHub for any issues related to this experimental feature.\n",
      "  checkpoint = torch.load(filename, map_location=\"cuda\")\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Model loaded from lora_dp_medical_llama328.pth\n",
      "Generator model loaded successfully!\n"
     ]
    }
   ],
   "source": [
    "from transformers import AutoTokenizer, AutoModelForCausalLM, pipeline\n",
    "\n",
    "def load_model(model,filename='lora_dp_medical_llama328.pth'):\n",
    "    checkpoint = torch.load(filename, map_location=\"cuda\")\n",
    "\n",
    "    # Resize model embeddings before loading state dict\n",
    "    tokenizer_vocab_size = len(tokenizer)\n",
    "    model_vocab_size = checkpoint[\"model_state_dict\"][\"base_model.model.model.embed_tokens.weight\"].shape[0]\n",
    "    \n",
    "    if tokenizer_vocab_size != model_vocab_size:\n",
    "        print(f\"Resizing model embeddings: {model_vocab_size} → {tokenizer_vocab_size}\")\n",
    "        model.resize_token_embeddings(model_vocab_size)\n",
    "\n",
    "    model.load_state_dict(checkpoint[\"model_state_dict\"], strict=False)\n",
    "    \n",
    "    epoch = checkpoint[\"epoch\"]\n",
    "    print(f\"Model loaded from {filename}\")\n",
    "    return model, epoch\n",
    "generator_model, start_epoch = load_model(model)\n",
    "\n",
    "print(\"Generator model loaded successfully!\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "3bdb5920-4f0f-4357-902c-a58476900509",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Defaulting to user installation because normal site-packages is not writeable\n",
      "Requirement already satisfied: rouge in ./.local/lib/python3.8/site-packages (1.0.1)\n",
      "Requirement already satisfied: six in /usr/local/lib/python3.8/dist-packages (from rouge) (1.15.0)\n",
      "\u001b[33mWARNING: Error parsing dependencies of mlnx-tools: Invalid version: '-5.2.0-'\u001b[0m\u001b[33m\n",
      "\u001b[0m\n",
      "\u001b[1m[\u001b[0m\u001b[34;49mnotice\u001b[0m\u001b[1;39;49m]\u001b[0m\u001b[39;49m A new release of pip is available: \u001b[0m\u001b[31;49m24.2\u001b[0m\u001b[39;49m -> \u001b[0m\u001b[32;49m25.0\u001b[0m\n",
      "\u001b[1m[\u001b[0m\u001b[34;49mnotice\u001b[0m\u001b[1;39;49m]\u001b[0m\u001b[39;49m To update, run: \u001b[0m\u001b[32;49mpython3 -m pip install --upgrade pip\u001b[0m\n"
     ]
    }
   ],
   "source": [
    "!pip install rouge"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "4400096e-4151-4e85-87fb-f3bf914c346e",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "The attention mask is not set and cannot be inferred from input because pad token is same as eos token. As a consequence, you may observe unexpected behavior. Please pass your input's `attention_mask` to obtain reliable results.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Sample 0: Perplexity = 3.4402\n",
      "Sample 1: Perplexity = 2.5866\n",
      "Sample 2: Perplexity = 2.8166\n",
      "Sample 3: Perplexity = 3.2004\n",
      "Sample 4: Perplexity = 4.4227\n",
      "Sample 5: Perplexity = 3.3087\n",
      "Sample 6: Perplexity = 2.8027\n",
      "Sample 7: Perplexity = 4.0231\n",
      "Sample 8: Perplexity = 2.3739\n",
      "Sample 9: Perplexity = 4.1105\n",
      "Sample 10: Perplexity = 4.2021\n",
      "Sample 11: Perplexity = 2.1621\n",
      "Sample 12: Perplexity = 3.7700\n",
      "Sample 13: Perplexity = 2.0665\n",
      "Sample 14: Perplexity = 4.1341\n",
      "Sample 15: Perplexity = 6.1420\n",
      "Sample 16: Perplexity = 3.9825\n",
      "Sample 17: Perplexity = 3.6846\n",
      "Sample 18: Perplexity = 4.9728\n",
      "Sample 19: Perplexity = 4.2174\n",
      "Sample 20: Perplexity = 2.9683\n",
      "Sample 21: Perplexity = 2.7167\n",
      "Sample 22: Perplexity = 4.2280\n",
      "Sample 23: Perplexity = 2.7209\n",
      "Sample 24: Perplexity = 2.6443\n",
      "Sample 25: Perplexity = 3.3746\n",
      "Sample 26: Perplexity = 2.7279\n",
      "Sample 27: Perplexity = 3.8531\n",
      "Sample 28: Perplexity = 2.1696\n",
      "Sample 29: Perplexity = 2.9298\n",
      "Sample 30: Perplexity = 2.4968\n",
      "Sample 31: Perplexity = 2.5748\n",
      "Sample 32: Perplexity = 8.5231\n",
      "Sample 33: Perplexity = 3.1614\n",
      "Sample 34: Perplexity = 3.6715\n",
      "Sample 35: Perplexity = 2.6596\n",
      "Sample 36: Perplexity = 2.4238\n",
      "Sample 37: Perplexity = 3.3281\n",
      "Sample 38: Perplexity = 2.5733\n",
      "Sample 39: Perplexity = 2.2085\n",
      "Sample 40: Perplexity = 2.9476\n",
      "Sample 41: Perplexity = 3.2675\n",
      "Sample 42: Perplexity = 3.0478\n",
      "Sample 43: Perplexity = 3.4359\n",
      "Sample 44: Perplexity = 3.3815\n",
      "Sample 45: Perplexity = 2.8187\n",
      "Sample 46: Perplexity = 4.6452\n",
      "Sample 47: Perplexity = 3.3701\n",
      "Sample 48: Perplexity = 3.9850\n",
      "Sample 49: Perplexity = 2.5921\n",
      "Sample 50: Perplexity = 2.7213\n",
      "Sample 51: Perplexity = 3.6213\n",
      "Sample 52: Perplexity = 3.1577\n",
      "Sample 53: Perplexity = 2.5287\n",
      "Sample 54: Perplexity = 3.0390\n",
      "Sample 55: Perplexity = 2.8146\n",
      "Sample 56: Perplexity = 8.3819\n",
      "Sample 57: Perplexity = 4.1357\n",
      "Sample 58: Perplexity = 2.3365\n",
      "Sample 59: Perplexity = 2.4294\n",
      "Sample 60: Perplexity = 9.0346\n",
      "Sample 61: Perplexity = 12.1790\n",
      "Sample 62: Perplexity = 4.5161\n",
      "Sample 63: Perplexity = 2.9766\n",
      "Sample 64: Perplexity = 8.7153\n",
      "Sample 65: Perplexity = 2.3423\n",
      "Sample 66: Perplexity = 3.1615\n",
      "Sample 67: Perplexity = 3.6382\n",
      "Sample 68: Perplexity = 3.1816\n",
      "Sample 69: Perplexity = 5.0434\n",
      "Sample 70: Perplexity = 6.8575\n",
      "Sample 71: Perplexity = 3.5142\n",
      "Sample 72: Perplexity = 3.7464\n",
      "Sample 73: Perplexity = 2.6926\n",
      "Sample 74: Perplexity = 4.0372\n",
      "Sample 75: Perplexity = 5.8314\n",
      "Sample 76: Perplexity = 5.5957\n",
      "Sample 77: Perplexity = 3.7079\n",
      "Sample 78: Perplexity = 2.7460\n",
      "Sample 79: Perplexity = 8.6975\n",
      "Sample 80: Perplexity = 2.7754\n",
      "Sample 81: Perplexity = 4.7523\n",
      "Sample 82: Perplexity = 2.3942\n",
      "Sample 83: Perplexity = 3.9190\n",
      "Sample 84: Perplexity = 5.4193\n",
      "Sample 85: Perplexity = 2.4681\n",
      "Sample 86: Perplexity = 8.8560\n",
      "Sample 87: Perplexity = 3.2675\n",
      "Sample 88: Perplexity = 3.3840\n",
      "Sample 89: Perplexity = 2.1274\n",
      "Sample 90: Perplexity = 3.1069\n",
      "Sample 91: Perplexity = 3.4373\n",
      "Sample 92: Perplexity = 2.8956\n",
      "Sample 93: Perplexity = 3.2776\n",
      "Sample 94: Perplexity = 4.4936\n",
      "Sample 95: Perplexity = 3.0627\n",
      "Sample 96: Perplexity = 2.5170\n",
      "Sample 97: Perplexity = 3.6579\n",
      "Sample 98: Perplexity = 2.9214\n",
      "Sample 99: Perplexity = 3.2889\n",
      "Sample 100: Perplexity = 11.3000\n",
      "Sample 101: Perplexity = 5.2404\n",
      "Sample 102: Perplexity = 2.9400\n",
      "Sample 103: Perplexity = 3.3466\n",
      "Sample 104: Perplexity = 3.5166\n",
      "Sample 105: Perplexity = 2.3388\n",
      "Sample 106: Perplexity = 2.8691\n",
      "Sample 107: Perplexity = 3.4800\n",
      "Sample 108: Perplexity = 2.8285\n",
      "Sample 109: Perplexity = 3.9932\n",
      "Sample 110: Perplexity = 4.4268\n",
      "Sample 111: Perplexity = 2.7995\n",
      "Sample 112: Perplexity = 2.3104\n",
      "Sample 113: Perplexity = 3.0922\n",
      "Sample 114: Perplexity = 3.4617\n",
      "Sample 115: Perplexity = 6.4803\n",
      "Sample 116: Perplexity = 2.1271\n",
      "Sample 117: Perplexity = 6.2343\n",
      "Sample 118: Perplexity = 4.2474\n",
      "Sample 119: Perplexity = 1.8275\n",
      "Sample 120: Perplexity = 2.8968\n",
      "Sample 121: Perplexity = 2.3225\n",
      "Sample 122: Perplexity = 2.3596\n",
      "Sample 123: Perplexity = 4.1850\n",
      "Sample 124: Perplexity = 2.3720\n",
      "Sample 125: Perplexity = 4.0131\n",
      "Sample 126: Perplexity = 6.3658\n",
      "Sample 127: Perplexity = 4.2713\n",
      "Sample 128: Perplexity = 2.4632\n",
      "Sample 129: Perplexity = 2.9814\n",
      "Sample 130: Perplexity = 4.6930\n",
      "Sample 131: Perplexity = 2.5338\n",
      "Sample 132: Perplexity = 2.8499\n",
      "Sample 133: Perplexity = 2.5786\n",
      "Sample 134: Perplexity = 3.9048\n",
      "Sample 135: Perplexity = 3.2379\n",
      "Sample 136: Perplexity = 3.4377\n",
      "Sample 137: Perplexity = 6.8474\n",
      "Sample 138: Perplexity = 2.1324\n",
      "Sample 139: Perplexity = 3.3167\n",
      "Sample 140: Perplexity = 4.7061\n",
      "Sample 141: Perplexity = 4.0538\n",
      "Sample 142: Perplexity = 11.3494\n",
      "Sample 143: Perplexity = 3.1327\n",
      "Sample 144: Perplexity = 3.2077\n",
      "Sample 145: Perplexity = 6.1237\n",
      "Sample 146: Perplexity = 2.1742\n",
      "Sample 147: Perplexity = 4.3255\n",
      "Sample 148: Perplexity = 3.9355\n",
      "Sample 149: Perplexity = 2.4440\n",
      "Sample 150: Perplexity = 2.8603\n",
      "Sample 151: Perplexity = 2.1006\n",
      "Sample 152: Perplexity = 2.8336\n",
      "Sample 153: Perplexity = 2.6659\n",
      "Sample 154: Perplexity = 2.7907\n",
      "Sample 155: Perplexity = 4.5389\n",
      "Sample 156: Perplexity = 3.5214\n",
      "Sample 157: Perplexity = 2.9500\n",
      "Sample 158: Perplexity = 3.8165\n",
      "Sample 159: Perplexity = 2.1576\n",
      "Sample 160: Perplexity = 2.1955\n",
      "Sample 161: Perplexity = 2.4888\n",
      "Sample 162: Perplexity = 2.8559\n",
      "Sample 163: Perplexity = 3.2965\n",
      "Sample 164: Perplexity = 3.3408\n",
      "Sample 165: Perplexity = 2.8943\n",
      "Sample 166: Perplexity = 3.4668\n",
      "Sample 167: Perplexity = 2.9337\n",
      "Sample 168: Perplexity = 2.7598\n",
      "Sample 169: Perplexity = 6.1294\n",
      "Sample 170: Perplexity = 7.1044\n",
      "Sample 171: Perplexity = 3.9696\n",
      "Sample 172: Perplexity = 3.4677\n",
      "Sample 173: Perplexity = 3.2117\n",
      "Sample 174: Perplexity = 2.1690\n",
      "Sample 175: Perplexity = 2.2653\n",
      "Sample 176: Perplexity = 3.2238\n",
      "Sample 177: Perplexity = 1.9051\n",
      "Sample 178: Perplexity = 3.2972\n",
      "Sample 179: Perplexity = 3.3427\n",
      "Sample 180: Perplexity = 3.4186\n",
      "Sample 181: Perplexity = 4.5030\n",
      "Sample 182: Perplexity = 4.5505\n",
      "Sample 183: Perplexity = 2.3844\n",
      "Sample 184: Perplexity = 3.3358\n",
      "Sample 185: Perplexity = 3.9747\n",
      "Sample 186: Perplexity = 3.7984\n",
      "Sample 187: Perplexity = 2.7183\n",
      "Sample 188: Perplexity = 3.3330\n",
      "Sample 189: Perplexity = 2.2958\n",
      "Sample 190: Perplexity = 4.1531\n",
      "Sample 191: Perplexity = 2.1809\n",
      "Sample 192: Perplexity = 3.8772\n",
      "Sample 193: Perplexity = 1.9998\n",
      "Sample 194: Perplexity = 2.7531\n",
      "Sample 195: Perplexity = 4.9589\n",
      "Sample 196: Perplexity = 4.7814\n",
      "Sample 197: Perplexity = 1.9988\n",
      "Sample 198: Perplexity = 3.4936\n",
      "Sample 199: Perplexity = 3.1016\n",
      "Perplexity scores saved to perplexity_scores.csv\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import torch\n",
    "import matplotlib.pyplot as plt\n",
    "from transformers import AutoTokenizer, AutoModelForCausalLM\n",
    "from nltk.translate.bleu_score import sentence_bleu\n",
    "from rouge import Rouge\n",
    "from sklearn.metrics.pairwise import cosine_similarity\n",
    "from sklearn.feature_extraction.text import CountVectorizer\n",
    "\n",
    "device = torch.device(\"cuda:0\" if torch.cuda.is_available() else \"cpu\")\n",
    "generator_model = generator_model.to(device)\n",
    "# Load the dataset\n",
    "train_df = pd.read_csv(\"medical_tc_test.csv\")\n",
    "texts = train_df[\"medical_abstract\"][:200].tolist()\n",
    "\n",
    "# Ensure tokenizer has a pad token\n",
    "if tokenizer.pad_token is None:\n",
    "    tokenizer.pad_token = tokenizer.eos_token\n",
    "\n",
    "# Create prompts from the first 50 words\n",
    "prompts = [' '.join(str(text).split()[:50]) for text in texts]\n",
    "\n",
    "def generate_long_text(model, tokenizer, prompt, max_length=300):    \n",
    "    input_ids = tokenizer(prompt, return_tensors=\"pt\").input_ids.to(device)\n",
    "    output_ids = model.generate(input_ids, max_length=max_length, pad_token_id=tokenizer.eos_token_id)\n",
    "    generated_text = tokenizer.decode(output_ids[0], skip_special_tokens=True)\n",
    "    return generated_text\n",
    "\n",
    "def calculate_perplexity(model, tokenizer, text):\n",
    "    input_ids = tokenizer(text, return_tensors=\"pt\").input_ids.to(device)\n",
    "    with torch.no_grad():\n",
    "        outputs = model(input_ids, labels=input_ids)\n",
    "        loss = outputs.loss\n",
    "    return torch.exp(loss).item()\n",
    "\n",
    "# Loop over prompts, generate text, and record perplexity scores\n",
    "perplexity_scores = []\n",
    "for i, prompt in enumerate(prompts):\n",
    "    generated_text_str = generate_long_text(generator_model, tokenizer, prompt, max_length=300)\n",
    "    perplexity = calculate_perplexity(generator_model, tokenizer, generated_text_str)\n",
    "    perplexity_scores.append(perplexity)\n",
    "    print(f\"Sample {i}: Perplexity = {perplexity:.4f}\")\n",
    "\n",
    "# Save perplexity scores to a CSV file\n",
    "df = pd.DataFrame({\n",
    "    \"Index\": range(len(perplexity_scores)),\n",
    "    \"Perplexity\": perplexity_scores\n",
    "})\n",
    "df.to_csv(\"lora_dp_med_llm32_perplexity_scores.csv\", index=False)\n",
    "print(\"Perplexity scores saved to perplexity_scores.csv\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "eba586c2-7556-4cf0-9b75-51fa1adeb506",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "3.6875418037176133"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import numpy as np\n",
    "np.mean(perplexity_scores)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "f531aa29-849a-4687-8e17-5b56b8ee4789",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1000x600 with 2 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Group perplexity scores into defined ranges.\n",
    "# For this example, we group scores as: 0-20, 20-40, 40-60, 60-80, 80-100, and 100+\n",
    "bins = [0,2,3,4,5,6,7,8,9,10,20, 40, 60, 80, 100, float('inf')]\n",
    "labels = [\"0-2\", \"2-3\",\"3-4\",\"4-5\",\"5-6\",\"6-7\",\"7-8\",\"8-9\",\"9-10\",\"10-20\",\"20-40\", \"40-60\", \"60-80\", \"80-100\", \"100+\"]\n",
    "df[\"Perplexity Group\"] = pd.cut(df[\"Perplexity\"], bins=bins, labels=labels)\n",
    "\n",
    "# Create a scatter plot of perplexity scores.\n",
    "plt.figure(figsize=(10, 6))\n",
    "# Color-code by perplexity group using categorical codes.\n",
    "scatter = plt.scatter(df[\"Index\"], df[\"Perplexity\"], \n",
    "                      c=df[\"Perplexity Group\"].cat.codes, cmap=\"viridis\", s=60, edgecolor=\"k\")\n",
    "plt.xlabel(\"Sample Index\", fontweight=\"bold\", fontsize=14)\n",
    "plt.ylabel(\"Perplexity Score\", fontweight=\"bold\", fontsize=14)\n",
    "plt.xticks(fontsize=14, fontweight='bold')  # Increase font size and make it bold\n",
    "plt.yticks(fontsize=14, fontweight='bold')  # Increase font size and make it bold\n",
    "\n",
    "plt.title(\"\", fontweight=\"bold\", fontsize=16)\n",
    "\n",
    "# Fix y-axis range from 0 to 100\n",
    "plt.ylim(0, 30)\n",
    "\n",
    "# Create a colorbar with group labels.\n",
    "cbar = plt.colorbar(scatter, ticks=range(len(labels)))\n",
    "cbar.ax.set_yticklabels(labels)\n",
    "\n",
    "plt.savefig(\"lora_dp_med_llm32_perplexity_scatter_plot.png\", dpi=300, bbox_inches=\"tight\")\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "6764c498-ee8c-41f6-90a2-26a47637c06b",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Reference Text: Obstructive sleep apnea following topical oropharyngeal anesthesia in loud snorers. Previous studies support the presence of an upper airway reflex mechanism that contributes to the maintenance of upper airway patency during sleep. We investigated the possibility that interference with this reflex mechanism contributes to the development of obstructive sleep apnea. Eight otherwise asymptomatic snorers (seven male and one female), age 39 +/- 5.3 yr (mean +/- SEM), underwent overnight sleep studies on three successive nights. An acclimatization night was followed by two study nights randomly assigned to control (C) and oropharyngeal anesthesia (OPA). On the OPA night topical anesthesia was induced using 10% lidocaine spray and 0.25% bupivacaine gargle. A saline placebo was used on night C. All subjects slept well on both study nights (mean sleep duration was 6.2 h on both study nights), and sleep stage distribution was similar on both nights. Obstructive apneas and hypopneas (OAH) rose from 114 +/- 43 during C to 170 +/- 49 during OPA (p less than 0.02). Central apneas and hypopneas (CAH) were unchanged between the two nights (8 +/- 4.9 versus 7 +/- 3). The duration of OAH was similar on both study nights (20 +/- 1.9 s during C versus 20 +/- 1.5 s during OPA). The frequency of movement arousals terminating OAH tended to be higher during OPA (7 +/- 2.9/h) than during C (3 +/- 0.7); P = NS. The frequency of oxyhemoglobin desaturations was also higher during OPA (5 +/- 2.1/h) than during C (3 +/- 1.4), p less than 0.07. \n",
      "Generated Text: Obstructive sleep apnea following topical oropharyngeal anesthesia in loud snorers. Previous studies support the presence of an upper airway reflex mechanism that contributes to the maintenance of upper airway patency during sleep. We investigated the possibility that interference with this reflex mechanism contributes to the development of obstructive sleep apnea. We studied 20 subjects (10 men and 10 women) with obstructive sleep apnea and 10 subjects without obstructive sleep apnea. We used a computerized polysomnography technique to measure the degree of upper airway obstruction during sleep. We then studied the effects of topical oropharyngeal anesthesia on the degree of upper airway obstruction. In subjects with obstructive sleep apnea, topical anesthesia reduced the degree of upper airway obstruction by 40% to 60%. The reduction in the degree of upper airway obstruction was accompanied by a reduction in the frequency of sleep apnea. We conclude that the reflex mechanism that maintains upper airway patency during sleep is not the only mechanism that contributes to the development of obstructive sleep apnea. We also conclude that the presence of upper airway obstruction during sleep is associated with a reduction in the frequency of sleep apnea. We propose that the presence of upper airway obstruction during sleep is a necessary condition for the development of obstructive sleep apnea.\n",
      "BLEU: 0.21656344964450774, ROUGE-L: {'r': 0.29411764705882354, 'p': 0.5844155844155844, 'f': 0.39130434337202274}, Perplexity: 3.1520798206329346, Cosine Similarity: 0.5984\n",
      "Reference Text: Neutrophil function and pyogenic infections in bone marrow transplant recipients. In a consecutive entry trial, the incidence and time course of decreased neutrophil function was assessed in 20 patients treated with allogeneic bone marrow transplantation (BMT). The aim of the study was to assess the prognostic value of low neutrophil function for late pyogenic infections. Chemotaxis, superoxide production, and phagocytic-bactericidal activity were studied before and 2, 6, 9, and 12 months after BMT. Skin window migration was quantitatively assessed 2 months after BMT. Infectious complications were recorded prospectively with preset criteria during 1 year. Six of the 20 leukemic patients had defective neutrophil function before BMT. Two months after BMT all 10 patients with greater than stage II graft-versus-host disease (GVHD), and 6 of 10 patients with less than or equal to stage II GVHD had at least one decreased function. At this time, patients with subsequent pyogenic infections had lower chemotaxis (P less than .05), phagocytic-bactericidal activity (P less than .005), and superoxide production (P less than .025) than those without. Defective skin window migration and combined defects were predictive for late pyogenic infections. At 9 months all tests were normal in seven patients surviving without GVHD. In contrast, at 9 months three of three patients, and at 1 year two of three with chronic GVHD had still decreased neutrophil function. In conclusion, neutrophil function is frequently impaired during the first months after BMT. Combined neutrophil defects predispose to pyogenic infections and indicate the patient at risk. \n",
      "Generated Text: Neutrophil function and pyogenic infections in bone marrow transplant recipients. In a consecutive entry trial, the incidence and time course of decreased neutrophil function was assessed in 20 patients treated with allogeneic bone marrow transplantation (BMT). The aim of the study was to assess the prognostic value of low neutrophil function for the development of bacterial infections. Neutrophil function was assessed by measurement of the neutrophil chemotactic index (NCTI) and the neutrophil chemotactic index (NCTI) in response to the chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine (FMLP). The NCTI and NCTI were significantly decreased at 2 weeks after BMT, but not at 4 weeks. The decrease in NCTI and NCTI was significantly correlated with the development of bacterial infections. The NCTI and NCTI were not significantly correlated with the development of bacterial infections. The results suggest that low neutrophil function is a poor prognostic indicator for bacterial infections.\n",
      "BLEU: 0.1983517849236066, ROUGE-L: {'r': 0.3409090909090909, 'p': 0.6428571428571429, 'f': 0.4455445499264778}, Perplexity: 3.1855545043945312, Cosine Similarity: 0.6297\n",
      "Reference Text: A phase II study of combined methotrexate and teniposide infusions prior to reinduction therapy in relapsed childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study. Teniposide (VM-26) can increase intracellular methotrexate (MTX) and its polyglutamate derivatives in vitro and thus has the potential to improve the therapeutic index of regimens containing MTX. In this phase II study, children and adolescents with acute lymphoblastic leukemia (ALL) in first or second marrow relapse were randomly assigned to receive either simultaneous (n = 11) or sequential (n = 12) continuous infusions of MTX and VM-26 prior to reinduction. Infusions of VM-26 were begun 12 hours after completion of MTX infusion in the sequential group. Dosages were individually adjusted to maintain plasma concentration levels of 10 microns for MTX and 15 microns for VM-26; total infusion times were 24 and 72 hours, respectively. Significant toxicity in the first six patients who received the scheduled 72-hour VM-26 infusion (including one drug-related death) prompted a 50% reduction in infusion duration. The reduced dose was associated with similar but more manageable toxicity. Examination of bone marrow aspirates 10 days after therapy was begun showed one complete and two partial marrow remissions; a fourth patient who had an aplastic marrow on day 10 received no further chemotherapy and had a complete remission (CR) documented on day 31. There was no obvious clinical advantage associated with either infusion schedule, although small sample sizes preclude definitive conclusions. The 17% response rate to the MTX/VM-26 therapeutic window in patients with refractory disease suggests the need for further investigation to evaluate alternative schedules and concomitant therapy for this drug combination. \n",
      "Generated Text: A phase II study of combined methotrexate and teniposide infusions prior to reinduction therapy in relapsed childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study. Teniposide (VM-26) can increase intracellular methotrexate (MTX) and its polyglutamate derivatives in vitro and thus has the potential to improve the therapeutic index of regimens containing MTX. We conducted a phase II study of teniposide plus MTX prior to reinduction therapy in relapsed childhood acute lymphoblastic leukemia. Fifty-three patients were treated with a 5-day regimen of teniposide 30 mg/m2 and MTX 5 mg/m2 on days 1, 3, 5, and 7. The median number of courses of MTX was 2. The median age was 12 years (range, 3 to 18 years). The median number of previous MTX courses was 2 (range, 1 to 6). The median duration of remission was 14 months (range, 1 to 43 months). There were 18 complete responses, 12 partial responses, and 23 stable responses. There were 11 deaths. The most common adverse events were bone marrow suppression (grade 3 or 4) and mucositis. The median number of MTX courses given to achieve a complete response was 2 (range, 1 to 4). A total of 38 patients had a complete response, 4 had a partial response, and 11 had a stable response. There were 6 deaths. This regimen was well tolerated, with a high response rate and a low toxicity profile. Teniposide plus MTX appears to be an effective regimen for relapsed childhood acute lymphoblastic leukemia.\n",
      "BLEU: 0.23978630218147512, ROUGE-L: {'r': 0.3872832369942196, 'p': 0.5234375, 'f': 0.4451827193642454}, Perplexity: 2.8078694343566895, Cosine Similarity: 0.7026\n",
      "Reference Text: Flow cytometric DNA analysis of parathyroid tumors. Implication of aneuploidy for pathologic and biologic classification. The previous cytometric studies on parathyroid tumors have provided conflicting data regarding the relationship between DNA content and histopathology, resulting from differences in technical methods and data analysis. This study measured nuclear DNA of parathyroid tumors by flow cytometry in fresh material and determined whether DNA aneuploidy really assists in making a pathologic diagnosis of carcinoma or not. From May 1987 through April 1989, 65 consecutive patients operated on for primary hyperparathyroidism had DNA analysis of the freshly excised parathyroid tumors. Three of the patients had metastatic lesions of parathyroid carcinoma in the lung, cervical lymph nodes, and lung and mediastinal lymph nodes, respectively. Pathologic classifications of the lesions from the other 62 patients were 54 adenomas, four carcinomas, and four hyperplasias. In all the latter patients, hyperplasia was associated with a multiple endocrine neoplasia syndrome. Unequivocal evidence of aneuploidy was found in all of the metastatic lesions and 60% of the primary lesions of the carcinomas, in 9% of the adenomas and in 50% of the hyperplasias. Therefore, parathyroid carcinomas were more apt to be aneuploid than were adenomas (P = 0.0015, both-sided testing). In each of the cases of aneuploid hyperplasia, a small aneuploid peak was found. The high incidence of aneuploidy in patients with multiple endocrine neoplasia type 1 may indicate the presence of clonal heterogeneity of hyperplastic glands and the presence of an abnormal subset of cells that have malignant potential. Cell distribution analysis did not provide any significant information beyond ploidy level. In conclusion, DNA flow cytometric analysis of DNA ploidy patterns is a valuable adjunct to the histopathologic diagnosis of parathyroid neoplasms. \n",
      "Generated Text: Flow cytometric DNA analysis of parathyroid tumors. Implication of aneuploidy for pathologic and biologic classification. The previous cytometric studies on parathyroid tumors have provided conflicting data regarding the relationship between DNA content and histopathology, resulting from differences in technical methods and data analysis. This study measured nuclear DNA of parathyroid tumors by flow cytometry, using a monoclonal antibody to the parathyroid hormone receptor. The results are compared with previous studies on parathyroid tumors. The mean DNA content of parathyroid tumors was 1.0 +/- 0.1 (SD), which is similar to that of normal parathyroid tissue. The mean DNA content of benign parathyroid tumors was 1.0 +/- 0.1, which is similar to that of benign parathyroid tissue. The mean DNA content of malignant parathyroid tumors was 1.2 +/- 0.1, which is higher than that of malignant parathyroid tissue. The mean DNA content of parathyroid adenomas was 1.1 +/- 0.1, which is similar to that of parathyroid adenomas. The mean DNA content of parathyroid hyperplasia was 1.0 +/- 0.1, which is similar to that of parathyroid hyperplasia. The mean DNA content of parathyroid carcinomas was 1.1 +/- 0.1, which is similar to that of parathyroid carcinomas. The mean DNA content of parathyroid hyperplasia, adenoma, and carcinoma was 1.0 +/- 0.1, which is similar to that of benign parathyroid tissue. The mean DNA content of parathyroid hyperplasia, adenoma, and carcinoma was 1.0 +/- 0.1, which is similar to that of malignant parathyroid tissue. The mean DNA content of parathyroid hyperplasia, adenoma, and carcinoma was 1.0 +/- 0.1, which is similar to that of malignant parathyroid tissue. The mean DNA content of parathyroid hyperplasia, adenoma, and carcinoma was 1.0 +/- 0.1, which is similar to that of malignant parathyroid tissue. The mean DNA content of parathyroid hyperplasia, adenoma, and carcinoma was 1.0 +/- 0.1, which is similar to that of\n",
      "BLEU: 0.20781755898625423, ROUGE-L: {'r': 0.3395061728395062, 'p': 0.7236842105263158, 'f': 0.46218486960242927}, Perplexity: 1.92124605178833, Cosine Similarity: 0.6621\n",
      "Reference Text: Paraneoplastic vasculitic neuropathy: a treatable neuropathy. Paraneoplastic vasculitic neuropathy has been recently described. We report the first case of this disorder which responded both clinically and electrophysiologically to cyclophosphamide treatment. A 54-year-old woman with a history of metastatic endometrial carcinoma in remission had asymmetrical polyneuropathy, electrophysiological findings consistent with a diffuse axonal neuropathy, high sedimentation rate and spinal fluid protein, and microvasculitis with axonal degeneration on nerve biopsy. The patient was treated with 150 mg of cyclophosphamide daily with gradual clinical and electrophysiological improvement. \n",
      "Generated Text: Paraneoplastic vasculitic neuropathy: a treatable neuropathy. Paraneoplastic vasculitic neuropathy has been recently described. We report the first case of this disorder which responded both clinically and electrophysiologically to cyclophosphamide treatment. A 54-year-old woman with a history of metastatic endometrial carcinoma in remission had asymmetrical polyneuropathy, electrophysiological findings consistent with a neuropathy, and a positive antinuclear antibody test. Cyclophosphamide was administered with good clinical and electrophysiological response. This is the first report of a successful treatment for paraneoplastic vasculitic neuropathy.\n",
      "BLEU: 0.6188416444701386, ROUGE-L: {'r': 0.6764705882352942, 'p': 0.7796610169491526, 'f': 0.7244094438440078}, Perplexity: 3.8069777488708496, Cosine Similarity: 0.8411\n",
      "Reference Text: Treatment of childhood angiomatous diseases with recombinant interferon alfa-2a. A heterogeneous group of five patients with progressive, invasive angiomatous diseases including pulmonary hemangiomatosis, angiosarcoma, or massive hemangioma with associated consumptive coagulopathy were treated with interferon alfa-2a for periods of 17 to 33 months. One patient with a large thoracic hemangioma, cardiorespiratory failure, and consumptive coagulopathy died after less than 2 months of treatment. The remaining four patients have shown beneficial responses, including (1) regression of abnormal vessels on pulmonary angiogram and improved exercise tolerance in pulmonary hemangiomatosis (two patients), (2) decreased corticosteroid and/or platelet transfusion requirements in consumptive coagulopathy (two patients), and (3) decreased size and number of tumor nodules in the one patient with angiosarcoma arising in preexisting angiomatous lesions. Responses occurred during periods of 2 to 20 months of treatment. There was no measurable progression of angiomatous lesions in any patient receiving interferon at the therapeutic dose, except possibly in the one who died. Each of the four surviving patients had improved linear growth and weight gain during interferon treatment. \n",
      "Generated Text: Treatment of childhood angiomatous diseases with recombinant interferon alfa-2a. A heterogeneous group of five patients with progressive, invasive angiomatous diseases including pulmonary hemangiomatosis, angiosarcoma, or massive hemangioma with associated consumptive coagulopathy were treated with interferon alfa-2a for periods of 17 to 33 months. One patient with a large thoracic hemangioma, pulmonary hemangiomatosis, and a thromboembolic event had complete regression of the disease. Three patients with pulmonary hemangiomatosis had marked regression of the disease after treatment with interferon alfa-2a. One patient with angiosarcoma had a partial response to interferon alfa-2a. No serious adverse effects were noted. Interferon alfa-2a is a safe and effective therapy for these angiomatous diseases.\n",
      "BLEU: 0.28047529496938856, ROUGE-L: {'r': 0.4107142857142857, 'p': 0.6865671641791045, 'f': 0.5139664757629288}, Perplexity: 4.057054042816162, Cosine Similarity: 0.7141\n",
      "Reference Text: Expression of major histocompatibility complex class II antigens and interleukin-1 by epithelial cells of Warthin's tumor. The immunoreactivity for class II antigens of the major histocompatibility complex and interleukin-1 (IL-1) in Warthin's tumor (WT) cells was studied. In addition to macrophages, dendritic cells, and capillary endothelia, the luminal tumor cells and some keratinocytes in the metaplastic squamous foci exhibited immunoreactivity for both class II antigens and IL-1. The distribution of the class II antigens in the luminal tumor cells was limited to their basolateral membrane. These data, together with previous findings, strongly suggest that the luminal tumor cells of WT introduce the luminal antigen to the underlying lymphoid tissue and, thus, act as an antigen-presenting cell. \n",
      "Generated Text: Expression of major histocompatibility complex class II antigens and interleukin-1 by epithelial cells of Warthin's tumor. The immunoreactivity for class II antigens of the major histocompatibility complex and interleukin-1 (IL-1) in Warthin's tumor (WT) cells was studied. In addition to macrophages, dendritic cells, and capillary endothelia, the luminal tumor cells were found to express class II antigens. The class II antigen expression was studied by the use of monoclonal antibodies to class II antigens. The class II antigen expression was not associated with the presence of IL-1. The presence of class II antigens and IL-1 in WT cells was not associated with the presence of cytotoxic T lymphocytes. The results suggest that the expression of class II antigens and IL-1 by WT cells is not associated with the presence of cytotoxic T lymphocytes.\n",
      "BLEU: 0.4408407568012197, ROUGE-L: {'r': 0.5507246376811594, 'p': 0.7037037037037037, 'f': 0.6178861739361492}, Perplexity: 3.2204878330230713, Cosine Similarity: 0.8526\n",
      "Reference Text: Questionable role of CNS radioprophylaxis in the therapeutic management of childhood rhabdomyosarcoma with meningeal extension. A series of 15 consecutive children with head and neck nonorbital rhabdomyosarcoma (RMSA) with meningeal extension were prospectively treated with chemotherapy consisting of Adriamycin (doxorubicin; Adria Laboratory, Columbus, OH) (ADM), vincristine (VCR), cyclophosphamide (CPM), and dactinomycin (DACT) followed by radiotherapy (60 Gy) to the primary tumor volume, along with intrathecal methotrexate (IT MTX). Thirteen of 15 responded to preradiation chemotherapy. Four of 13 relapsed. Relapse occurred at the level of the primary tumor in three of four. The 3-year progression-free survival (PFS) was 59%, similar to that achieved in a previous series treated with a comparable therapeutic approach that also included whole-brain radiotherapy as a prophylaxis of possible occult meningeal seeding. It is concluded that CNS prophylaxis with radiotherapy is questionable in the management of childhood RMSA with meningeal extension. \n",
      "Generated Text: Questionable role of CNS radioprophylaxis in the therapeutic management of childhood rhabdomyosarcoma with meningeal extension. A series of 15 consecutive children with head and neck nonorbital rhabdomyosarcoma (RMSA) with meningeal extension were prospectively treated with chemotherapy consisting of Adriamycin (doxorubicin; Adria Laboratory, Columbus, OH) (ADM), vincristine (VCR), cyclophosphamide (CPM), and cisplatin (CDDP). In addition to the intrathecal therapy, 10 children also received intrathecal CDDP. Seven children (46%) had CNS involvement at diagnosis. Five of these seven children (71%) had meningeal extension. Two children (14%) had leptomeningeal involvement. The median age of the children with meningeal extension was 10 years (range 7-14 years). The median time from diagnosis to the start of intrathecal therapy was 12 days (range 2-28 days). The median number of cycles of intrathecal therapy was 4 (range 2-6). The median duration of intrathecal therapy was 6 months (range 1-18 months). The median number of intrathecal CDDP doses was 3 (range 2-6). The median duration of intrathecal CDDP therapy was 6 months (range 1-18 months). The median number of CDDP doses was 3 (range 2-6). There were no CNS recurrences at a median follow-up of 30 months (range 3-60 months). The median survival time was 26 months (range 1-60 months). The median survival time for children with meningeal extension was 19 months (range 1-60 months). The median survival time for children with leptomeningeal involvement was 16 months (range 1-60 months). In children with meningeal extension, intrathecal therapy with CDDP was effective in preventing CNS recurrences. In children with leptomeningeal involvement, intrathecal therapy with CDDP was not effective in preventing CNS recurrences. The results of this study suggest that the use of intrathecal CDDP is not necessary in the treatment of children with head and neck nonorbital RMSA with meningeal extension.\n",
      "BLEU: 0.19804782881397404, ROUGE-L: {'r': 0.53125, 'p': 0.42857142857142855, 'f': 0.4744185997083829}, Perplexity: 2.746884822845459, Cosine Similarity: 0.6321\n",
      "Reference Text: Reversibility of hepatic fibrosis in experimentally induced cholestasis in rat. The reversibility of hepatic fibrosis was investigated in an experimental model of extrahepatic cholestasis in the rat after common bile duct ligation for 2 weeks, followed by bilioduodenal anastomosis for 3 weeks. Bile duct ligation resulted in a transitory marked elevation in the serum concentration of 5'-nucleotidase, alkaline phosphatase, and bilirubin during the first 3 days. Then these levels decreased to threefold, twofold, and 100-fold the normal values, respectively, during the following 4 weeks. Histologic examination of the liver disclosed extensive bile duct proliferation and the formation of periportal fibrosis, with only slight inflammation and necrosis. The distribution of the major components of the hepatic extracellular matrix was analyzed 2 weeks after bile duct ligation, using the indirect immunoperoxidase method. Fibrous septa were found to be strongly stained for collagens I, pro-III, III and IV, fibronectin, and laminin. The most intense staining was found in enlarged periportal areas, collagen IV and laminin being particularly abundant around newly formed bile ducts. These changes paralleled high steady-state levels of alpha 1(I) and alpha 1(IV) collagen and B2 chain laminin mRNAs. Relief of the obstruction for 2 weeks resulted in a shift in the serum concentration of 5'-nucleotidase, alkaline phosphatase, and bilirubin toward normal values. A dramatic resorption of bile duct proliferations and periportal fibrosis were observed. Three weeks after bile duct repermeabilization, immunohistochemical study showed that the pattern of distribution of extracellular matrix components was almost normal, except for collagen IV, which remained abundant in the sinusoids when compared with the normal liver. In parallel, the steady-state B2-chain laminin mRNA level became lower than in cholestatic livers, whereas alpha 1(I) and alpha 1(IV) mRNAs were almost undetectable. These results show that hepatic fibrosis induced by experimental extrahepatic cholestasis in rat disappears in less than 3 weeks after relief of bile duct obstruction, suggesting that an active degradation of matrix protein occurs, except for collagen IV in the sinusoid. \n",
      "Generated Text: Reversibility of hepatic fibrosis in experimentally induced cholestasis in rat. The reversibility of hepatic fibrosis was investigated in an experimental model of extrahepatic cholestasis in the rat after common bile duct ligation for 2 weeks, followed by bilioduodenal anastomosis for 3 weeks. Bile duct ligation resulted in a transitory marked increase in the activity of the serum hepatic dehydrogenase system, which returned to normal levels by the end of the experiment. The degree of hepatic fibrosis was determined by the histologic appearance of the liver, and the fibrosis was found to be reversible in the experimental model of cholestasis. The fibrosis was more pronounced in the areas of the liver that were most heavily involved with bile duct ligation. The histologic appearance of the liver after bilioduodenal anastomosis was also normal. These results suggest that the hepatic fibrosis induced by bile duct ligation is reversible.\n",
      "BLEU: 0.13120611725751352, ROUGE-L: {'r': 0.2857142857142857, 'p': 0.684931506849315, 'f': 0.40322580229741156}, Perplexity: 3.607228994369507, Cosine Similarity: 0.8173\n",
      "Reference Text: Current status of duplex Doppler ultrasound in the examination of the abdominal vasculature. Duplex Doppler ultrasound has come to play a central role in the diagnosis of a broad spectrum of vascular diseases such as carotid artery occlusive disease and deep vein thrombosis. The role of duplex Doppler in the evaluation of intra-abdominal vascular disease remains unclear. This article summarizes the current status of duplex scanning in the investigation of the mesenteric arteries, the renal arteries, and the portal venous system. The examination is technically demanding, operator-dependent, time-consuming, and frequently unsatisfactory due to bowel gas, obesity, complex anatomy, or postoperative alterations in the normal anatomic patterns. Its advantages reside primarily in the absence of toxicity and in the generation of physiologic as well as anatomic information. In centers with the proper instrumentation and a skilled technician, duplex examination can be useful in the diagnosis and management of abdominal vascular disease and avoids the inherent dangers of contrast angiography. \n",
      "Generated Text: Current status of duplex Doppler ultrasound in the examination of the abdominal vasculature. Duplex Doppler ultrasound has come to play a central role in the diagnosis of a broad spectrum of vascular diseases such as carotid artery occlusive disease and deep vein thrombosis. The role of duplex Doppler in the evaluation of the abdominal vasculature is less clear. In this review we present the current status of duplex Doppler ultrasound in the evaluation of the abdominal vasculature. The techniques of duplex Doppler ultrasound are presented. The role of duplex Doppler ultrasound in the diagnosis of a broad spectrum of abdominal vascular diseases is reviewed. The use of duplex Doppler ultrasound in the diagnosis of deep vein thrombosis is reviewed. The role of duplex Doppler ultrasound in the evaluation of the abdominal aorta and the renal vessels is reviewed. The role of duplex Doppler ultrasound in the evaluation of the hepatic vessels is reviewed. The use of duplex Doppler ultrasound in the evaluation of the splenic vessels is reviewed. The use of duplex Doppler ultrasound in the evaluation of the renal and mesenteric vessels is reviewed. The use of duplex Doppler ultrasound in the evaluation of the iliac and femoral vessels is reviewed. The use of duplex Doppler ultrasound in the evaluation of the pelvic vessels is reviewed. The use of duplex Doppler ultrasound in the evaluation of the renal and mesenteric vessels is reviewed. The use of duplex Doppler ultrasound in the evaluation of the renal and mesenteric vessels is reviewed. The use of duplex Doppler ultrasound in the evaluation of the renal and mesenteric vessels is reviewed. The use of duplex Doppler ultrasound in the evaluation of the renal and mesenteric vessels is reviewed. The use of duplex Doppler ultrasound in the evaluation of the renal and mesenteric vessels is reviewed. The use of duplex Doppler ultrasound in the evaluation of the renal and mesenteric vessels is reviewed. The use of duplex Doppler ultrasound in the evaluation of the renal and mesenteric vessels is reviewed. The use of duplex Doppler ultrasound in the evaluation of the renal and mesenteric vessels is reviewed. The use of duplex Doppler ultrasound in the evaluation of the renal and mesenteric vessels is reviewed. The use of duplex Doppler ultrasound in the evaluation of the renal and mesenteric vessels is reviewed. The use of duplex Doppler ultrasound in the evaluation of the renal and mesenteric vessels is reviewed. The use of duplex\n",
      "BLEU: 0.15846415172071285, ROUGE-L: {'r': 0.4020618556701031, 'p': 0.6610169491525424, 'f': 0.49999999529668}, Perplexity: 1.6018441915512085, Cosine Similarity: 0.8279\n",
      "Reference Text: The importance of congenital hypertrophy of the retinal pigment epithelium in familial adenomatous polyposis. We describe a family with familial adenomatous polyposis (FAP) and congenital hypertrophy of the retinal pigment epithelium (RPE). Three of five members with FAP showed flat, well-demarcated, round to oval pigmented patches of congenital hypertrophy of the RPE. We stress the importance of congenital hypertrophy of the RPE as a clinical marker in identifying patients with FAP since they are at risk for cancer. \n",
      "Generated Text: The importance of congenital hypertrophy of the retinal pigment epithelium in familial adenomatous polyposis. We describe a family with familial adenomatous polyposis (FAP) and congenital hypertrophy of the retinal pigment epithelium (RPE). Three of five members with FAP showed flat, well-demarcated, round to oval pigmented patches of congenital hypertrophy of the RPE. The pigmented patches were not associated with any other pigmentary abnormalities. All three affected members with FAP and congenital hypertrophy of the RPE had adenomatous polyposis of the colon and ileum. The congenital hypertrophy of the RPE in the affected members with FAP was associated with the presence of adenomatous polyposis in the colon and ileum. This suggests that the pigmented patches of congenital hypertrophy of the RPE are a manifestation of the adenomatous polyposis of the colon and ileum in this family. The pigmented patches of congenital hypertrophy of the RPE may be a useful marker for the presence of adenomatous polyposis in patients with FAP.\n",
      "Congenital hypertrophy of the retinal pigment epithelium in familial adenomatous polyposis. We describe a family with familial adenomatous polyposis (FAP) and congenital hypertrophy of the retinal pigment epithelium (RPE). Three of five members with FAP showed flat, well-demarcated, round to oval pigmented patches of congenital hypertrophy of the RPE. The pigmented patches were not associated with any other pigmentary abnormalities. All three affected members with FAP and congenital hypertrophy of the RPE had adenomatous polyposis of the colon and ileum. The congenital hypertrophy of the RPE in the affected members with FAP was associated with the presence of adenomatous polyposis in the colon and ileum. This suggests that the pigmented patches of congenital hypertrophy of the RPE are a manifestation of the adenomatous polyposis of the colon and ileum in this family. The pigmented patches of congenital hypertrophy of the RPE may be a useful marker for the presence of adenomatous polyposis in patients with FAP.\n",
      "BLEU: 0.18401309037638086, ROUGE-L: {'r': 0.75, 'p': 0.5806451612903226, 'f': 0.6545454496264465}, Perplexity: 1.6840178966522217, Cosine Similarity: 0.8976\n",
      "Reference Text: Human papillomavirus in women with vulvar intraepithelial neoplasia III. Untreated cases of vulvar intraepithelial neoplasia (VIN) III may progress to invasive vulvar carcinoma. Tissues from 29 New Zealand women with VIN III were examined for the presence of human papillomavirus (HPV) types 6, 11, 16 and 18 by in situ hybridization and polymerase chain reaction. HPV 16, the only HPV type detected in the lesions, was identified in about half the cases. HPV-positive women were younger than HPV-negative women, and their lesions displayed koilocytosis more often. In four of five cases in which there was a progression to invasive cancer, HPV 16 was detected in both the VIN III and invasive cancer tissue. \n",
      "Generated Text: Human papillomavirus in women with vulvar intraepithelial neoplasia III. Untreated cases of vulvar intraepithelial neoplasia (VIN) III may progress to invasive vulvar carcinoma. Tissues from 29 New Zealand women with VIN III were examined for the presence of human papillomavirus (HPV) types 6, 11, 16 and 18 by in situ hybridization (ISH) and/or PCR. HPV DNA was detected in 10 of 29 (34.5%) cases, and 9 of 10 (90%) of the HPV-positive cases were HPV types 6 and 11. HPV was detected in 11 of 29 (37.9%) cases by ISH, and in 5 of 10 (50%) of the HPV-positive cases. HPV DNA was detected in 2 of 29 (6.9%) cases by PCR, and in 2 of 10 (20%) of the HPV-positive cases. These results indicate that HPV is present in VIN III cases and may be involved in the progression of VIN III to invasive vulvar carcinoma.\n",
      "BLEU: 0.39357014130599843, ROUGE-L: {'r': 0.5789473684210527, 'p': 0.5945945945945946, 'f': 0.5866666616675557}, Perplexity: 2.577687978744507, Cosine Similarity: 0.8147\n",
      "Reference Text: Gentamicin iontophoresis in the treatment of bacterial otitis externa in the guinea pig model. Pseudomonas otitis externa is one of the most common infections treated by otolaryngologists. Infections induced in 30 guinea pigs appeared similar to that seen in humans. The ears were then placed into four treatment groups: group A, which received a single cleaning; group B, which received a single cleaning followed by gentamicin drops 4 times daily; group C, which received a single cleaning followed by a single gentamicin iontophoresis treatment; and group D, the control group, which received no treatment. Infections were analyzed by grading edema, purulence, and erythema. An average of 10.2 days was required for control group to return to normal appearance. Groups A, B, and C had mean resolution times of 5.9, 4.7, and 4.3 days, respectively. Gentamicin iontophoresis appears to be promising, with results as good as drop therapy in otitis externa in the guinea pig model. \n",
      "Generated Text: Gentamicin iontophoresis in the treatment of bacterial otitis externa in the guinea pig model. Pseudomonas otitis externa is one of the most common infections treated by otolaryngologists. Infections induced in 30 guinea pigs appeared similar to that seen in humans. The ears were then placed into four treatment groups: group 1, gentamicin iontophoresis with a 30-minute pulse; group 2, gentamicin iontophoresis with a 60-minute pulse; group 3, gentamicin iontophoresis with a 120-minute pulse; and group 4, no treatment. The results were compared with those of a control group of untreated animals. The results of the 120-minute pulse group were similar to those of the control group. The results of the 60-minute pulse group were similar to those of the 120-minute pulse group. The results of the 30-minute pulse group were similar to those of the untreated group. The results of the 30-minute pulse group were similar to those of the untreated group. These results suggest that gentamicin iontophoresis is a useful treatment for bacterial otitis externa.\n",
      "BLEU: 0.338597787077922, ROUGE-L: {'r': 0.4897959183673469, 'p': 0.75, 'f': 0.5925925878128334}, Perplexity: 2.8952486515045166, Cosine Similarity: 0.6538\n",
      "Reference Text: Repeat hepatic resection for primary and metastatic carcinoma of the liver. During the last 15 years, 19 patients underwent repeated hepatic resections for malignant lesions of the liver. The first hepatic resection had been performed four to 40 months earlier for treatment of hepatocellular carcinoma (nine patients) or hepatic metastases (ten patients), eight of which were of colorectal origin. Repeat resection was an extensive hepatectomy in six, a segmentectomy in six and a local excision in seven. In one patient, three wedge resections and, finally, hepatic transplantation were subsequently performed after an initial extended right lobectomy. The operative mortality rate was 5.2 per cent. The three year actuarial survival rate was 64 per cent after the second resection. \n",
      "Generated Text: Repeat hepatic resection for primary and metastatic carcinoma of the liver. During the last 15 years, 19 patients underwent repeated hepatic resections for malignant lesions of the liver. The first hepatic resection had been performed four to 40 months earlier for treatment of hepatocellular carcinoma (nine patients) or hepatic metastases (10 patients). The second hepatic resection was performed for recurrent hepatocellular carcinoma (five patients) or hepatic metastases (four patients). The third and fourth hepatic resections were performed for recurrent hepatocellular carcinoma (three patients) or hepatic metastases (three patients). The fifth hepatic resection was performed for recurrent hepatocellular carcinoma (one patient) or hepatic metastases (one patient). The sixth hepatic resection was performed for recurrent hepatocellular carcinoma (one patient). The seventh hepatic resection was performed for recurrent hepatocellular carcinoma (one patient) or hepatic metastases (one patient). The eighth hepatic resection was performed for recurrent hepatocellular carcinoma (one patient) or hepatic metastases (one patient). The ninth hepatic resection was performed for recurrent hepatocellular carcinoma (one patient) or hepatic metastases (one patient). The tenth hepatic resection was performed for recurrent hepatocellular carcinoma (one patient) or hepatic metastases (one patient). The eleventh hepatic resection was performed for recurrent hepatocellular carcinoma (one patient). The twelfth hepatic resection was performed for recurrent hepatocellular carcinoma (one patient) or hepatic metastases (one patient). The thirteenth hepatic resection was performed for recurrent hepatocellular carcinoma (one patient). The fourteenth hepatic resection was performed for recurrent hepatocellular carcinoma (one patient) or hepatic metastases (one patient). The fifteenth hepatic resection was performed for recurrent hepatocellular carcinoma (one patient) or hepatic metastases (one patient). The sixteenth hepatic resection was performed for recurrent hepatocellular carcinoma (one patient) or hepatic metastases (one patient). The seventeenth hepatic resection was performed for recurrent hepatocellular carcinoma (one patient). The eighteenth hepatic resection was performed for recurrent hepatocellular carcinoma (one patient). The nineteenth hepatic resection was performed for recurrent hepatocellular carcinoma (one patient). The twenty-first hepatic resection was performed for\n",
      "BLEU: 0.16146129684854485, ROUGE-L: {'r': 0.4880952380952381, 'p': 0.6212121212121212, 'f': 0.5466666617386667}, Perplexity: 1.4362879991531372, Cosine Similarity: 0.6165\n",
      "Reference Text: Evidence for intraluminal Ca++ regulatory site defect in sarcoplasmic reticulum from malignant hyperthermia pig muscle. Malignant hyperthermia (MH) is a pharmacogenetic disease of humans and various animal species that predisposes to a life-threatening, anesthetic agent-induced syndrome. MH is thought to be a consequence of abnormal, sustained increases in myoplasmic Ca++ and sarcoplasmic reticulum (SR) membranes from MH muscle have been shown to have a Ca++ release channel defect. In the present study we have tested a hypothesis that the abnormal Ca++ release mechanism in MH can be expressed when Ca++ is loaded in the presence of pyrophosphate. SR membrane vesicles isolated from normal and MH pig muscle were loaded with Ca++ in the presence and absence of pyrophosphate until Ca(++)-induced Ca++ release occurred. Under both circumstances the threshold amount of Ca++ loaded until Ca++ release occurred was lower in the SR from MH pig skeletal muscle. This difference in amount of Ca++ preload is not explained by results obtained comparing rates of Ca++ uptake, number of ryanodine binding sites or the amounts of calsequestrin among SR vesicles from MH and normal muscle. We conclude from this study that use of pyrophosphate for Ca++ loading does not ablate the abnormal Ca++ release in SR from MH muscle, suggesting the study can be done on small amounts of SR from biopsied human muscle. The data also suggest that abnormality in an intraluminal, low affinity Ca++ binding site regulating Ca++ release occurs in the SR membrane of MH pig muscle. \n",
      "Generated Text: Evidence for intraluminal Ca++ regulatory site defect in sarcoplasmic reticulum from malignant hyperthermia pig muscle. Malignant hyperthermia (MH) is a pharmacogenetic disease of humans and various animal species that predisposes to a life-threatening, anesthetic agent-induced syndrome. MH is thought to be a consequence of abnormal, sustained increases in myoplasmic Ca++ concentration. The present study was designed to investigate the nature of the intraluminal Ca++ regulatory site defect in sarcoplasmic reticulum (SR) from MH pigs. The SR from MH pigs was compared with SR from control pigs in terms of Ca++ regulatory properties. The SR from MH pigs exhibited a defect in the Ca++ regulatory properties of SR. The SR from MH pigs exhibited a defect in the Ca++ regulatory properties of SR. The SR from MH pigs exhibited a defect in the Ca++ regulatory properties of SR. The SR from MH pigs exhibited a defect in the Ca++ regulatory properties of SR. The SR from MH pigs exhibited a defect in the Ca++ regulatory properties of SR. The SR from MH pigs exhibited a defect in the Ca++ regulatory properties of SR. The SR from MH pigs exhibited a defect in the Ca++ regulatory properties of SR. The SR from MH pigs exhibited a defect in the Ca++ regulatory properties of SR. The SR from MH pigs exhibited a defect in the Ca++ regulatory properties of SR. The SR from MH pigs exhibited a defect in the Ca++ regulatory properties of SR. The SR from MH pigs exhibited a defect in the Ca++ regulatory properties of SR. The SR from MH pigs exhibited a defect in the Ca++ regulatory properties of SR. The SR from MH pigs exhibited a defect in the Ca++ regulatory properties of SR. The SR from MH pigs exhibited a defect in the Ca++ regulatory properties of SR. The SR from MH pigs exhibited a defect in the Ca++ regulatory properties of SR. The SR from MH pigs exhibited a defect in the Ca++ regulatory properties of SR. The SR from MH pigs exhibited a defect in the Ca++ regulatory properties of SR. The SR from MH pigs exhibited a defect in the Ca++ regulatory properties of SR. The SR from MH pigs exhibited a defect in the Ca++ regulatory properties of SR. The SR from MH pigs exhibited a defect in the Ca++ regulatory properties of SR. The SR from MH pigs exhibited a defect in the Ca++ regulatory properties of SR. The SR from MH\n",
      "BLEU: 0.16094815123728626, ROUGE-L: {'r': 0.3828125, 'p': 0.8166666666666667, 'f': 0.5212765913988231}, Perplexity: 1.7767579555511475, Cosine Similarity: 0.6815\n",
      "Reference Text: Glutamic acid and gamma-aminobutyric acid neurotransmitters in central control of breathing. We review recent cross-disciplinary experimental and theoretical investigations on metabolism of the amino acid neurotransmitters glutamic acid and gamma-aminobutyric acid (GABA) in the brain during hypoxia and hypercapnia and their possible role in central control of breathing. The roles of classical modifiers of central chemical drive to breathing (H+ and cholinergic mechanisms) are summarized. A brief perspective on the current widespread interest in GABA and glutamate in central control is given. The basic biochemistry of these amino acids and their roles in ammonia and bicarbonate metabolism are discussed. This review further addresses recent work on central respiratory effects of inhibitory GABA and excitatory glutamate. Current understanding of the sites and mechanisms of action of these amino acids on or near the ventral surface of the medulla is reviewed. We focus particularly on tracer kinetic investigations of glutamatergic and GABAergic mechanisms in hypoxia and hypercapnia and their possible role in the ventilatory response to hypoxia. We conclude with some speculative remarks on the critical importance of these investigations and suggest specific directions of research in central mechanisms of respiratory control. \n",
      "Generated Text: Glutamic acid and gamma-aminobutyric acid neurotransmitters in central control of breathing. We review recent cross-disciplinary experimental and theoretical investigations on metabolism of the amino acid neurotransmitters glutamic acid and gamma-aminobutyric acid (GABA) in the brain during hypoxia and hypercapnia and their possible role in central control of breathing. The roles of these neurotransmitters in central control of breathing are discussed in the context of the brain's oxygen and carbon dioxide chemoreceptor systems and the central neural pathways involved in the control of breathing.\n",
      "BLEU: 0.18572287956710112, ROUGE-L: {'r': 0.35714285714285715, 'p': 0.7777777777777778, 'f': 0.48951048519732027}, Perplexity: 4.976823806762695, Cosine Similarity: 0.8766\n",
      "Reference Text: A useful technique for measurement of back strength in osteoporotic and elderly patients. Improvement of back extensor strength (BES) can be used as a therapeutic method for patients with chronic back pain and osteoporosis. The method of evaluation must be reliable and accurate without compromising the condition of the patient. We report the development of a back isometric dynamometer (BID-2000) designed specifically by two of us to address these concerns in elderly patients with osteopenia or osteoporosis. As the demographics of the general population change, increasing numbers of patients will need the type of monitoring that the BID-2000 provides. Aging has been shown to cause a reduction in the number of functional muscle motor units. To examine this effect on BES, we tested 50 normal, healthy women who were 30 to 79 years old. Proper testing of BES in patients with fragile vertebrae should include isometric measurement in the prone position, maneuverability of the device to allow comfortable positioning of the patient, and simplicity of technique to minimize repetitious performance of maximal contraction. The BID-2000 incorporates each of these features and also provides meaningful results inexpensively. The device offers a safe, reliable (coefficient of variation = 2.33%), and valid (P = 0.001) method of evaluation. The results of our study demonstrated moderate, steady reduction of BES with increasing age and with each successive decade. \n",
      "Generated Text: A useful technique for measurement of back strength in osteoporotic and elderly patients. Improvement of back extensor strength (BES) can be used as a therapeutic method for patients with chronic back pain and osteoporosis. The method of evaluation must be reliable and accurate without compromising the condition of the patient. The BES test is a reliable method for evaluating the back extensor strength in osteoporotic patients. The test is simple and can be performed in the clinic or at home. The test consists of the patient lying on his or her back on a table with a seat belt and a backrest. The test is repeated three times with 2-min rest between each trial. The test is performed by the examiner who holds the patient's body in a sitting position with the backrest. The patient is instructed to extend the back and to perform three repetitions of this exercise. The test is performed by the examiner who holds the patient's body in a sitting position with the backrest. The patient is instructed to extend the back and to perform three repetitions of this exercise. The test is performed by the examiner who holds the patient's body in a sitting position with the backrest. The patient is instructed to extend the back and to perform three repetitions of this exercise. The test is performed by the examiner who holds the patient's body in a sitting position with the backrest. The patient is instructed to extend the back and to perform three repetitions of this exercise. The test is performed by the examiner who holds the patient's body in a sitting position with the backrest. The patient is instructed to extend the back and to perform three repetitions of this exercise. The test is performed by the examiner who holds the patient's body in a sitting position with the backrest. The patient is instructed to extend the back and to perform three repetitions of this exercise. The test is performed by the examiner who holds the patient's body in a sitting position with the backrest. The patient is instructed to extend the back and to perform three repetitions of this exercise. The test is performed by the examiner who holds the patient's body in a sitting position with the backrest. The patient is instructed to extend the back and to perform three repetitions of this exercise. The test is performed by the examiner who holds the patient's body in a sitting position with the backrest. The patient is instructed to extend the back and to perform three repetitions of this exercise. The test is performed by the examiner who holds the patient's\n",
      "BLEU: 0.13347784143104732, ROUGE-L: {'r': 0.30344827586206896, 'p': 0.5569620253164557, 'f': 0.39285713829121494}, Perplexity: 1.9529106616973877, Cosine Similarity: 0.6275\n",
      "Reference Text: The natural history of ultraviolet radiation-induced herpes simplex labialis and response to therapy with peroral and topical formulations of acyclovir. The lips of 196 patients with a history of sun-induced herpes labialis were exposed to experimental ultraviolet radiation (UVR) and treated with acyclovir (ACV) or placebo at different times and by different routes. Of 98 placebo recipients, 39 (40%) developed 43 lesions inside or within 10 mm of the irradiated zone. The temporal distribution of lesions was bimodal. 11 (26%) occurring within 48 h (immediate) and 32 (72%) 2-7 days after UVR exposure (delayed). Prophylactic peroral ACV begun 7 days before or 5 min after UVR prevented the development of the delayed but not the immediate lesions (P less than .001). When peroral ACV was started 48 h after UVR, delayed lesions developed but were less severe (P = .01-.05). Prophylactic topical ACV begun 5 min after UVR did not reduce lesion frequency or severity. ACV therapy can be efficacious, but some rapidly developing lesions are unresponsive to treatment. This suggests that more than one process may contribute to the pathogenesis of herpes labialis. \n",
      "Generated Text: The natural history of ultraviolet radiation-induced herpes simplex labialis and response to therapy with peroral and topical formulations of acyclovir. The lips of 196 patients with a history of sun-induced herpes labialis were exposed to experimental ultraviolet radiation (UVR) and treated with acyclovir (ACV) or placebo at different times and dosages. The natural history of UVR-induced labial lesions and the response to ACV and placebo were evaluated. The mean number of lesions was 2.5 +/- 1.0. UVR induced lesions occurred at the same sites as the initial lesions. The lesions healed with a mean time of 6.8 +/- 2.7 days. The lesions appeared 1 to 3 days after UVR exposure and healed 7.3 +/- 2.2 days later. The mean number of lesions at the end of the 4-week study was 2.0 +/- 1.0. The mean time from the start of therapy to the end of therapy was 6.2 +/- 2.0 days. The lesions healed with a mean time of 8.4 +/- 2.0 days. The response to ACV was significantly better than that to placebo (P less than.001). The response to ACV was significantly better than that to placebo (P less than.001). The response to ACV was significantly better than that to placebo (P less than.001). The response to ACV was significantly better than that to placebo (P less than.001). The response to ACV was significantly better than that to placebo (P less than.001). The response to ACV was significantly better than that to placebo (P less than.001). The response to ACV was significantly better than that to placebo (P less than.001). The response to ACV was significantly better than that to placebo (P less than.001). The response to ACV was significantly better than that to placebo (P less than.001). The response to ACV was significantly better than that to placebo (P less than.001). The response to ACV was significantly better than that to placebo (P less than.001). The response to ACV was significantly better than that to placebo (P less than.001). The response to ACV was significantly better than that to placebo (P less than.001). The response to ACV was significantly better than that to placebo\n",
      "BLEU: 0.1686577877627209, ROUGE-L: {'r': 0.4152542372881356, 'p': 0.6049382716049383, 'f': 0.4924623067306382}, Perplexity: 2.1049556732177734, Cosine Similarity: 0.5887\n",
      "Reference Text: Hereditary internal anal sphincter myopathy causing proctalgia fugax and constipation. A newly identified condition. A newly identified myopathy of the internal anal sphincter is described. In the affected family, at least one member from each of five generations had severe proctalgia fugax; onset was usually in the third to fifth decades of life. Three members of the family have been studied in detail. Each had severe pain intermittently during the day and hourly during the night. Constipation was an associated symptom, in particular difficulty with rectal evacuation. Clinically the internal anal sphincter was thickened and of decreased compliance. The maximum anal canal pressure was usually increased with marked ultraslow wave activity. Anal endosonography confirmed a grossly thickened internal anal sphincter. Two patients were treated by internal anal sphincter strip myectomy; one showed marked improvement and one was relieved of the constipation but had only slight improvement of the pain. The hypertrophied muscle in two of the patients showed unique myopathic changes, consisting of vacuolar changes with periodic acid-Schiff-positive polyglycosan bodies in the smooth muscle fibers and increased endomysial fibrosis. In vitro organ-bath studies showed insensitivity of the muscle to noradrenaline, isoprenaline, carbachol, dimethylpiperazinium, and electrical-field stimulation. Immunohistochemical studies for substance P, calcitonin gene-related peptide, galanin, neuropeptide Y, and vasoactive intestinal peptide showed staining in a similar distribution to that in control tissue. A specific autosomal-dominant inherited myopathy of the internal anal sphincter that causes anal pain and constipation has been identified and characterized. \n",
      "Generated Text: Hereditary internal anal sphincter myopathy causing proctalgia fugax and constipation. A newly identified condition. A newly identified myopathy of the internal anal sphincter is described. In the affected family, at least one member from each of five generations had severe proctalgia fugax; onset was usually in the third to fifth decade. Rectal prolapse was present in two members of the fifth generation. The condition is characterized by severe constipation, proctalgia fugax, and rectal prolapse. It is not known whether the internal anal sphincter myopathy is the cause of the proctalgia or whether the constipation is a manifestation of the myopathy. The myopathy is characterized by a failure of the myofibers of the internal anal sphincter to undergo hypertrophy. The myopathy is inherited as an autosomal dominant trait. The myofibers of the internal anal sphincter are the only sphincter muscle to undergo hypertrophy in this disease. The myopathy is not associated with other abnormalities of the internal anal sphincter. The myopathy is not a form of achalasia. The myopathy is not associated with other myopathies. The myopathy is not associated with other abnormalities of the sphincter musculature. The myopathy is not a form of amyloidosis. The myopathy is not a form of collagen disease. The myopathy is not associated with other myopathies. The myopathy is not associated with other abnormalities of the internal anal sphincter. The myopathy is not associated with other myopathies. The myopathy is not associated with other abnormalities of the sphincter musculature. The myopathy is not a form of amyloidosis. The myopathy is not associated with other myopathies. The myopathy is not associated with other abnormalities of the internal anal sphincter. The myopathy is not associated with other myopathies. The myopathy is not associated with other abnormalities of the sphincter musculature. The myopathy is not a form of amyloidosis. The myopathy is not associated with other myopathies. The myopathy is not associated with other abnormalities of the internal anal sphincter. The myopathy is not associated with other myopathies. The myopathy is not associated with other abnormalities of the sphincter musculature. The myopathy is not a form\n",
      "BLEU: 0.19505484452638588, ROUGE-L: {'r': 0.34459459459459457, 'p': 0.6, 'f': 0.4377682357088913}, Perplexity: 2.197352409362793, Cosine Similarity: 0.6126\n",
      "Reference Text: Immune response of peripheral blood mononuclear cells to HBx-antigen of hepatitis B virus. The hepatitis B virus genome encodes a transcriptional transactivator protein designated HBxAg. We have investigated whether this antigen is a target structure for human T-lymphocytes. Using recombinant HBxAg protein, we found HBxAg-specific stimulation of peripheral blood mononuclear cells in patients with acute hepatitis B virus infection (6 of 6) and chronic hepatitis B virus infection (6 of 17) but not in healthy individuals. With HBxAg-specific synthetic polypeptides, several T-cell epitopes were identified. Most were located in the carboxyterminal half of the HBxAg protein. Five T-cell clones specific for a T-cell epitope located at the carboxyterminal region of HBxAg were established and found to belong to the CD2/CD4-positive, CD8-negative subtype. These data establish for the first time HBxAg as an antigen in the cellular immune response. \n",
      "Generated Text: Immune response of peripheral blood mononuclear cells to HBx-antigen of hepatitis B virus. The hepatitis B virus genome encodes a transcriptional transactivator protein designated HBxAg. We have investigated whether this antigen is a target structure for human T-lymphocytes. Using recombinant HBxAg protein, we found HBxAg-specific stimulation of peripheral blood mononuclear cells (PBMCs) from healthy carriers of the hepatitis B virus. This response was shown to be specific for HBxAg, since it was not induced by the hepatitis B virus surface antigen (HBsAg) or by the hepatitis B virus core antigen (HBcAg). This HBxAg-specific stimulation was not observed in PBMCs from patients with chronic hepatitis B. The T-cell proliferation induced by HBxAg was inhibited by anti-CD3 monoclonal antibody, and the inhibition was dose-dependent. The HBxAg-specific T-cell proliferation was inhibited by the anti-HBxAg monoclonal antibody 6H4, but not by anti-HBsAg monoclonal antibody 2H6. The HBxAg-specific T-cell proliferation was also inhibited by the anti-CD3 monoclonal antibody OKT3, and by the anti-CD8 monoclonal antibody 2.4G2. The HBxAg-specific T-cell proliferation was also inhibited by anti-CD4 monoclonal antibody 11B11. The HBxAg-specific T-cell proliferation was not inhibited by anti-CD8 monoclonal antibody 2.4G2, anti-CD4 monoclonal antibody 11B11, or anti-CD3 monoclonal antibody OKT3. The HBxAg-specific T-cell proliferation was not inhibited by the anti-CD8 monoclonal antibody 2.4G2. The HBxAg-specific T-cell proliferation was not inhibited by the anti-CD4 monoclonal antibody 11B11. The HBxAg-specific T-cell proliferation was not inhibited by the anti-CD8 monoclonal antibody 2.4G2. The HBxAg-specific T-cell proliferation was not inhibited by the anti-CD4 monoclonal antibody 11B11. The HBxAg-specific T-cell proliferation was not inhibited by the anti-CD8 monoclonal antibody 2.4G2. The HBxAg-specific T-cell proliferation was not inhibited by the anti-\n",
      "BLEU: 0.21930540042442875, ROUGE-L: {'r': 0.5681818181818182, 'p': 0.5376344086021505, 'f': 0.5524861828491194}, Perplexity: 2.058969736099243, Cosine Similarity: 0.5310\n",
      "Reference Text: Expression of neural cell adhesion molecule in normal and neoplastic human neuroendocrine tissues. The neural cell adhesion molecule (N-CAM) is a group of cell surface glycoproteins involved in direct cell--cell adhesion. N-CAM expression in normal and neoplastic tissues was examined with specific antibodies and oligonucleotide probes by immunohistochemistry and in situ hybridization. Most neuroendocrine cells and tumors with secretory granules expressed N-CAM protein and mRNA. Parathyroid adenomas (4) were somewhat unusual, because N-CAM mRNA, but not protein, was detected in some of these benign neoplasms. Most non-neuroendocrine cells and tumors did not express N-CAM, although uterine smooth muscle and an adrenal cortical carcinoma were both positive. Western blots disclosed proteins of 180, 140, and 120 kd in normal adult brain, whereas two pheochromocytomas, a null cell adenoma, and a gastrinoma had proteins of approximately 180 and 140 kd. These results indicate that N-CAM protein and mRNA are widely expressed in neuroendocrine cells and neoplasms. N-CAM oligonucleotide probes as well as antibodies against N-CAM can be used as broad-spectrum neuroendocrine markers. In addition, these molecular probes can be used to examine the role of N-CAM in the development and regulation of neuroendocrine tissues. \n",
      "Generated Text: Expression of neural cell adhesion molecule in normal and neoplastic human neuroendocrine tissues. The neural cell adhesion molecule (N-CAM) is a group of cell surface glycoproteins involved in direct cell--cell adhesion. N-CAM expression in normal and neoplastic tissues was examined with specific antibodies and oligonucleotide probes by immunohistochemistry and in situ hybridization. N-CAM was expressed in the normal human endocrine pancreas, duodenum, and colon. In the normal human endocrine pancreas, N-CAM was expressed in the islets and ductal epithelium. In the normal human endocrine pancreas, N-CAM was expressed in the islets and ductal epithelium. N-CAM was also expressed in the normal human endocrine pancreas, duodenum, and colon. N-CAM was expressed in the normal human endocrine pancreas, duodenum, and colon. N-CAM was expressed in the normal human endocrine pancreas, duodenum, and colon. N-CAM was expressed in the normal human endocrine pancreas, duodenum, and colon. N-CAM was expressed in the normal human endocrine pancreas, duodenum, and colon. N-CAM was expressed in the normal human endocrine pancreas, duodenum, and colon. N-CAM was expressed in the normal human endocrine pancreas, duodenum, and colon. N-CAM was expressed in the normal human endocrine pancreas, duodenum, and colon. N-CAM was expressed in the normal human endocrine pancreas, duodenum, and colon. N-CAM was expressed in the normal human endocrine pancreas, duodenum, and colon. N-CAM was expressed in the normal human endocrine pancreas, duodenum, and colon. N-CAM was expressed in the normal human endocrine pancreas, duodenum, and colon. N-CAM was expressed in the normal human endocrine pancreas, duodenum, and colon. N-CAM was expressed in the normal human endocrine pancreas, duodenum, and colon. N-CAM was expressed in the normal human endocrine pancreas, duodenum, and colon. N-CAM was expressed in the normal human endocrine pancreas, duodenum, and colon. N-CAM was expressed in the normal human\n",
      "BLEU: 0.19348378004948474, ROUGE-L: {'r': 0.3305084745762712, 'p': 0.8297872340425532, 'f': 0.4727272686530763}, Perplexity: 1.4588900804519653, Cosine Similarity: 0.5559\n",
      "Reference Text: Genetics of cerebrovascular disease. Stroke is a complex disease, with both genetic and environmental factors having a role in its pathogenesis. A review of past studies shows some evidence of genetic influences in the development of stroke. This is supported by studies of cardiovascular disease, which indicate major genetic influences at several levels including the development of risk factors. New approaches to phenotypic classifications, patient ascertainment, and genetic analysis will stimulate research into the role of genetics in cerebrovascular disease. \n",
      "Generated Text: Genetics of cerebrovascular disease. Stroke is a complex disease, with both genetic and environmental factors having a role in its pathogenesis. A review of past studies shows some evidence of genetic influences in the development of stroke. This is supported by studies of cardiovascular disease, which indicate major genetic influences on the risk of developing stroke. In addition, some studies suggest that genetic influences on the risk of stroke are also present in the risk of developing other forms of vascular disease. These studies suggest that the genetics of stroke are complex and that the genetic factors influencing the development of stroke may be different from those that influence the risk of developing other forms of vascular disease.\n",
      "BLEU: 0.4441120557823501, ROUGE-L: {'r': 0.6842105263157895, 'p': 0.65, 'f': 0.6666666616699541}, Perplexity: 4.956523418426514, Cosine Similarity: 0.8324\n",
      "Reference Text: Appraisal of gut lavage in the study of intestinal humoral immunity. Direct investigation of intestinal humoral immunity requires collection of intestinal secretions or mucosal biopsy specimens, or both. A non-invasive technique of gut lavage, with a polyethyleneglycol electrolyte lavage solution as a means of collecting intestinal secretions for immunoglobulin and antibody studies, was evaluated. Fifty patients were studied--25 immunologically normal patients or volunteers, 15 patients with untreated coeliac disease, and 10 patients with active Crohn's disease. Protease inhibitors were added promptly to samples to prevent proteolysis of immunoglobulin content. Treated lavage samples were assayed by enzyme linked immunosorbent assay for immunoglobulin and antibody content. Studies of serial lavage specimens showed that early, faecally contaminated specimens contained negligible quantities of immunoglobulin, but once the specimens became clear a steady state was reached, with little variation in immunoglobulin content between serial specimens and with a uniform dilution (around 20%) of the ingested polyethyleneglycol. Gut lavage fluid IgA was predominantly secretory, comprising 92%, 81.6%, and 76.7% respectively of the total IgA gut lavage fluid content in the control, coeliac, and Crohn's groups. High values of total IgM and IgA and IgM antigliadin antibodies were detected in the coeliac group, and high values of IgG in the Crohn's disease group. This method of gut lavage is not only an effective bowel cleanser, but also a noninvasive means of obtaining intestinal secretions for the study of humoral immunity in gastrointestinal disease. \n",
      "Generated Text: Appraisal of gut lavage in the study of intestinal humoral immunity. Direct investigation of intestinal humoral immunity requires collection of intestinal secretions or mucosal biopsy specimens, or both. A non-invasive technique of gut lavage, with a polyethyleneglycol electrolyte lavage solution as a means of collecting intestinal secretions for immunoglobulin and immunoreactive substance P studies, was evaluated in 16 patients with suspected small bowel disease. The lavage fluid was examined for the presence of immunoglobulin and immunoreactive substance P. The results of the study were compared with those of histologic examination and with those of other intestinal secretions and mucosal biopsy specimens. The lavage fluid was positive for immunoglobulin in 11 of 16 patients. Immunoreactive substance P was positive in 4 of 5 patients with small bowel disease and in 1 of 5 patients with other gastrointestinal disease. The lavage fluid was positive for immunoglobulin in 5 of 5 patients with small bowel disease. The positive results of the lavage fluid were confirmed by histologic examination in 1 of 5 patients with small bowel disease. The positive results of the lavage fluid were confirmed by mucosal biopsy in 1 of 5 patients with small bowel disease. The positive results of the lavage fluid were not confirmed by histologic examination in 3 of 5 patients with small bowel disease. The positive results of the lavage fluid were not confirmed by mucosal biopsy in 1 of 5 patients with small bowel disease. In 6 of 16 patients with suspected small bowel disease, the results of the lavage fluid were negative for immunoglobulin and immunoreactive substance P. In 2 of 6 patients, the results of the lavage fluid were negative for immunoglobulin and immunoreactive substance P. In 2 of 6 patients, the results of the lavage fluid were negative for immunoglobulin and immunoreactive substance P. The results of the lavage fluid were not confirmed by histologic examination in 2 of 6 patients with small bowel disease. The results of the lavage fluid were not confirmed by mucosal biopsy in 2 of 6 patients with small bowel disease. In 2 of 6 patients with small bowel disease, the results of the lavage fluid were negative for immunoglobulin and immunoreactive substance P. The results of the lavage fluid were not\n",
      "BLEU: 0.1737324313100881, ROUGE-L: {'r': 0.34306569343065696, 'p': 0.618421052631579, 'f': 0.44131454940069215}, Perplexity: 2.2014124393463135, Cosine Similarity: 0.7643\n",
      "Reference Text: Subsite distribution and incidence of colorectal cancer in New Zealand, 1974-1983. The purpose of this study was to examine changes in subsite distribution and incidence of colorectal cancer within different age groups. Registration of colorectal cancer by the National Cancer Registry of New Zealand approached 100 percent by 1974. The present study was based on 15,395 individuals aged 25 years and over and registered for colorectal cancer between 1974 and 1983. Subsite distribution (right colon, left colon, rectum) for different age groups (25-49, 50-69, 70+ years) was significantly skewed, with an excess of right colonic cancer in individuals aged 25-49 years and 70+ years. This right colonic excess was accompanied by a relative reduction in left colonic cancer. Age adjusted incidence rates for the periods 1974-78 and 1979-83 were compared and stratified by age group and subsite. Incidence rates increased in all subsites in individuals aged 50+ years. This was particularly evident for right sided cancer in the elderly of both sexes. There was a marked reduction in the incidence of left colonic cancer and rectal cancer in individuals under 50 years. In contrast, the incidence of right colonic cancer remained relatively stable in young individuals. Time trend studies indicate that the skewed subsite distribution of large bowel cancer in different age groups may increase with time and is probably due to varying etiological factors acting on different cohorts. \n",
      "Generated Text: Subsite distribution and incidence of colorectal cancer in New Zealand, 1974-1983. The purpose of this study was to examine changes in subsite distribution and incidence of colorectal cancer within different age groups. Registration of colorectal cancer by the National Cancer Registry of New Zealand approached 100 percent by 1974. The subsite distribution and incidence of colorectal cancer were examined by age groups. The subsite distribution was examined for the period 1974-1978 and the incidence of colorectal cancer was examined for the period 1979-1983. There was a slight increase in the incidence of colorectal cancer in the 40-49-year-old age group from 1979 to 1983. There was also a slight increase in the incidence of colorectal cancer in the 50-59-year-old age group from 1979 to 1983. The subsite distribution in the 60-69-year-old age group remained the same. There was a slight increase in the incidence of colorectal cancer in the 70-79-year-old age group from 1979 to 1983. The subsite distribution in the 80-89-year-old age group remained the same. The incidence of colorectal cancer in the 90-year-old age group remained the same. The incidence of colorectal cancer in the 80-89-year-old age group remained the same. The incidence of colorectal cancer in the 90-year-old age group remained the same. The incidence of colorectal cancer in the 90-year-old age group remained the same. The incidence of colorectal cancer in the 80-89-year-old age group remained the same. The incidence of colorectal cancer in the 90-year-old age group remained the same. The incidence of colorectal cancer in the 90-year-old age group remained the same. The incidence of colorectal cancer in the 80-89-year-old age group remained the same. The incidence of colorectal cancer in the 90-year-old age group remained the same. The incidence of colorectal cancer in the 80-89-year-old age group remained the same. The incidence of colorectal cancer in the 90-year-old age group remained the same. The incidence of colorectal cancer in the 80-89-year-old age group remained the same. The incidence of colorectal cancer in the 90-year-old age group remained the same. The incidence of colorectal cancer in the \n",
      "BLEU: 0.19030395333456268, ROUGE-L: {'r': 0.34710743801652894, 'p': 0.7241379310344828, 'f': 0.46927373863612254}, Perplexity: 1.7406386137008667, Cosine Similarity: 0.6174\n",
      "Reference Text: Bolus, front-loaded, and accelerated thrombolytic infusions for myocardial infarction and pulmonary embolism. Thrombolytic therapy decreases mortality in patients with acute myocardial infarction and is now widely used in such patients. The choice of which thrombolytic agent to use in such patients, either streptokinase or recombinant tissue plasminogen activator (rt-PA), is based on regional preferences. The standard dose of streptokinase is 1.5 million units over 60 min, and the dose of rt-PA that is commonly used is 100 mg over 3 h. Experiments in animals have demonstrated that rt-PA produces continuing thrombolysis after it is cleared from the circulation and that thrombolysis is both increased and accelerated and bleeding is reduced when rt-PA is administered over a short time period. Based on these studies, there have been a number of recent trials examining alternative dosage regimens for rt-PA (bolus, front-loaded, and accelerated) in patients with myocardial infarction. To date, there is no convincing evidence that such regimens are superior to the more traditional rt-PA regimen. Future randomized trials will determine whether attempts to optimize rt-PA regimens will result in more efficacious treatment regimens. Interest in the use of thrombolytic therapy for patients with acute pulmonary embolism has been rekindled. The traditional 12- to 24-h regimens of streptokinase and urokinase are not optimal because of their logistic complexity and associated hemorrhagic complications. Clinical studies have demonstrated that rt-PA, 100 mg over 2 h, is an effective thrombolytic agent in patients with acute pulmonary embolism. In a recent double-blind trial in patients with acute pulmonary embolism, rt-PA, 0.6 mg/kg infused over 2 min, improved pulmonary perfusion. This bolus regimen is attractive because it is simple to administer. Future studies will compare the relative efficacy and safety of these two rt-PA regimens in patients with acute pulmonary embolism. \n",
      "Generated Text: Bolus, front-loaded, and accelerated thrombolytic infusions for myocardial infarction and pulmonary embolism. Thrombolytic therapy decreases mortality in patients with acute myocardial infarction and is now widely used in such patients. The choice of which thrombolytic agent to use in such patients, either streptokinase or recombinant tissue plasminogen activator (rt-PA), is controversial. We evaluated the safety and efficacy of bolus, front-loaded, and accelerated thrombolytic infusions of rt-PA in 46 patients with acute myocardial infarction or pulmonary embolism. A 5-mL bolus of rt-PA (5,000 IU) was administered within 6 hours of symptom onset. Patients were randomized to receive either a front-loaded infusion (0.5 mg of rt-PA per kilogram of body weight per hour) or an accelerated infusion (1 mg of rt-PA per kilogram of body weight per hour). The front-loaded and accelerated infusions were administered within 1 hour of the bolus infusion. A total of 41 patients received 1,000 IU of rt-PA, and 5 patients received 5,000 IU. There were no deaths in either group. There was no difference in the incidence of bleeding complications between the front-loaded and accelerated infusions. There was no difference in the incidence of myocardial infarction or death between the two groups. In conclusion, the use of a front-loaded infusion of rt-PA for patients with acute myocardial infarction or pulmonary embolism is safe and effective. (J Am Coll Cardiol 1997;30:1473-1478.)\n",
      "BLEU: 0.2123427069665503, ROUGE-L: {'r': 0.35625, 'p': 0.5229357798165137, 'f': 0.42379181674106225}, Perplexity: 2.556809902191162, Cosine Similarity: 0.7160\n",
      "Reference Text: Effects of site-specific mutations on biologic activities of recombinant human IL-6. To examine structure-activity relationships of human IL-6, we have determined the effects of specific mutations on the biologic activity of a human rIL-6 expressed in bacteria. Three types of mutants were examined: 1) a variant that contains serines in place of the four naturally occurring cysteines; 2) a series of cysteine-containing deletion mutants, each having a single internal 20 amino acid deletion; and 3) a cysteine-free variant containing a single 20 amino acid deletion. The mutants of the second type constitute a set of nonoverlapping, adjacent deletions spanning amino acids 4 through 183 of the 184 amino acids in natural human IL-6. All of the mutants were expressed, along with the full length, cysteine-containing analogue, in Escherichia coli as fusion proteins, joined to beta-galactosidase through a collagen linker. This system allows microgram quantities of the rIL-6 variants to be partially purified from small bacterial cultures without chromatographic or refolding steps. Each of the rIL-6 variants was released from the beta-galactosidase fusion protein with collagenase, and the recovered rIL-6 was quantitated by laser densitometry of Coomassie-stained, SDS polyacrylamide gels. The sp. ac. of each of the rIL-6 variants was determined using four assays: induction of IgM secretion from an EBV transformed human B cell line, induction of fibrinogen secretion from a human hepatoma cell line, induction of fibrinogen secretion from a rat hepatoma cell line, and induction of proliferation of a murine hybridoma cell line. Replacement of cysteines with serines reduced activity relative to cysteine-containing rIL-6 to about 20% in the rat hepatoma assay and about 3% in the mouse hybridoma assay, whereas activity in both of the human cell lines was reduced to less than 0.1%. These data suggest that the murine and rat cell lines are less selective than the human cell lines in their requirements for recognition of biologically active IL-6. Each of the deletions, except that of amino acids 4 through 23, resulted in loss of activity in all four assays. These results suggest that the information necessary for activity is not contained within any one portion of the IL-6 molecule, but rather that multiple segments of the protein are required for each of the biologic activities that we tested. \n",
      "Generated Text: Effects of site-specific mutations on biologic activities of recombinant human IL-6. To examine structure-activity relationships of human IL-6, we have determined the effects of specific mutations on the biologic activity of a human rIL-6 expressed in bacteria. Three types of mutants were examined: 1) a variant that contains serines in the C-terminal region of the mature molecule; 2) a variant that contains serines and asparagines in the C-terminal region of the mature molecule; and 3) a variant that contains serines and asparagines in the N-terminal region of the mature molecule. The N-terminal variant showed no activity, but the C-terminal variants were biologically active. The C-terminal variants showed the same activity as the wild-type molecule, suggesting that the N-terminal region is not essential for activity. The serine mutants were biologically active, suggesting that the biologic activity of IL-6 is not associated with a unique structure in the C-terminal region.\n",
      "BLEU: 0.09135816371043151, ROUGE-L: {'r': 0.25, 'p': 0.7, 'f': 0.3684210487534626}, Perplexity: 3.7057056427001953, Cosine Similarity: 0.7360\n",
      "Reference Text: Prophylactic sclerotherapy for esophageal varices: long-term results of a single-center trial. Survival after prophylactic sclerotherapy was assessed in a single-center study involving 99 cirrhotic (41 alcoholic) patients enrolled over 8-yr. The wedged hepatic vein pressure gradient was measured; those with pressure greater than or equal to 12 mm Hg were randomized to receive sclerotherapy or no treatment. The rest were not randomized. Patients in all three groups who bled were treated with emergency endoscopy and sclerotherapy. Stratification according to presence of ascites was also undertaken. Median follow-up was 61 mo (range = 14 to 107 mo). Survival among unrandomized patients was significantly longer than among randomized patients (p less than 0.006), but there was no significant difference between those treated by sclerotherapy and the controls (p = 0.27). Alcoholic cirrhotic patients undergoing sclerotherapy had better 2-yr survival than did the controls (80% vs. 43%; p = 0.09), but this benefit was not sustained at 5 yr. Survival in the nonalcoholic patient groups was identical. Only 10 of 50 deaths were caused by variceal bleeding. Forty-eight percent of patients with large varices bled, compared with 20% of patients with small varices. Wedged hepatic vein pressure less than 12 mm Hg accurately identified alcoholic patients at low risk of variceal bleeding but not nonalcoholic patients. Only four episodes of variceal bleeding were attributable to elective sclerotherapy. We conclude that in our population, prophylactic sclerotherapy alone does not improve survival. The discrepancy in survival between alcoholic and nonalcoholic cirrhotic patients suggests that factors other than variceal hemorrhage may be responsible for the difference. \n",
      "Generated Text: Prophylactic sclerotherapy for esophageal varices: long-term results of a single-center trial. Survival after prophylactic sclerotherapy was assessed in a single-center study involving 99 cirrhotic (41 alcoholic) patients enrolled over 8-yr. The wedged hepatic vein pressure gradient was measured; those with pressure greater than or equal to 12 mm Hg were treated with sclerotherapy. The median time of follow-up was 36 mo (range, 6-80 mo). Overall survival was 76% at 5 yr. The 5-yr survival rate was 83% for those with a wedge hepatic vein pressure gradient of less than 12 mm Hg and 55% for those with a gradient of 12-19 mm Hg. The 5-yr survival rate was 78% for those with a pressure gradient of 20-29 mm Hg and 47% for those with a gradient of 30-39 mm Hg. Overall survival was 81% for those with a wedge hepatic vein pressure gradient of less than 12 mm Hg and 66% for those with a pressure gradient of 12-19 mm Hg. The 5-yr survival rate was 82% for those with a wedge hepatic vein pressure gradient of less than 12 mm Hg and 66% for those with a pressure gradient of 20-29 mm Hg. The 5-yr survival rate was 81% for those with a wedge hepatic vein pressure gradient of less than 12 mm Hg and 66% for those with a pressure gradient of 30-39 mm Hg. The 5-yr survival rate was 82% for those with a wedge hepatic vein pressure gradient of less than 12 mm Hg and 66% for those with a pressure gradient of 20-29 mm Hg. The 5-yr survival rate was 81% for those with a wedge hepatic vein pressure gradient of less than 12 mm Hg and 66% for those with a pressure gradient of 30-39 mm Hg. The 5-yr survival rate was 82% for those with a wedge hepatic vein pressure gradient of less than 12 mm Hg and 66% for those with a pressure gradient of 30-39 mm Hg. The 5-yr survival rate was \n",
      "BLEU: 0.19041221635252648, ROUGE-L: {'r': 0.3525641025641026, 'p': 0.7333333333333333, 'f': 0.4761904718052512}, Perplexity: 1.8863452672958374, Cosine Similarity: 0.5461\n",
      "Reference Text: A case of cerebrotendinous xanthomatosis. II: The sterol content of a cataractous lens. The cholestanol content of a cataractous lens nucleus from a patient with cerebrotendinous xanthomatosis (CTX) was quantified by gas chromatography-mass spectrometry and found to be 0.27 micrograms per mg freeze-dried lens tissue. The cholestanol-cholesterol ratio of 1.7% in the lens nucleus was similar to that in the serum of the CTX patient. The cholestanol content and cholestanol-cholesterol ratio in the CTX lens were approximately four-fold and six-fold greater respectively than the mean levels found in three senile cataractous lens nuclei analysed simultaneously for comparative purposes. \n",
      "Generated Text: A case of cerebrotendinous xanthomatosis. II: The sterol content of a cataractous lens. The cholestanol content of a cataractous lens nucleus from a patient with cerebrotendinous xanthomatosis (CTX) was quantified by gas chromatography-mass spectrometry and found to be 0.27 micrograms per mg freeze-dried lens tissue. The cholestanol-cholesterol ratio of 1.7% was similar to that of the liver. The sterol content of the lens was not altered by treatment with 1% cholesterol in the diet. The sterol content of a cataractous lens from a patient with CTX was quantified by gas chromatography-mass spectrometry and found to be 0.27 micrograms per mg freeze-dried lens tissue. The cholestanol-cholesterol ratio of 1.7% was similar to that of the liver. The sterol content of the lens was not altered by treatment with 1% cholesterol in the diet. The sterol content of the lens was not altered by treatment with 1% cholesterol in the diet.\n",
      "BLEU: 0.3857395768098181, ROUGE-L: {'r': 0.6825396825396826, 'p': 0.8431372549019608, 'f': 0.7543859599676824}, Perplexity: 2.5865910053253174, Cosine Similarity: 0.8568\n",
      "Reference Text: Idiopathic intracranial hypertension without papilledema. We describe 10 patients with idiopathic intracranial hypertension who did not have papilledema. Idiopathic intracranial hypertension without papilledema, although rarely reported, may well be a clinically important headache syndrome. Historical and demographic features of patients with idiopathic intracranial hypertension without papilledema are similar to those of patients with papilledema. Obese women with chronic daily headache and symptoms of increased intracranial pressure, pulsatile tinnitus, history of head trauma or meningitis, an empty sella on imaging studies, or a headache that is unrelieved by standard therapy should have a diagnostic lumbar puncture. Findings from laboratory and neurologic investigations are normal in most patients with idiopathic intracranial hypertension without papilledema. Initial management should include removal of possible inciting agents, weight loss if applicable, and standard headache therapy. Lumbar puncture and diuretic therapy should precede a trial of corticosteroids. Surgery (lumboperitoneal or ventriculoperitoneal shunt or perhaps optic nerve sheath fenestration) may be indicated for prolonged incapacitating headache that is not responsive to medical management or lumbar puncture. \n",
      "Generated Text: Idiopathic intracranial hypertension without papilledema. We describe 10 patients with idiopathic intracranial hypertension who did not have papilledema. Idiopathic intracranial hypertension without papilledema, although rarely reported, may well be a clinically important headache syndrome. Historical and demographic features of patients with idiopathic intracranial hypertension without papilledema are similar to those of patients with papilledema. Although the incidence of papilledema is not increased in patients with idiopathic intracranial hypertension without papilledema, the incidence of papilledema in patients with papilledema is increased in patients with idiopathic intracranial hypertension without papilledema. The incidence of papilledema in patients with idiopathic intracranial hypertension without papilledema is not increased. The incidence of papilledema in patients with idiopathic intracranial hypertension without papilledema is increased in patients with idiopathic intracranial hypertension with papilledema. The incidence of papilledema in patients with idiopathic intracranial hypertension without papilledema is not increased.\n",
      "BLEU: 0.35862107184967756, ROUGE-L: {'r': 0.36792452830188677, 'p': 0.9069767441860465, 'f': 0.5234899287797847}, Perplexity: 2.1194069385528564, Cosine Similarity: 0.7108\n",
      "Reference Text: Acute lower respiratory tract infection due to virus among hospitalized children in Dhaka, Bangladesh. The nature of acute lower respiratory tract infection (ALRI) in hospitalized children and of the associated viral agents was assessed in a study of 601 children less than 5 years old over a 24-month period. Of these children, 80% were less than 24 months of age and the ratio of boys to girls was 1.7:1. Pneumonia (86.5% of cases) was the most frequently observed clinical manifestation. Shedding of virus was detected in 21.1% of the children; the highest rate occurred in infants 0-5 months old (27%) as compared with a rate of only 12.5% in children 25-60 months old. Virus was detected in 33.3%, 32.8%, 21.2%, and 20% of the cases of tracheobronchitis, bronchiolitis, pneumonia, and croup, respectively. Among the viruses detected, 78% were respiratory syncytial virus (RSV) (91% of infections with this virus occurred in children less than 2 years old) and 14.4% were influenza virus types A and B. Of the RSV infections, 61% occurred in infants less than 1 year old. The case-fatality rate was 6.8% overall and was 4.8% in virus-associated cases. No consistent pattern of seasonal occurrence of viral infections was discerned. RSV was detected throughout the year, with increased prevalence from January to April. \n",
      "Generated Text: Acute lower respiratory tract infection due to virus among hospitalized children in Dhaka, Bangladesh. The nature of acute lower respiratory tract infection (ALRI) in hospitalized children and of the associated viral agents was assessed in a study of 601 children less than 5 years old over a 24-month period. Of 601 children, 18.3% had ALRI. Of these, 12.8% had pneumonia, 0.8% had bronchiolitis, 4.2% had bronchitis, 0.8% had laryngotracheobronchitis, and 2.3% had croup. In the 17 cases of ALRI, 8 (47%) were caused by a virus, 6 (35%) were caused by bacteria, 1 (6%) was caused by a fungus, and 1 (6%) was caused by a rickettsial agent. In 14 of the 17 children with a virus, the virus was influenza A. In 4 of the 14 children with influenza A, the virus was associated with bronchiolitis, and in 1 of the 4 children with influenza A, the virus was associated with pneumonia. In 1 of the 14 children with influenza A, the virus was associated with bronchitis. The 3 other children with influenza A had no other signs of ALRI. In 8 of the 17 children with a virus, the virus was associated with pneumonia. In 4 of the 8 children with a virus, the virus was associated with bronchitis. In 1 of the 8 children with a virus, the virus was associated with bronchiolitis. In 1 of the 8 children with a virus, the virus was associated with pneumonia. In 1 of the 8 children with a virus, the virus was associated with bronchitis. In 1 of the 8 children with a virus, the virus was associated with pneumonia. In 1 of the 8 children with a virus, the virus was associated with pneumonia. In 1 of the 8 children with a virus, the virus was associated with pneumonia. In 1 of the 8 children with a virus, the virus was associated with pneumonia. In 1 of the 8 children with a virus, the virus was associated with pneumonia. In 1 of the 8 children with a virus, the virus was\n",
      "BLEU: 0.17385807879976747, ROUGE-L: {'r': 0.3923076923076923, 'p': 0.6, 'f': 0.4744185998702001}, Perplexity: 1.9857133626937866, Cosine Similarity: 0.7574\n",
      "Reference Text: Endocrine function in children with human immunodeficiency virus infection. We sought to determine if failure to thrive in pediatric patients with the human immunodeficiency virus could be explained based on endocrine dysfunction. Fourteen human immunodeficiency virus-infected pediatric patients, all of whom had adequate nutritional status, underwent endocrine evaluation. Growth hormone and cortisol responses to glucagon stimulation were adequate. Despite this, eight of the 12 subjects had low somatomedin C levels. Although all patients were clinically and biochemically euthyroid, 36% (5/14) demonstrated elevated baseline and peak thyrotropin levels in response to thyroid releasing hormone, suggesting a state of compensated hypothyroidism. Although the importance of these findings is unclear, it is possible that subtle alterations of thyroid regulation may contribute to failure to thrive in some pediatric patients infected with human immunodeficiency virus and may represent a potentially correctable defect. \n",
      "Generated Text: Endocrine function in children with human immunodeficiency virus infection. We sought to determine if failure to thrive in pediatric patients with the human immunodeficiency virus could be explained based on endocrine dysfunction. Fourteen human immunodeficiency virus-infected pediatric patients, all of whom had adequate nutritional status, underwent endocrine evaluation. Growth hormone, prolactin, and luteinizing hormone levels were measured by radioimmunoassay. Twenty-five pediatric patients without human immunodeficiency virus infection served as controls. Growth hormone, prolactin, and luteinizing hormone levels were similar in the two groups. There were no significant differences in the levels of growth hormone, prolactin, or luteinizing hormone between the two groups. The prevalence of adrenal insufficiency was higher in the human immunodeficiency virus-infected group than in the control group (p = 0.005). The prevalence of adrenal insufficiency was 43% in the human immunodeficiency virus-infected group and 7% in the control group. The prevalence of adrenal insufficiency was not related to age, weight, or height. In conclusion, we found no evidence of endocrine dysfunction in pediatric patients with human immunodeficiency virus infection. The prevalence of adrenal insufficiency was higher in these patients than in controls.\n",
      "BLEU: 0.29734062026589797, ROUGE-L: {'r': 0.4421052631578947, 'p': 0.4666666666666667, 'f': 0.4540540490577064}, Perplexity: 2.60689377784729, Cosine Similarity: 0.6973\n",
      "Reference Text: Leukaemia complicating treatment for Hodgkin's disease: the experience of the British National Lymphoma Investigation. OBJECTIVE--To determine the incidence of and risk factors for the development of secondary acute leukaemia and myelodysplasia in patients treated in British National Lymphoma Investigation's studies of Hodgkin's disease since 1970. PATIENTS--2676 Patients entered into Hodgkin's disease studies between February 1970 and November 1986. Data accrued up to November 1988 were analysed, ensuring a minimum follow up period of two years. DESIGN--Retrospective analysis of multicentre trial data by case-control and life table methods. RESULTS--17 Cases of secondary leukaemia were recorded in this group of 2676 patients, giving an overall risk at 15 years of 1.7%. The risks of leukaemia after chemotherapy alone and chemotherapy with radiotherapy were not significantly different. The risk of leukaemia increased sharply with the amount of treatment given as measured by the number of attempts at treatment. The 15 year risks of leukaemia were 0.2%, 2.3%, and 8.1% for patients receiving one, two, or three or more attempts at treatment. The highest risk, 22.8% at 15 years, was observed in patients treated with lomustine (CCNU), and a case-control study suggested that this was an independent risk factor. The risk of secondary leukaemia was largely related to the overall quantity of treatment, although exposure to lomustine seemed to be an important risk factor. Treatment with both drugs and radiation was not more leukaemogenic than treatment with drugs alone. The greatest risk of secondary leukaemia was seen in multiply treated patients who were unlikely to be cured of Hodgkin's disease. CONCLUSIONS--Avoidance of secondary leukaemia should be a minor factor in the choice of treatment for Hodgkin's disease. \n",
      "Generated Text: Leukaemia complicating treatment for Hodgkin's disease: the experience of the British National Lymphoma Investigation. OBJECTIVE--To determine the incidence of and risk factors for the development of secondary acute leukaemia and myelodysplasia in patients treated in British National Lymphoma Investigation's studies of Hodgkin's disease since 1970. PATIENTS--2676 Patients entered into Hodgkin's disease studies between 1970 and 1985, and 236 patients entered into the National Lymphoma Investigation's studies of Hodgkin's disease since 1970. METHODS--Secondary acute leukaemia and myelodysplasia were defined according to the criteria of the National Cancer Institute. RESULTS--The incidence of secondary acute leukaemia and myelodysplasia was 2.5 per 1000 patient-years. Leukaemia occurred in 0.3% of patients treated in the Hodgkin's disease studies and in 0.5% of patients treated in the National Lymphoma Investigation's studies. In the Hodgkin's disease studies, the incidence of leukaemia was significantly lower in patients with Hodgkin's disease treated with radiotherapy (0.1% in those treated with radiotherapy and 1.5% in those treated with chemotherapy alone) than in those treated with chemotherapy alone (2.4%). The risk of leukaemia was significantly lower in patients with Hodgkin's disease treated with radiotherapy than in those treated with chemotherapy alone (0.1% in those treated with radiotherapy and 1.5% in those treated with chemotherapy alone). CONCLUSIONS--The incidence of secondary acute leukaemia and myelodysplasia is low and is not increased by treatment with radiotherapy.\n",
      "BLEU: 0.24404464499663217, ROUGE-L: {'r': 0.35570469798657717, 'p': 0.654320987654321, 'f': 0.4608695606544424}, Perplexity: 2.53055477142334, Cosine Similarity: 0.7591\n",
      "Reference Text: Extensive vulvar and vaginal varicella necessitating abdominal delivery. Maternal varicella occurs in fewer than five per 10,000 pregnancies in the United States. A case is reported in which markedly painful, extensive vulvar and vaginal ulcers prevented cervical examination, and cesarean section was performed with the patient under general anesthesia. \n",
      "Generated Text: Extensive vulvar and vaginal varicella necessitating abdominal delivery. Maternal varicella occurs in fewer than five per 10,000 pregnancies in the United States. A case is reported in which markedly painful, extensive vulvar and vaginal ulcers prevented cervical examination, and cesarean section was performed with the patient under general anesthesia. The case illustrates the need for a high index of suspicion in the evaluation of the patient with genital varicella and a high index of suspicion for maternal varicella in the patient with a vulvar or vaginal lesion.\n",
      "BLEU: 0.5554491069473153, ROUGE-L: {'r': 0.9761904761904762, 'p': 0.7454545454545455, 'f': 0.8453608198320758}, Perplexity: 7.3188581466674805, Cosine Similarity: 0.8437\n",
      "Reference Text: Tissue dose estimates following the selective uptake of 125IUdR and other radiolabelled thymidine precursors in resistant tumours. For the purposes of evaluation of the therapeutic potential of the radiohalogenated thymidine analogue 125IUdR, estimation of the radiation dose to the tumour cells and normal tissues is important. To determine the dose to any tissue from the radionuclide 125I is not simple, since the major emissions are very short-range Auger electrons. The cytotoxicity of 125I is strongly dependent on the position of the decay relative to the DNA, the principal target for cell sterilization. Estimates of the cytotoxicity of 125I based on the traditional MIRD recommended formulation (ICRU Report 32, 1979) may produce gross underestimates if it is incorporated into the DNA via the thymidine precursor 125IUdR. In this work, tissue count and autoradiography (ARG) data from studies by Bagshawe et al were used to estimate tissue doses following the administration of 125IUdR to LS174/T (a colorectal carcinoma) and CC3 (a choriocarcinoma) tumour-bearing animals, after a hydroxyurea block of the normal tissue turnover. The tumour cell toxicity is estimated from ARG data on the degree of 125I incorporation into the cell nucleus. Major drawbacks with 125I for this type of therapy are the long 60-day half-life, leading to radiological and waste disposal problems and the extreme short range of the radiotoxic effects. Possible alternative radiohalogens, 13I, 77Br, 131I and 211At, are suggested in place of 125I in the thymidine analog iododeoxyuridine. Dose calculations are performed and cytotoxicities estimated on the assumption that their biological retention characteristics are the same as for 125IUdR. \n",
      "Generated Text: Tissue dose estimates following the selective uptake of 125IUdR and other radiolabelled thymidine precursors in resistant tumours. For the purposes of evaluation of the therapeutic potential of the radiohalogenated thymidine analogue 125IUdR, estimation of the radiation dose to the tumour cells and normal tissues is important. To determine the dose to the tumour and normal tissues, the uptake of 125IUdR by the tumours and their surrounding normal tissues was studied in the rat. The uptake of 125IUdR by the tumours was studied in 10 tumours of the rat, and the uptake of 125IUdR by the surrounding normal tissues was studied in 10 tumours of the rat. The tumour dose was calculated by the use of a computer program. The tumour dose was found to be 0.8-1.2 rad for 125IUdR and 0.4-0.7 rad for 125IUdR. The surrounding normal tissue dose was 0.1-0.4 rad for 125IUdR. It is concluded that the 125IUdR administered to the tumours of the rat is selectively taken up by the tumours and the surrounding normal tissues, and the tumour dose is 0.8-1.2 rad and the surrounding normal tissue dose is 0.1-0.4 rad. The results are consistent with the selective uptake of 125IUdR by the tumours and the surrounding normal tissues. The results are also consistent with the selective uptake of 125IUdR by the tumours and the surrounding normal tissues. The results are consistent with the selective uptake of 125IUdR by the tumours and the surrounding normal tissues. The results are consistent with the selective uptake of 125IUdR by the tumours and the surrounding normal tissues. The results are consistent with the selective uptake of 125IUdR by the tumours and the surrounding normal tissues. The results are consistent with the selective uptake of 125IUdR by the tumours and the surrounding normal tissues. The results are consistent with the selective uptake of 125IUdR by the tumours and the surrounding normal tissues. The results are consistent with the selective uptake of 125IUdR by the tumours and the surrounding normal tissues. The results are consistent with the selective uptake of 125IU\n",
      "BLEU: 0.18831603576886444, ROUGE-L: {'r': 0.27439024390243905, 'p': 0.5921052631578947, 'f': 0.37499999567222225}, Perplexity: 2.209876298904419, Cosine Similarity: 0.8143\n",
      "Reference Text: Combined vesicovaginal-ureterovaginal fistulas associated with a vaginal foreign body. A case is presented of vesicovaginal-ureterovaginal fistulas associated with a neglected vaginal foreign body. The patient complained of a foul-smelling vaginal discharge and was found to have a 4-cm hard vaginal mass on examination. Urinary incontinence developed subsequently. Examination under anesthesia was performed, and an aerosol deodorant cap was operatively removed from her posterior vagina/perirectal space. Subsequent work-up demonstrated the presence of both a vesicovaginal fistula and a right ureterovaginal fistula. The patient underwent a combined vaginal repair of the vesicovaginal fistula and abdominal ureteroneocystostomy. The frequency, types, etiology, and treatment of genitourinary fistulas are reviewed with particular attention to those associated with a vaginal foreign body. \n",
      "Generated Text: Combined vesicovaginal-ureterovaginal fistulas associated with a vaginal foreign body. A case is presented of vesicovaginal-ureterovaginal fistulas associated with a neglected vaginal foreign body. The patient complained of a foul-smelling vaginal discharge and was found to have a 4-cm hard vaginal mass on examination. Urinary incontinence developed subsequently. Examination under anesthesia revealed a large vesicovaginal fistula. A 5-cm long foreign body was found in the vagina. The patient had no history of vaginal surgery and the foreign body was removed by dilatation. A ureteral fistula was also present. The patient was treated with ureteral stents and the foreign body was removed by dilatation. The ureteral fistula was closed by sutures. The foreign body was removed by dilatation. The patient was discharged on the third postoperative day. The patient had no further complaints of urinary incontinence. The patient was treated with ureteral stents and the foreign body was removed by dilatation. The patient was discharged on the third postoperative day. The patient had no further complaints of urinary incontinence. The patient was treated with ureteral stents and the foreign body was removed by dilatation. The patient was discharged on the third postoperative day. The patient had no further complaints of urinary incontinence. The patient was treated with ureteral stents and the foreign body was removed by dilatation. The patient was discharged on the third postoperative day. The patient had no further complaints of urinary incontinence. The patient was treated with ureteral stents and the foreign body was removed by dilatation. The patient was discharged on the third postoperative day. The patient had no further complaints of urinary incontinence. The patient was treated with ureteral stents and the foreign body was removed by dilatation. The patient was discharged on the third postoperative day. The patient had no further complaints of urinary incontinence. The patient was treated with ureteral stents and the foreign body was removed by dilatation. The patient was discharged on the third postoperative day. The patient had no further complaints of urinary incontinence. The patient was treated with ureteral stents and the foreign body was removed by dilatation. The patient was discharged on the third postoperative day\n",
      "BLEU: 0.1516251087048322, ROUGE-L: {'r': 0.5466666666666666, 'p': 0.6119402985074627, 'f': 0.5774647837482643}, Perplexity: 1.8033825159072876, Cosine Similarity: 0.5791\n",
      "Reference Text: Epidural anaesthesia for labour and caesarean section in a parturient with a single ventricle and transposition of the great arteries. We describe a case of a 29-year-old parturient with a single ventricle and transposition of the great arteries who had lumbar epidural analgesia/anaesthesia with a local anaesthetic for labour, emergency Caesarean section and postoperative pain. Her outcome and that of her baby was successful. The anaesthetic techniques used in other parturients with similar congenital cardiac anomalies are reviewed. \n",
      "Generated Text: Epidural anaesthesia for labour and caesarean section in a parturient with a single ventricle and transposition of the great arteries. We describe a case of a 29-year-old parturient with a single ventricle and transposition of the great arteries who had lumbar epidural analgesia/anaesthesia with a local anaesthetic for labour, emergency caesarean section and postoperative analgesia. The patient was in sinus venosus type 2. The epidural catheter was placed at the L2-3 level with a loss of resistance technique. The patient received 4 ml of 0.5% bupivacaine with adrenaline 1:200 000 in a dose of 1.5 mg kg-1 and 0.5 ml of 0.5% bupivacaine with adrenaline 1:200 000 in a dose of 0.5 mg kg-1 for labour and 0.5 ml of 0.5% bupivacaine with adrenaline 1:200 000 in a dose of 0.5 mg kg-1 for caesarean section. The patient was extubated without any problems. The patient was discharged 2 days after surgery. We conclude that epidural analgesia/anaesthesia is a useful alternative to general anaesthesia for labour and caesarean section in a parturient with a single ventricle and transposition of the great arteries.\n",
      "BLEU: 0.2870435634030606, ROUGE-L: {'r': 0.660377358490566, 'p': 0.45454545454545453, 'f': 0.5384615336319527}, Perplexity: 2.323688507080078, Cosine Similarity: 0.8126\n",
      "Reference Text: A prospective analysis of intramuscular meperidine, promethazine, and chlorpromazine in pediatric emergency department patients. STUDY OBJECTIVE: To examine physiologic responses and efficacy of 2, 1, and 1 mg/kg IM meperidine, promethazine, and chlorpromazine (MPC), respectively, in children. DESIGN: Prospective, unblinded trial. SETTING: A university and community emergency department. PATIENTS: Sixty-three hemodynamically and neurologically stable children. INTERVENTION: Single dose of IM MPC. MEASUREMENTS AND MAIN RESULTS: Serial respirations, heart rate, arterial systolic blood pressure, oxygen saturation, and Glasgow Coma Scale were measured at 30-minute intervals. Effectiveness was assessed by two independent observers using separate visual analog scales for cooperation and sedation. Times to sleep (27 +/- 24 minutes), sitting upright (103 +/- 87 minutes), ED discharge (4.7 +/- 2.4 hours), eating (11 +/- 7.9 hours), and normal behavior (19 +/- 15 hours) were acceptable. Minor, but statistically significant, changes in respiration rate (-1.9 +/- 0.4), heart rate (+4.5 +/- 1.8), oxygen saturation (-0.7 +/- 0.3%), and Glasgow Coma Scale (-2.5 +/- 0.6) occurred for 120 minutes after MPC. No serious complications or resuscitation were required. Mean visual analog scale scores were 5.0/10.4 or more in 71% of cases, with interobserver agreement very good (cooperation, r = .79; effectiveness, r = .80). Twenty-nine percent of children were judged insufficiently sedated. CONCLUSION: IM MPC is a safe and generally effective agent for ED procedures in selected children. \n",
      "Generated Text: A prospective analysis of intramuscular meperidine, promethazine, and chlorpromazine in pediatric emergency department patients. STUDY OBJECTIVE: To examine physiologic responses and efficacy of 2, 1, and 1 mg/kg IM meperidine, promethazine, and chlorpromazine (MPC), respectively, in children. DESIGN: Prospective, unblinded trial. SETTING: A university and community emergency department. PATIENTS: Sixty-three children (age range, 1 to 17 years) presenting with a variety of illnesses. INTERVENTIONS: Children received 2, 1, or 1 mg/kg of MPCA or MPC, respectively. MEASUREMENTS AND MAIN RESULTS: Children received 2, 1, or 1 mg/kg of MPCA or MPC. RESULTS: The mean age of the children was 4.3 years (range, 1 to 17 years). The mean body weight was 32.8 kg (range, 11.5 to 72.0 kg). The mean height was 134.3 cm (range, 89.0 to 168.0 cm). The mean initial hemodynamic values were systolic blood pressure (SBP) 87.3 mm Hg (range, 40 to 120 mm Hg) and diastolic blood pressure (DBP) 51.0 mm Hg (range, 19 to 90 mm Hg). The mean initial heart rate was 120 beats per minute (range, 70 to 180 beats per minute). The mean initial oxygen saturation was 96% (range, 90% to 100%). The mean initial urine output was 0.5 mL/kg/h (range, 0.2 to 1.5 mL/kg/h). The mean initial urine osmolality was 180 mOsm/kg (range, 100 to 320 mOsm/kg). The mean initial serum sodium concentration was 125 mEq/L (range, 120 to 140 mEq/L). The mean initial serum potassium concentration was 4.0 mEq/L (range, 2.0 to 6.0 mEq/L). The mean initial serum chloride concentration was 101 mEq/L (range, 89 to 113 mEq/L). The mean initial serum glucose concentration was 4.5 mEq/L (range, 2\n",
      "BLEU: 0.20899284581979685, ROUGE-L: {'r': 0.35294117647058826, 'p': 0.42857142857142855, 'f': 0.3870967692403746}, Perplexity: 2.403655529022217, Cosine Similarity: 0.3696\n",
      "Reference Text: Teniposide (VM-26) and continuous infusion cytosine arabinoside for initial induction failure in childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study. Twenty-six evaluable children with newly diagnosed acute lymphoblastic leukemia (ALL) who failed to achieve initial remission after receiving two to seven drugs for at least a 4-week period were given teniposide (VM-26) and continuous infusion cytosine arabinoside (Ara-C). Twenty-two received 150 mg/m2 of VM-26 on days 1 and 2 with 100 mg/2 of Ara-C as a continuous infusion on days 1 through 5; a second shortened course was given on day 14 to eight patients who had evidence of some antileukemic effect or were clinically judged able to tolerate a second course. The last four patients received three daily doses of VM-26 and a 7-day infusion of Ara-C at the same daily dosages. Twelve (48%) achieved complete remission (CR) of ALL. There was a trend toward decreasing response rates with an increasing number of drugs used in the initial induction regimen, i.e., five CR among seven patients with a prior two-drug induction attempt, six CR among 14 patients with a prior three- to four-drug induction attempt, and one CR among four patients with a prior five- to seven-drug induction attempt (P = 0.14). Ten of 17 non-T-cell patients and two of nine T-cell patients achieved remission (P = 0.10). The median time required to achieve a complete remission from the initiation of treatment was 26 days (range, 14-72 days). This period was shorter in those who required one course compared with those who required two induction courses, i.e., 25 days median vs. 44 days median. Toxicity was significant and due mainly to marrow aplasia and infection; one patient had severe prolonged VM-26-induced hypotension. Of the 12 patients entering remission, two were removed for marrow transplant and one was removed due to parental request. In the remaining nine patients, median remission duration was only 2 months (range, 1-18 months). All nine patients relapsed in the marrow. Among the entire group of 26 patients, only one patient is alive and a long-term event-free survivor (after allogeneic marrow transplant). Due to the current use of more aggressive initial induction regimens and the extremely poor prognosis in children who fail to achieve initial remission, more intensive regimens of continuation therapy or alternative therapies, such as bone marrow transplant, should be considered. \n",
      "Generated Text: Teniposide (VM-26) and continuous infusion cytosine arabinoside for initial induction failure in childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study. Twenty-six evaluable children with newly diagnosed acute lymphoblastic leukemia (ALL) who failed to achieve initial remission after receiving two to seven drugs for at least a 4-week period were randomized to receive teniposide (VM-26) or cytosine arabinoside (Ara-C) at 6 mg/m2/day for 10 days followed by continuous infusion of Ara-C for 10 days. The two groups were similar in age, sex, and initial treatment response. Teniposide was administered to 13 children (51%) and Ara-C to 13 (49%) of the patients. All 26 children had at least one complete remission (CR) and 18 (69%) had a CR. The median time to CR was 9.5 months (range 2.4 to 20.1). The median number of drugs given in the first 10 days of induction was 6.5 (range 3 to 7). Teniposide was given to 12 of 13 patients (92%) who had achieved CR and to 9 of 13 patients (69%) who had not. All 26 patients (100%) achieved a CR with teniposide and Ara-C. The most common adverse events were nausea and vomiting. Teniposide is a new agent with a high rate of response and a low rate of toxicity. The combination of teniposide and Ara-C is a promising regimen for initial induction of acute lymphoblastic leukemia in children.\n",
      "BLEU: 0.15442856400776686, ROUGE-L: {'r': 0.3333333333333333, 'p': 0.6153846153846154, 'f': 0.43243242787436087}, Perplexity: 3.2886788845062256, Cosine Similarity: 0.7900\n",
      "Reference Text: Increase of calmodulin activator in hypertension. Modulation by dietary sodium and calcium. The aim of this study was to investigate the effects of dietary calcium and sodium on blood pressure (BP) in normotensive rats (Wistar, WKY), spontaneously hypertensive rats (SHR) and Dahl rats and on calmodulin (CaM) activator, a newly-discovered hydrophobic compound that increases CaM activity in SHR and spontaneously hypertensive mice (SHM) tissues (J Clin Invest 82:276, 1988). The CaM activator was assessed by its capacity to stimulate a CaM-dependent phosphodiesterase (CaM-PDE). In Wistar rats, which were fed a high sodium diet (3.5%), BP significantly increased (P less than .01) from 106 +/- 4 to 128 +/- 8 mm Hg in parallel to an elevation of the CaM activator from 1.57 +/- 0.14 to 2.80 +/- 0.18 U. WKY, SHR, and Dahl salt-sensitive (DS/JR) and salt-resistant (DR/JR) rats were given low (0.15%) or high (2.5%) Ca diets, both with 1% sodium. In rats receiving high dietary Ca the progression of hypertension diminished and BP was lower in SHR (156 +/- 4 mm Hg) and young DS/JR rats (125 +/- 3 mm Hg) than in those receiving low dietary Ca (192 +/- 10 and 183 +/- 2 mm Hg). There was a concomitant decrease of CaM activator in these animals to levels indistinguishable from those of WKY or DR/JR rats. The activator was also found in the heart, kidneys and erythrocytes from SHM. In the presence of exogenously added CaM, lipidic extracts from the SHM heart showed augmented CaM-PDE activity relative to normotensive preparations. This difference was eliminated by trifluoperazine. \n",
      "Generated Text: Increase of calmodulin activator in hypertension. Modulation by dietary sodium and calcium. The aim of this study was to investigate the effects of dietary calcium and sodium on blood pressure (BP) in normotensive rats (Wistar, WKY), spontaneously hypertensive rats (SHR) and Dahl rats and on calmodulin (CaM) activator, a newly-discovered CaM binding protein, in vitro. CaM activator was measured in plasma and in cultured vascular smooth muscle cells (VSMC) in normotensive rats and in cultured aortic smooth muscle cells (AASMC) in SHR and Dahl rats. CaM activator was increased by dietary sodium and calcium in WKY, but not in SHR and Dahl rats. In vitro, dietary sodium and calcium increased CaM activator in cultured VSMC from normotensive rats. In SHR and Dahl rats, dietary sodium and calcium increased CaM activator in cultured AASMC. These results suggest that dietary sodium and calcium modulate CaM activator in normotensive rats and in cultured VSMC and AASMC from SHR and Dahl rats. This study provides a new insight into the regulation of CaM activator in hypertension.\n",
      "Dietary calcium and sodium modulate calmodulin activator in normotensive rats and cultured vascular smooth muscle cells. Modulation by dietary sodium and calcium. The aim of this study was to investigate the effects of dietary calcium and sodium on blood pressure (BP) in normotensive rats (Wistar, WKY), spontaneously hypertensive rats (SHR) and Dahl rats and on calmodulin (CaM) activator, a newly-discovered CaM binding protein, in vitro. CaM activator was measured in plasma and in cultured vascular smooth muscle cells (VSMC) in normotensive rats and in cultured aortic smooth muscle cells (AASMC) in SHR and Dahl rats. CaM activator was increased by dietary sodium and calcium in WKY, but not in SHR and Dahl rats. In vitro, dietary sodium and calcium increased CaM activator in cultured VSMC from normotensive rats. In SHR and Dahl rats, dietary sodium and calcium increased CaM activator in cultured AASMC. These results suggest that dietary sodium and calcium modulate CaM activator in normotensive rats and in cultured VSMC and AASMC from SHR and Dahl rats. This study provides\n",
      "BLEU: 0.18817404868753193, ROUGE-L: {'r': 0.2830188679245283, 'p': 0.6081081081081081, 'f': 0.3862660900860212}, Perplexity: 1.7741267681121826, Cosine Similarity: 0.7493\n",
      "Reference Text: Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. The relation between serum cholesterol and mortality was investigated in 822 elderly hypertensive patients randomly assigned to treatment with diuretics, with or without methyldopa, or placebo. Cox's proportional hazards model showed that pretreatment serum total cholesterol levels were independently and inversely correlated with total mortality (p = 0.03), noncardiovascular mortality (p = 0.02), and cancer mortality (p = 0.04) during treatment. Total and noncardiovascular mortality were also negatively correlated with pretreatment hemoglobin levels and body weight. All factors being equal, an increase in total serum cholesterol of 2.3 mmol/L was associated with a one-year prolongation of survival. After adjustment for gender, age, pretreatment cardiovascular complications, and systolic pressure, the correlations between serum cholesterol and cardiovascular and cardiac mortality were not significant. \n",
      "Generated Text: Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. The relation between serum cholesterol and mortality was investigated in 822 elderly hypertensive patients randomly assigned to treatment with diuretics, with or without methyldopa, or placebo. Mortality was significantly lower in the treatment groups than in the placebo group, and the differences were most pronounced in the treatment with diuretics. The relative risk of mortality associated with a 10 mg/dl increase in serum cholesterol was 1.2 (95% CI, 1.0 to 1.5) in the placebo group, 1.3 (95% CI, 1.0 to 1.7) in the diuretic group, and 1.6 (95% CI, 1.2 to 2.1) in the methyldopa group. The results were similar in patients with and without diabetes. The findings suggest that the effect of cholesterol on mortality is dependent on treatment and that the mortality benefit of diuretics is not due to the reduction of serum cholesterol. The results support the hypothesis that high serum cholesterol levels are a risk factor for mortality in elderly hypertensive patients, and that the effect of cholesterol on mortality is dependent on treatment.\n",
      "BLEU: 0.2998102510759976, ROUGE-L: {'r': 0.5263157894736842, 'p': 0.5434782608695652, 'f': 0.5347593532900569}, Perplexity: 2.8065991401672363, Cosine Similarity: 0.6956\n",
      "Reference Text: Pulmonary arterial and venous constriction during hypoxia in 3- to 5-wk-old and adult ferrets. We have determined the sites of hypoxic vasoconstriction in ferret lungs. Lungs of five 3- to 5-wk-old and five adult ferrets were isolated and perfused with blood. Blood flow was adjusted initially to keep pulmonary arterial pressure at 20 cmH2O and left atrial and airway pressures at 6 and 8 cmH2O, respectively (zone 3). Once adjusted, flow was kept constant throughout the experiment. In each lung, pressures were measured in subpleural 20- to 50-microns-diam arterioles and venules with the micropipette servo-nulling method during normoxia (PO2 approximately 100 Torr) and hypoxia (PO2 less than 50 Torr). In normoxic adult ferret lungs, approximately 40% of total vascular resistance was in arteries, approximately 40% was in microvessels, and approximately 20% was in veins. With hypoxia, the total arteriovenous pressure drop increased by 68%. Arterial and venous pressure drops increased by 92 and 132%, respectively, with no change in microvascular pressure drop. In 3- to 5-wk-old ferret lungs, the vascular pressure profile during normoxia and the response to hypoxia were similar to those in adult lungs. We conclude that, in ferret lungs, arterial and venous resistances increase equally during hypoxia, resulting in increased microvascular pressures for fluid filtration. \n",
      "Generated Text: Pulmonary arterial and venous constriction during hypoxia in 3- to 5-wk-old and adult ferrets. We have determined the sites of hypoxic vasoconstriction in ferret lungs. Lungs of five 3- to 5-wk-old and five adult ferrets were isolated and perfused with blood. Blood flow was adjusted initially to keep pulmonary arterial pressure constant. The lungs were then exposed to hypoxia (0.15% O2) and reperfused. Vasoconstriction was induced by increasing pulmonary arterial pressure to 30 mm Hg. The pulmonary arterial pressure was increased 10 mm Hg above baseline in all five adult ferrets, and in three of five 3- to 5-wk-old ferrets. In five adult ferrets, the mean pulmonary venous pressure was 7.5 +/- 1.6 mm Hg, and in five 3- to 5-wk-old ferrets, it was 9.5 +/- 1.5 mm Hg. In five adult ferrets, the mean pulmonary arterial pressure was 28.1 +/- 1.7 mm Hg, and in five 3- to 5-wk-old ferrets, it was 24.7 +/- 1.4 mm Hg. In the adult ferrets, the mean pulmonary venous pressure was 8.8 +/- 1.3 mm Hg. The pulmonary arterial pressure was 28.1 +/- 1.7 mm Hg. In the 3- to 5-wk-old ferrets, the mean pulmonary venous pressure was 9.5 +/- 1.5 mm Hg. The pulmonary arterial pressure was 24.7 +/- 1.4 mm Hg. In the adult ferrets, the pulmonary venous pressure was 8.8 +/- 1.3 mm Hg. The pulmonary arterial pressure was 28.1 +/- 1.7 mm Hg. In the 3- to 5-wk-old ferrets, the pulmonary venous pressure was 9.5 +/- 1.5 mm Hg. The pulmonary arterial pressure was 24.7 +/- 1.4 mm Hg. In the adult ferrets, the pulmonary venous pressure was 8.8 +/- 1.3 mm Hg. The pulmonary arterial pressure was 28.1 +/- 1.\n",
      "BLEU: 0.20892104177229776, ROUGE-L: {'r': 0.3793103448275862, 'p': 0.5866666666666667, 'f': 0.4607329795235876}, Perplexity: 2.0001630783081055, Cosine Similarity: 0.6129\n",
      "Reference Text: P-31 spectroscopy study of response of superficial human tumors to therapy. Studies were performed to characterize phosphorus-31 magnetic resonance (MR) spectra obtained from 10 superficial human tumors outside the brain and to determine whether P-31 MR spectroscopy could allow detection of a response to therapy before a change in tumor size was measured. The ratio of phosphomonoester to adenosine triphosphate peak intensities (PME/ATP) was unusually large in all tumors studied. The average PME/ATP in lymphomas (1.8 +/- 0.5) was greater than in nonlymphoma cancers (1.1 +/- 0.15). The average PME/ATP for all tumors studied (1.4 +/- 0.5) was much greater than that of underlying skeletal muscle (0.23 +/- .09). Eight of the tumors were studied before and after therapy. Responders were distinguished from nonresponders on the basis of changes in tumor size. PME/ATP decreased during therapy in three lymphomas that responded to therapy. In an adenocarcinoma and Ewing sarcoma that did not respond to therapy, PME/ATP increased. PME/ATP remained constant in two squamous cell carcinomas that responded to therapy and decreased in one squamous cell carcinoma that decreased in size by 40% but was classified as a nonresponder. Changes in PME/ATP did not always parallel changes in tumor size during therapy. In two patients, a decrease in PME/ATP preceded a decrease in tumor size. In four patients, PME/ATP increased transiently during periods when tumor size remained constant. \n",
      "Generated Text: P-31 spectroscopy study of response of superficial human tumors to therapy. Studies were performed to characterize phosphorus-31 magnetic resonance (MR) spectra obtained from 10 superficial human tumors outside the brain and to determine whether P-31 MR spectroscopy could allow detection of a response to therapy before a change in tumor appearance on computed tomography (CT) scans. The tumors were classified as either benign or malignant, and the phosphorus-31 spectra were compared before and after therapy. The malignant tumors were benign, whereas the benign tumors were malignant. The malignant tumors were all small, well-differentiated, and benign, whereas the benign tumors were large, poorly differentiated, and malignant. The benign tumors had a spectrum similar to that of normal muscle, whereas the malignant tumors had a spectrum similar to that of tumor. The malignant tumors showed a decrease in the phosphocreatine peak and a decrease in the phosphomonoester peak after therapy. The benign tumors showed a decrease in the phosphocreatine peak and an increase in the phosphomonoester peak after therapy. The malignant tumors were responsive to therapy, whereas the benign tumors were not. The benign tumors showed a spectrum similar to that of normal muscle, whereas the malignant tumors showed a spectrum similar to that of tumor. The malignant tumors were responsive to therapy, whereas the benign tumors were not. The malignant tumors showed a decrease in the phosphocreatine peak and a decrease in the phosphomonoester peak after therapy. The benign tumors showed a decrease in the phosphocreatine peak and an increase in the phosphomonoester peak after therapy. The malignant tumors were responsive to therapy, whereas the benign tumors were not. The malignant tumors showed a decrease in the phosphocreatine peak and a decrease in the phosphomonoester peak after therapy. The benign tumors showed a decrease in the phosphocreatine peak and an increase in the phosphomonoester peak after therapy. The malignant tumors were responsive to therapy, whereas the benign tumors were not. The malignant tumors showed a decrease in the phosphocreatine peak and a decrease in the phosphomonoester peak after therapy. The benign tumors showed a decrease in the phosphocreatine peak and an increase in the phosphomonoester peak after therapy. The malignant tumors were responsive to therapy, whereas the benign tumors were not. The malignant tumors showed a decrease in the phosphocreatine peak and a decrease in the phosphomonoester peak after therapy.\n",
      "BLEU: 0.1625086129306393, ROUGE-L: {'r': 0.3821138211382114, 'p': 0.6103896103896104, 'f': 0.4699999952645}, Perplexity: 1.9000688791275024, Cosine Similarity: 0.5255\n",
      "Reference Text: Failure to detect human T-cell leukemia virus-related sequences in multiple sclerosis blood. We tested 11 patients with multiple sclerosis for the presence of human T-cell leukemia virus type I (HTLV-I)- or type II (HTLV-II)-related sequences. DNA from blood mononuclear cells was analyzed by the polymerase chain reaction utilizing three different oligonucleotide primer pairs. Two of these primer pairs detect sequences shared between HTLV-I and HTLV-II in either p24, gag protein, or in p21, env transmembrane protein. The third primer pair was synthesized based on regions in the pol gene where amino acid sequences are conserved between HTLV-I, HTLV-II, and the related bovine leukemia virus. The multiple sclerosis samples were consistently negative while appropriate control samples were positive. We conclude that viruses related to HTLV-I, HTLV-II, or bovine leukemia virus are not present in the blood of patients with multiple sclerosis and, therefore, that HTLV-bovine leukemia virus-related viruses are not likely to be involved in the pathogenesis of multiple sclerosis. \n",
      "Generated Text: Failure to detect human T-cell leukemia virus-related sequences in multiple sclerosis blood. We tested 11 patients with multiple sclerosis for the presence of human T-cell leukemia virus type I (HTLV-I)- or type II (HTLV-II)-related sequences. DNA from blood mononuclear cells was analyzed by the polymerase chain reaction utilizing three different oligonucleotide primers for HTLV-I and one primer for HTLV-II. The results were compared with those of 11 age-matched healthy controls. All 11 patients were found to be HTLV-I seropositive. None of the patients was found to be HTLV-II seropositive. The results suggest that the frequency of HTLV-I infection in multiple sclerosis patients is low and that HTLV-II infection is rare in this disease.\n",
      "BLEU: 0.33228099445624987, ROUGE-L: {'r': 0.5102040816326531, 'p': 0.7142857142857143, 'f': 0.5952380903769843}, Perplexity: 3.272679090499878, Cosine Similarity: 0.8078\n",
      "Reference Text: Psychological outcomes of different treatment policies in women with early breast cancer outside a clinical trial OBJECTIVES--To assess outside a clinical trial the psychological outcome of different treatment policies in women with early breast cancer who underwent either mastectomy or breast conservation surgery depending on the surgeon's opinion or the patient's choice. To determine whether the extent of psychiatric morbidity reported in women who underwent breast conservation surgery was associated with their participation in a randomised clinical trial. DESIGN--Prospective, multicentre study capitalising on individual and motivational differences among patients and the different management policies among surgeons for treating patients with early breast cancer. SETTING--12 District general hospitals, three London teaching hospitals, and four private hospitals. PATIENTS--269 Women under 75 with a probable diagnosis of stage I or II breast cancer who were referred to 22 different surgeons. INTERVENTIONS--Surgery and radiotherapy or adjuvant chemotherapy, or both, depending on the individual surgeon's stated preferences for managing early breast cancer. MAIN OUTCOME MEASURES--Anxiety and depression as assessed by standard methods two weeks, three months, and 12 months after surgery. RESULTS--Of the 269 women, 31 were treated by surgeons who favoured mastectomy, 120 by surgeons who favoured breast conservation, and 118 by surgeons who offered a choice of treatment. Sixty two of the women treated by surgeons who offered a choice were eligible to choose their surgery, and 43 of these chose breast conserving surgery. The incidences of anxiety, depression, and sexual dysfunction were high in all treatment groups. There were no significant differences in the incidences of anxiety and depression between women who underwent mastectomy and those who underwent lumpectomy. A significant effect of surgeon type on the incidence of depression was observed, with patients treated by surgeons who offered a choice showing less depression than those treated by other surgeons (p = 0.06). There was no significant difference in psychiatric morbidity between women treated by surgeons who offered a choice who were eligible to choose their treatment and those in the same group who were not able to choose. Most of the women (159/244) gave fear of cancer as their primary fear rather than fear of losing a breast. The overall incidences of psychiatric morbidity in women who underwent mastectomy and those who underwent lumpectomy were similar to those found in the Cancer Research Campaign breast conservation study. At 12 months 28% of women who underwent mastectomy in the present study were anxious compared with 26% in the earlier study, and 27% of women in the present study who underwent lumpectomy were anxious compared with 31% in the earlier study. In both the present and earlier study 21% of women who underwent mastectomy were depressed, and 19% of women who underwent lumpectomy in the present study were depressed compared with 27% in the earlier study.) CONCLUSIONS--There is still no evidence that women with early breast cancer who undergo breast conservation surgery have less psychiatric morbidity after treatment than those who undergo mastectomy. Women who surrender autonomy for decision making by agreeing to participate in randomised clinical trials do not experience any different psychological, sexual, or social problems from those women who are treated for breast cancer outside a clinical trial. \n",
      "Generated Text: Psychological outcomes of different treatment policies in women with early breast cancer outside a clinical trial OBJECTIVES--To assess outside a clinical trial the psychological outcome of different treatment policies in women with early breast cancer who underwent either mastectomy or breast conservation surgery depending on the surgeon's opinion or the patient's preference. PATIENTS AND METHODS--One hundred and twenty-nine women with early breast cancer were treated between 1984 and 1991. All patients were followed up for a minimum of 3 years. RESULTS--One hundred and twenty-six women were treated according to the surgeon's preference (SOP) and 3 were treated according to the patient's preference (PP). The psychological outcome was assessed by the Hospital Anxiety and Depression Scale (HADS) and the Hospital Anxiety and Depression Scale--Short Form (HADS-SF). The HADS-SF score was significantly lower in the group of women treated according to the SOP than in the PP group (P<.001). The mean HADS-SF score in the PP group was significantly lower than in the SOP group (P<.001). The mean HADS score was significantly lower in the PP group than in the SOP group (P<.001). The mean HADS-SF score in the PP group was significantly lower than in the SOP group (P<.001). The mean HADS score in the PP group was significantly lower than in the SOP group (P<.001). The mean HADS-SF score in the PP group was significantly lower than in the SOP group (P<.001). The mean HADS score in the PP group was significantly lower than in the SOP group (P<.001). The mean HADS score in the PP group was significantly lower than in the SOP group (P<.001). The mean HADS score in the PP group was significantly lower than in the SOP group (P<.001). The mean HADS score in the PP group was significantly lower than in the SOP group (P<.001). The mean HADS score in the PP group was significantly lower than in the SOP group (P<.001). The mean HADS score in the PP group was significantly lower than in the SOP group (P<.001). The mean HADS score in the PP group was significantly lower than in the SOP group (P<.001). The mean HADS score in the PP group was significantly lower than in the SOP group (P<.\n",
      "BLEU: 0.12135776104742324, ROUGE-L: {'r': 0.2102803738317757, 'p': 0.5421686746987951, 'f': 0.3030302990030496}, Perplexity: 1.8542495965957642, Cosine Similarity: 0.4736\n",
      "Reference Text: Partial laryngectomy after irradiation failure. Forty-three patients who had partial laryngectomies after radiotherapy were evaluated. Forty-two had failed irradiation for laryngeal carcinoma. Nine had supraglottic procedures, 3 endoscopic, and 31 vertical partial. Twelve (28%) required subsequent completion laryngectomy. Major complications included laryngeal stenosis in 1, incompetent laryngeal sphincters in 2, mucocutaneous fistulas in 3, and delayed deglutition in 3. Six patients had positive permanent section margins. In 5 of those, intraoperative frozen sections had been taken and were negative. Recurrent or persistent disease was eventually demonstrated in all patients with positive margins. The 2-year determinant disease-free survival rate for stage I and II disease was 85%. Three-year disease-free survival was 50% for stage III and IV disease. Partial laryngectomies, including supraglottic, can be done after irradiation failure with a high expectation of cure and acceptable morbidity. Immediate additional operation should be considered in patients with positive margins. \n",
      "Generated Text: Partial laryngectomy after irradiation failure. Forty-three patients who had partial laryngectomies after radiotherapy were evaluated. Forty-two had failed irradiation for laryngeal carcinoma. Nine had supraglottic procedures, 3 endoscopic, and 31 vertical partial. Twelve (28%) required subsequent completion laryngectomy. Major complications included laryngeal stenosis in 1, incompetent laryngeal sphincters in 2, and respiratory failure in 1. Median follow-up was 29 months. The 3-year actuarial survival rate for the entire group was 62%. Survival was worse for those who had failed irradiation (55%) than for those who had not (75%). The actuarial survival rate for those who had failed irradiation was 41% at 3 years. The actuarial survival rate for those who had failed irradiation was 55% at 3 years for those who had not. The actuarial survival rate for those who had failed irradiation was 41% at 3 years. The actuarial survival rate for those who had failed irradiation was 55% at 3 years. The actuarial survival rate for those who had failed irradiation was 55% at 3 years. The actuarial survival rate for those who had failed irradiation was 55% at 3 years. The actuarial survival rate for those who had failed irradiation was 55% at 3 years. The actuarial survival rate for those who had failed irradiation was 55% at 3 years. The actuarial survival rate for those who had failed irradiation was 55% at 3 years. The actuarial survival rate for those who had failed irradiation was 55% at 3 years. The actuarial survival rate for those who had failed irradiation was 55% at 3 years. The actuarial survival rate for those who had failed irradiation was 55% at 3 years. The actuarial survival rate for those who had failed irradiation was 55% at 3 years. The actuarial survival rate for those who had failed irradiation was 55% at 3 years. The actuarial survival rate for those who had failed irradiation was 55% at 3 years. The actuarial survival rate for those who had failed\n",
      "BLEU: 0.16149011235748442, ROUGE-L: {'r': 0.4411764705882353, 'p': 0.6617647058823529, 'f': 0.5294117599058824}, Perplexity: 1.9113129377365112, Cosine Similarity: 0.4026\n",
      "Reference Text: Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. We conducted a randomized, controlled trial in 72 patients with heterozygous familial hypercholesterolemia to test whether reducing plasma low-density lipoprotein levels by diet and combined drug regimens can induce regression of coronary lesions. Four hundred fifty-seven lesions were measured before and after a 26-month interval by computer-based quantitative angiography. The primary outcome variable was within-patient mean change in percent area stenosis. Mean low-density lipoprotein cholesterol levels decreased from 7.32 +/- 1.5 to 4.45 +/- 1.6 mmol/L. The mean change in percent area stenosis among controls was +0.80, indicating progression, while the mean change for the treatment group was -1.53, indicating regression (P = .039 by two-tailed t test for the difference between groups). Regression among women, analyzed separately, was also significant. The change in percent area stenosis was correlated with low-density lipoprotein levels on trial. We conclude that reduction of low-density lipoprotein cholesterol levels can induce regression of atherosclerotic lesions of the coronary arteries in patients with familial hypercholesterolemia. The anticipation of benefit from treatment applies to women and men alike. \n",
      "Generated Text: Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. We conducted a randomized, controlled trial in 72 patients with heterozygous familial hypercholesterolemia to test whether reducing plasma low-density lipoprotein levels by diet and combined drug regimens can induce regression of coronary lesions. Four hundred fifty-seven lesions were analyzed by coronary angiography before and after therapy. In 19 patients (26%) the coronary lesions regressed. Regression was most frequent in patients who received the combined drug regimen and had a low initial low-density lipoprotein level (p = 0.01) and the highest initial total cholesterol level (p = 0.01). Regression was associated with a reduction in the total cholesterol level (p = 0.03) and the low-density lipoprotein level (p = 0.04). Regression was also associated with a reduction in the plasma triglyceride level (p = 0.04). Regression was associated with a reduction in the mean coronary artery diameter (p = 0.01). Regression of coronary lesions was associated with a reduction in the plasma low-density lipoprotein level. Regression of coronary lesions was associated with a reduction in the plasma triglyceride level. Regression of coronary lesions was associated with a reduction in the mean coronary artery diameter. Regression of coronary lesions was associated with a reduction in the total cholesterol level. Regression of coronary lesions was associated with a reduction in the total cholesterol level. Regression of coronary lesions was associated with a reduction in the plasma triglyceride level. Regression of coronary lesions was associated with a reduction in the plasma triglyceride level. Regression of coronary lesions was associated with a reduction in the mean coronary artery diameter. Regression of coronary lesions was associated with a reduction in the mean coronary artery diameter. Regression of coronary lesions was associated with a reduction in the mean coronary artery diameter. Regression of coronary lesions was associated with a reduction in the mean coronary artery diameter. Regression of coronary lesions was associated with a reduction in the mean coronary artery diameter. Regression of coronary lesions was associated with a reduction in the mean coronary artery diameter. Regression of coronary lesions was associated with a reduction in the mean coronary artery diameter. Regression of coronary lesions was associated with a reduction in the mean coronary artery diameter. Regression of coronary lesions was associated with a reduction in the mean coronary artery diameter. Regression of coronary lesions was associated with a reduction in the mean coronary artery diameter. Regression\n",
      "BLEU: 0.15083872364370207, ROUGE-L: {'r': 0.45535714285714285, 'p': 0.6623376623376623, 'f': 0.5396825348540075}, Perplexity: 1.8714983463287354, Cosine Similarity: 0.6432\n",
      "Reference Text: Doxazosin in the treatment of mild or moderate essential hypertension: an echocardiographic study. Sixteen patients with mild or moderate essential hypertension received 1 to 8 mg/day of doxazosin (mean daily dose, 2.7 mg). Blood pressure reduction (supine and standing) was highly significant (p less than 0.001), and no significant changes in heart rate were observed. A significant reduction (p less than 0.01) in left ventricular mass was seen without a change in left ventricular systolic function. All side effects were mild, and only one patient withdrew from the study. \n",
      "Generated Text: Doxazosin in the treatment of mild or moderate essential hypertension: an echocardiographic study. Sixteen patients with mild or moderate essential hypertension received 1 to 8 mg/day of doxazosin (mean daily dose, 2.7 mg). Blood pressure reduction (supine and standing) was highly significant (p less than 0.001), and no significant changes in heart rate or left ventricular ejection fraction were observed. However, no significant improvement in left ventricular mass index was observed. No adverse effects were noted. The efficacy of doxazosin in the treatment of mild or moderate essential hypertension is discussed.\n",
      "BLEU: 0.6361332047055246, ROUGE-L: {'r': 0.7571428571428571, 'p': 0.8153846153846154, 'f': 0.7851851801920439}, Perplexity: 3.7573769092559814, Cosine Similarity: 0.8661\n",
      "Reference Text: Should you cancel the operation when a child has an upper respiratory tract infection? Cancelling an operation when a child has an upper respiratory tract infection (URI) is not always feasible or practical. Yet we know very little about the additional risk posed by a URI occurring in a child undergoing anesthesia and surgery. Using a large prospectively collected pediatric anesthesia database, we studied 1283 children with a preoperative URI and 20,876 children without a URI. We found that children with a URI were two to seven times more likely to experience respiratory-related adverse events during the intraoperative, recovery room, and postoperative phases of their operative experience. Although these children also experienced significant disruptions in temperature regulation, they were not at risk for any other deleterious events. The elevation in risk after URI as compared with children without a URI was not explained by differences in age, physical status scores, surgical site, and emergency or elective status. However, if a child had a URI and had endotracheal anesthesia, the risk of a respiratory complication increased 11-fold (95% confidence intervals 6.8, 18.1). We conclude that the administration of general anesthesia to children with a URI is not benign and that these children require more observation/management in all perioperative phases of their surgical procedure. \n",
      "Generated Text: Should you cancel the operation when a child has an upper respiratory tract infection? Cancelling an operation when a child has an upper respiratory tract infection (URI) is not always feasible or practical. Yet we know very little about the additional risk posed by a URI occurring in a child undergoing surgery. We therefore reviewed the literature to determine whether cancelling an operation because of a URI was associated with an increased risk of postoperative morbidity. A literature search was performed using the MEDLINE database. We identified 13 studies, including 1,010 patients. The mean age of the patients was 13.4 years (range 2-18 years). The mean operation time was 62.4 minutes (range 30-160 minutes). There were no differences in the incidence of postoperative complications between the patients who cancelled their operation and those who did not. A child who has a URI should not be cancelled from surgery unless the condition is very severe. A decision to cancel an operation should be made on a case-by-case basis.\n",
      "BLEU: 0.2659131001117257, ROUGE-L: {'r': 0.366412213740458, 'p': 0.46601941747572817, 'f': 0.4102564053280007}, Perplexity: 4.537996768951416, Cosine Similarity: 0.5983\n",
      "Reference Text: A seromuscular stripping method to create a nipple valve without metal stapling for continent urinary reservoir. Urinary continence with a Kock or Mainz pouch is achieved by a nipple valve of the invaginated ileum which is usually fixed with metal staples. However, metal staples can cause various complications as a foreign body. The seromuscular stripping method, a new technique to create a nipple valve, was applied to 17 patients with bladder cancer in the construction of a continent urinary reservoir by the ileocolonic pouch (Mainz pouch). Metal staples were not used. The results were satisfactory except for 2 patients who became incontinent because of prolapse of the nipple in one and insufficient valve function due to ischemic change of the nipple valve in the other. Histology of the nipple valve from an autopsy case showed a good double layer nipple valve that functioned well to preserve continence. \n",
      "Generated Text: A seromuscular stripping method to create a nipple valve without metal stapling for continent urinary reservoir. Urinary continence with a Kock or Mainz pouch is achieved by a nipple valve of the invaginated ileum which is usually fixed with metal staples. However, metal staples can cause various complications as a result of the fixation of the nipple valve. A seromuscular method was developed to create a nipple valve without metal staples. This method was compared with the traditional method of metal stapling. The seromuscular method was applied to 10 patients with a Kock pouch and 10 patients with a Mainz pouch. The seromuscular method was found to be superior to the metal stapling method in terms of the incidence of urinary leakage, the number of operations, the amount of blood loss, the time of operation, and the duration of urinary drainage. The seromuscular method was also superior to the metal stapling method in terms of the amount of urine loss and the number of days of urinary drainage. The seromuscular method is a simple, safe, and effective method to create a nipple valve without metal staples.\n",
      "BLEU: 0.32926179338695005, ROUGE-L: {'r': 0.4946236559139785, 'p': 0.6133333333333333, 'f': 0.5476190426764457}, Perplexity: 4.753115653991699, Cosine Similarity: 0.8057\n",
      "Reference Text: Doppler echocardiographic assessment of changes in pulmonary artery pressure associated with vasodilating therapy in patients with congestive heart failure. Transpulmonic pressure gradient and pulmonary artery pressures can be estimated from the Doppler pulmonary regurgitant flow velocities by applying the simplified Bernoulli equation. In this study, continuous-wave Doppler echocardiography was used to assess changes in pulmonary regurgitant flow velocities associated with administration of vasodilators in 10 patients with congestive heart failure. M-Mode echocardiographic parameters such as left ventricular end-systolic and end-diastolic dimension and fractional shortening did not change with administration of vasodilators. Pulmonary regurgitant flow velocity at end diastole decreased from 1.9 +/- 0.6 to 1.3 +/- 0.3 m/sec (p less than 0.01), and Doppler-estimated transpulmonic pressure gradient at end diastole decreased from 16 +/- 11 to 8 +/- 4 mm Hg (p less than 0.01). Doppler-estimated transpulmonic pressure gradient at end diastole was compared with catheterization-determined pulmonary arterial end-diastolic pressure before and after administration of vasodilators in three patients, and there was a good agreement between these measurements. Thus noninvasive and sensitive assessment of the effect of vasodilators on pulmonary arterial end-diastolic pressure in patients with congestive heart failure is possible with continuous-wave Doppler echocardiographic measurement of pulmonary regurgitant flow velocities. \n",
      "Generated Text: Doppler echocardiographic assessment of changes in pulmonary artery pressure associated with vasodilating therapy in patients with congestive heart failure. Transpulmonic pressure gradient and pulmonary artery pressures can be estimated from the Doppler pulmonary regurgitant flow velocities by applying the simplified Bernoulli equation. In this study, continuous-wave Doppler echocardiography was used to assess the effects of vasodilating therapy on pulmonary artery pressure. A group of 15 patients with congestive heart failure and severe pulmonary hypertension was studied. The patients were randomized to receive either intravenous nitroglycerin or intravenous furosemide. The pulmonary artery pressures were estimated from the transpulmonic pressure gradient and the pulmonary regurgitant flow velocities. The pulmonary artery pressures were increased after intravenous nitroglycerin infusion, but not after intravenous furosemide infusion. In the nitroglycerin group, the transpulmonic pressure gradient increased from 4.3 +/- 1.5 mm Hg (mean +/- SD) to 9.4 +/- 2.3 mm Hg (P <.01), and the pulmonary artery pressures increased from 40 +/- 8 mm Hg to 44 +/- 6 mm Hg (P <.05). In the furosemide group, the transpulmonic pressure gradient increased from 2.9 +/- 1.3 mm Hg to 6.6 +/- 1.7 mm Hg (P <.01), and the pulmonary artery pressures increased from 35 +/- 6 mm Hg to 42 +/- 5 mm Hg (P <.05). The pulmonary artery pressures were increased after intravenous nitroglycerin infusion, but not after intravenous furosemide infusion. In the nitroglycerin group, the transpulmonic pressure gradient increased from 4.3 +/- 1.5 mm Hg to 9.4 +/- 2.3 mm Hg (P <.01), and the pulmonary artery pressures increased from 40 +/- 8 mm Hg to 44 +/- 6 mm Hg (P <.05). In the furosemide group, the transpulmonic pressure gradient increased from 2.9 +/- 1.3 mm Hg to 6.6 +/- 1.7 mm Hg (P <.01), and the pulmonary artery pressures increased from \n",
      "BLEU: 0.22071769854887632, ROUGE-L: {'r': 0.5229357798165137, 'p': 0.6333333333333333, 'f': 0.5728643166536199}, Perplexity: 1.860083818435669, Cosine Similarity: 0.5353\n",
      "Reference Text: Aberrant origin of the right coronary artery as a potential cause of sudden death: successful anatomical correction. A man with an aberrant right coronary artery and haemodynamically important prolapse of the mitral valve was successfully resuscitated. The aberrant right coronary artery was thought to be a possible cause of the cardiopulmonary arrest in this patient. Both lesions were corrected at a single operation. \n",
      "Generated Text: Aberrant origin of the right coronary artery as a potential cause of sudden death: successful anatomical correction. A man with an aberrant right coronary artery and haemodynamically important prolapse of the mitral valve was successfully resuscitated. The aberrant right coronary artery was thought to be a possible cause of the sudden death. The cause of the sudden death is unknown. The patient had a history of a sudden death from aortic regurgitation in the immediate preceeding year. The right coronary artery was thought to be the cause of the sudden death. The right coronary artery was not palpable at the time of the sudden death. The patient had a history of a sudden death from aortic regurgitation in the immediate preceeding year. The right coronary artery was thought to be the cause of the sudden death. The right coronary artery was not palpable at the time of the sudden death. A successful surgical correction of the aberrant origin of the right coronary artery was performed. The patient survived the operation and the post-operative course. The patient died of an acute myocardial infarction 2 years after the operation. A successful surgical correction of the aberrant origin of the right coronary artery was performed. The patient survived the operation and the post-operative course. The patient died of an acute myocardial infarction 2 years after the operation. The aberrant origin of the right coronary artery was thought to be a potential cause of the sudden death. The cause of the sudden death is unknown. The aberrant origin of the right coronary artery was thought to be a potential cause of the sudden death. The cause of the sudden death is unknown. The patient had a history of a sudden death from aortic regurgitation in the immediate preceeding year. The right coronary artery was not palpable at the time of the sudden death. The patient had a history of a sudden death from aortic regurgitation in the immediate preceeding year. The right coronary artery was thought to be the cause of the sudden death. The right coronary artery was not palpable at the time of the sudden death. The patient had a history of a sudden death from aortic regurgitation in the immediate preceeding year. The right coronary artery was thought to be the cause of the sudden death. The right coronary artery was not palpable at the time of the sudden death. The patient had a history of a sudden death from aortic regurgitation\n",
      "BLEU: 0.12070630239934159, ROUGE-L: {'r': 0.8125, 'p': 0.6, 'f': 0.6902654818388284}, Perplexity: 1.8418278694152832, Cosine Similarity: 0.7567\n",
      "Reference Text: Immunophenotypes in \"classical\" B-cell chronic lymphocytic leukemia. Correlation with normal cellular counterpart and clinical findings. This study evaluates the expression of a series of membrane antigens, normally expressed by B-lymphocytes of the lymphocytic mantle and marginal zone, in 90 selected cases of \"classical\" (mouse red blood cell-receptor+, CD20+, CD5+, surface immunoglobulin +/-) B-chronic lymphocytic leukemia (B-CLL) with the aim of contributing toward identifying the normal counterpart of B-CLL and any correlations between surface antigen pattern and certain clinical characteristics. Clustered (CD23, 25, 39, 40, 27, 1c, w75) and unclustered (NuB1, 7F7, KiB3) monoclonal antibodies (MoAb) were tested. Almost all cases showed high reactivity to CD23, 27, w75, 39, 40, and NuB1: expression of CD1c was very low and that of 7F7, KiB3, and CD25 was variable. The reactivity of 7F7 and KiB3 was strictly correlated, and they correlated individually with CD25. Results show that the most frequent B-CLL phenotype (CD19+, 5+, 23+, 27+, 39+, NuB1+, KiB3 +/-, 7F7 +/-, and CD25 +/-) corresponds to one or more cellular subsets in the mantle zone. No correlation was found between MoAb expression, surface immunoglobulin (SIg) class or type, clinical stage, disease activity, or age at diagnosis. The only difference (statistically borderline) was the expression of 7F7 and KiB3 (in young versus old patients). This suggests that modulations in the expression of surface antigens do not affect the clinical behavior of the disease. \n",
      "Generated Text: Immunophenotypes in \"classical\" B-cell chronic lymphocytic leukemia. Correlation with normal cellular counterpart and clinical findings. This study evaluates the expression of a series of membrane antigens, normally expressed by B-lymphocytes of the lymphocytic mantle and marginal zone, in 90 selected cases of \"classical\" (mouse red blood cell-receptor+, CD20+, CD5+, surface immunoglobulin+) B-cell chronic lymphocytic leukemia (B-CLL) and in 12 cases of B-cell chronic lymphocytic leukemia (B-CLL) with a normal expression of surface immunoglobulin. The expression of the following antigens was studied: CD19, CD21, CD22, CD23, CD25, CD79a, CD79b, CD40, CD43, CD81, CD81, CD80, and CD86. In 90% of cases of B-CLL, the expression of CD19, CD21, CD22, and CD23 was normal or only slightly decreased. In 10% of cases, however, a marked decrease in the expression of these antigens was observed. In 10% of cases, CD25, CD79a, and CD79b were expressed at a normal or increased level. In 10% of cases, CD40, CD43, CD81, CD81, CD80, and CD86 were expressed at a normal or increased level. In 10% of cases, the expression of CD86 was increased, whereas in 10% of cases it was decreased. In the 12 cases of B-CLL with normal expression of surface immunoglobulin, the expression of CD19, CD21, CD22, CD23, CD25, CD40, CD43, CD81, CD81, CD80, and CD86 was normal or only slightly decreased. In 10% of cases, CD25, CD79a, and CD79b were expressed at a normal or increased level. In 10% of cases, CD40, CD43, CD81, CD81, CD80, and CD86 were expressed at a normal or increased level. In 10% of cases, the expression of CD86 was increased, whereas in 10% of cases it was decreased. In the 12 cases of B-CLL with a normal expression of surface immunoglobulin, the expression of CD19\n",
      "BLEU: 0.22473693883764115, ROUGE-L: {'r': 0.3422818791946309, 'p': 0.5730337078651685, 'f': 0.42857142388920283}, Perplexity: 2.331937789916992, Cosine Similarity: 0.7023\n",
      "Reference Text: Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging. The c-myb protooncogene is preferentially expressed in hematopoietic cells, and its encoded protein, Myb, is required for hematopoietic cell proliferation. To analyze the relative Myb dependence of normal and leukemic human hematopoietic progenitor cells, normal bone marrow cells, several types of leukemic blast cells, and 1:1 mixtures of normal and leukemic cells were cultured in the presence of c-myb sense or antisense oligodeoxynucleotides; cell viability and cloning efficiency were then assessed. c-myb sense oligomers had negligible effects on normal and leukemic cells. In contrast, c-myb antisense oligomers strongly inhibited or completely abolished clonogenic growth of a T-cell leukemia line, 78% (18 of 23) of primary acute myelogenous leukemia cases examined, and 4 of 5 primary chronic myelogenous leukemia (CML) cases in blast crisis. In three of the latter patients, polymerase chain reaction analysis of a 1:1 mixture of c-myb antisense-treated normal and CML cells revealed a complete absence of bcr-abl expression, suggesting that the CML clonogenic units had been completely eliminated from the cultures. At antisense doses that inhibited leukemic cell growth, normal hematopoietic progenitor cells survived. Thus, normal and leukemic hematopoietic cells show differential sensitivity to the toxic effects of c-myb antisense DNA. Perturbation of c-myb function with antisense oligodeoxynucleotides might eventually form the basis for a molecular approach to leukemia therapy, perhaps most immediately as ex vivo bone marrow purging agents. \n",
      "Generated Text: Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging. The c-myb protooncogene is preferentially expressed in hematopoietic cells, and its encoded protein, Myb, is required for hematopoietic cell proliferation. To analyze the relative Myb dependence of hematopoietic cell proliferation, we have examined the effects of c-myb antisense oligodeoxynucleotides (ODN) on normal and leukemic hematopoietic cell proliferation. Normal hematopoietic cells, such as CD34+ cells, are less sensitive to the inhibitory effects of c-myb ODN than leukemic cells, such as CD34- cells. Furthermore, the degree of Myb dependence of hematopoietic cell proliferation is related to the degree of sensitivity of the cell to the inhibitory effects of c-myb ODN. Thus, CD34- cells are more sensitive to the inhibitory effects of c-myb ODN than CD34+ cells. These results suggest that the Myb protein is required for the proliferation of hematopoietic cells, and that the degree of Myb dependence of hematopoietic cell proliferation is related to the degree of sensitivity of the cell to the inhibitory effects of c-myb ODN.\n",
      "BLEU: 0.25351932928909027, ROUGE-L: {'r': 0.35, 'p': 0.7, 'f': 0.4666666622222223}, Perplexity: 2.6651577949523926, Cosine Similarity: 0.7787\n",
      "Reference Text: Treatment of ventricular tachycardia induced cardiogenic shock by percoronary chemical ablation. Incessant ventricular arrhythmias pose an especially challenging therapeutic dilemma. We describe the successful treatment and follow-up of a patient with refractory ventricular tachycardia-induced cardiogenic shock with percoronary chemical ablation. After endocardial mapping was used to identify the \"tachycardia-related\" coronary artery, temporary termination of the arrhythmia with balloon occlusion and subselective intracoronary installation of iced saline as previously advocated was unsuccessful. This was probably due to a dual arterial blood supply to the arrhythmogenic focus. However, infusion of 2 cc ethanol (99%) permanently terminated the arrhythmia. Contrary to previous experience, ethanol-induced arrhythmia termination did not result in arterial occlusion, further supporting a direct toxic effect on the myocardium as its mode of action. Use of standard angioplasty balloon inflation prevents \"backwash\" of distally infused ethanol and more generalized cell death. The only complication of this procedure was temporary third-degree AV block, requiring permanent pacemaker implantation. \n",
      "Generated Text: Treatment of ventricular tachycardia induced cardiogenic shock by percoronary chemical ablation. Incessant ventricular arrhythmias pose an especially challenging therapeutic dilemma. We describe the successful treatment and follow-up of a patient with refractory ventricular tachycardia-induced cardiogenic shock with percoronary chemical ablation. After endocardial mapping was used to identify the \"tachycardia-related\" coronary vessels, a 30-gauge catheter was used to perform percoronary chemical ablation. The catheter was advanced to the coronary sinus and the left anterior descending coronary artery. The catheter was then advanced into the left ventricle and positioned in the right ventricle. The catheter was then withdrawn and the percoronary chemical ablation was completed. The patient was discharged on postoperative day 10 without further ventricular arrhythmias. We believe that percoronary chemical ablation is a safe and effective method for treating ventricular tachycardia-induced cardiogenic shock.\n",
      "BLEU: 0.3379463308441286, ROUGE-L: {'r': 0.3706896551724138, 'p': 0.581081081081081, 'f': 0.45263157419168976}, Perplexity: 3.7831928730010986, Cosine Similarity: 0.6619\n",
      "Reference Text: Cardiorespiratory effects of endoscopic esophageal variceal sclerotherapy. Endoscopic variceal sclerotherapy (EVS) is an effective means of controlling variceal hemorrhage, which develops as a consequence of portal hypertension. While esophageal perforation, ulceration, strictures, and mediastinitis are potential complications associated with this procedure, it is not clear whether isolated pleuropulmonary events such as pleuritis, pneumonitis, and adult respiratory distress syndrome are causally related to the EVS. Endoscopy and sedation with the attendant risk of aspiration, particularly in the background of hepatic encephalopathy, may account for some of these events. Recent controlled studies of respiratory function demonstrate that EVS as such results in minor changes in gas exchange, lung volumes, and pulmonary and systemic hemodynamics. Most pulmonary complications have been reported with the use of sodium morrhuate sclerosant. Comparative studies among different sclerosants are necessary to evaluate relative safety. Finally, there have been rare reports of myocardial ischemia and pericarditis reported in association with EVS, but these are of a transient nature. Chest symptoms, roentgenographic pleuropulmonary changes, pulmonary hemodynamics, and cardiac perturbations are transient and should not preclude offering EVS to patients with variceal hemorrhage. \n",
      "Generated Text: Cardiorespiratory effects of endoscopic esophageal variceal sclerotherapy. Endoscopic variceal sclerotherapy (EVS) is an effective means of controlling variceal hemorrhage, which develops as a consequence of portal hypertension. While esophageal perforation, ulceration, strictures, and mediastinitis are potential complications associated with this procedure, it is not clear whether isolated pleuropulmonary events such as pleural effusions and atelectasis occur. The purpose of this study was to determine the incidence of pleuropulmonary complications associated with EVS. The study population consisted of 100 consecutive patients undergoing EVS for variceal hemorrhage. The incidence of atelectasis, pleural effusions, and mediastinitis was determined. The pleural effusions and mediastinitis occurred in 5 patients (5%) and 2 patients (2%), respectively. The incidence of atelectasis was 2.5%. The pleural effusions and atelectasis occurred in the setting of portal hypertension. The incidence of atelectasis and pleural effusions in this series is low compared with the incidence reported in the literature. These findings suggest that EVS is associated with a low incidence of pleuropulmonary complications, although it is not clear whether these events are related to portal hypertension or to the use of general anesthesia.\n",
      "BLEU: 0.33552728288310785, ROUGE-L: {'r': 0.42857142857142855, 'p': 0.5806451612903226, 'f': 0.4931506800450367}, Perplexity: 3.1186795234680176, Cosine Similarity: 0.7098\n",
      "Reference Text: Growth and spread of hepatocellular carcinoma. A review of 240 consecutive autopsy cases. All 240 consecutive cases of hepatocellular carcinoma (HCC) that underwent autopsy at the National Cancer Center Hospital (Tokyo, Japan) between September 1962 and August 1986 were reviewed. Among these cases, 162, for which photographs of cut surfaces of the primary tumors were available, were grossly classified using a combination of both Eggel's classification and our own into three major types, i.e., nodular, massive, and diffuse as described by Eggel (Eggel H, Beitr Pathol Anat 1901; 30:506-604), and three subgroups of nodular type, i.e., single nodular type (type 1), single nodular type with extranodular growth (type 2), and contiguous multinodular type (type 3) by our classification (Kanai T et al., Cancer 1987; 60:810-819). Seventy-eight cases were classified as nodular type, comprising seven cases of type 1, 61 cases of type 2, and ten cases of type 3. Sixty-seven and 17 cases were classified as massive and diffuse type, respectively. Of the 78 nodular-type tumors, 59 measured less than 10 cm, whereas 64 of 67 massive-type tumors were 10 cm or more in size. The incidence of intrahepatic and extrahepatic tumor spread of HCC was significantly higher for tumors measuring more than 5 cm. As to the relationship between macroscopic type and tumor spread, the frequency of spread was lowest for type 1 tumors, and high for the other types. Intrahepatic metastasis was detected in 28.6% of type 1, 93.4% of type 2, 100% of type 3, and 98.5% of massive-type tumors. Lymph node metastasis was detected in 14.3% of type 1, 24.6% of type 2, 70% of type 3, 38.8% of massive-type and 52.9% of diffuse-type tumors. Hematogenous extrahepatic metastasis was detected in 14.3% of type 1, 47.5% of type 2, 70% of type 3, 74.6% of massive-type and 82.4% of diffuse-type tumors. It appears that not only primary tumor size but also its macroscopic type has an important influence on the growth and spread of HCC. \n",
      "Generated Text: Growth and spread of hepatocellular carcinoma. A review of 240 consecutive autopsy cases. All 240 consecutive cases of hepatocellular carcinoma (HCC) that underwent autopsy at the National Cancer Center Hospital (Tokyo, Japan) between September 1962 and August 1986 were reviewed. Among these cases, 162, for which photographs of cut surfaces and sections of the liver were available, were included in this study. The mean age was 59.8 years, and the male-to-female ratio was 1.9:1. The most common primary site was the right lobe (62.5%). The mean duration of HCC was 11.9 months, and the mean size of the tumor was 2.7 cm. The most common tumor type was well-differentiated HCC (63.5%), followed by poorly differentiated HCC (29.5%), and the remaining 7.0% were undifferentiated. The most common tumor site was the right lobe (62.5%), followed by the left lobe (26.2%). The most common primary tumor was the right lobe (62.5%), followed by the left lobe (26.2%). The most common primary tumor was the right lobe (62.5%), followed by the left lobe (26.2%). The most common primary tumor was the right lobe (62.5%), followed by the left lobe (26.2%). The most common primary tumor was the right lobe (62.5%), followed by the left lobe (26.2%). The most common primary tumor was the right lobe (62.5%), followed by the left lobe (26.2%). The most common primary tumor was the right lobe (62.5%), followed by the left lobe (26.2%). The most common primary tumor was the right lobe (62.5%), followed by the left lobe (26.2%). The most common primary tumor was the right lobe (62.5%), followed by the left lobe (26.2%). The most common primary tumor was the right lobe (62.5%), followed by the left lobe (26.2%). The most common primary tumor was the right lobe (62.5%), followed by the left lobe (26.2%). The most common primary tumor was the right lobe (62.5%), followed by\n",
      "BLEU: 0.17555715515929024, ROUGE-L: {'r': 0.2849462365591398, 'p': 0.5824175824175825, 'f': 0.38267147573251314}, Perplexity: 1.78388512134552, Cosine Similarity: 0.2752\n",
      "Reference Text: Effect of exposure of miners to aluminium powder. 'McIntyre Powder' (finely ground aluminium and aluminium oxide) was used as a prophylactic agent against silicotic lung disease between 1944 and 1979 in mines in northern Ontario. To find out whether the practice produced neurotoxic effects a morbidity prevalence study was conducted between 1988 and 1989. There were no significant differences between exposed and non-exposed miners in reported diagnoses of neurological disorder; however, exposed miners performed less well than did unexposed workers on cognitive state examinations; also, the proportion of men with scores in the impaired range was greater in the exposed than non-exposed group. Likelihood of scores in the impaired range increased with duration of exposure. The findings are consistent with putative neurotoxicity of chronic aluminium exposure. \n",
      "Generated Text: Effect of exposure of miners to aluminium powder. 'McIntyre Powder' (finely ground aluminium and aluminium oxide) was used as a prophylactic agent against silicotic lung disease between 1944 and 1979 in mines in northern Ontario. To find out whether the practice produced neurotoxic effects a morbidity prevalence study was conducted. A questionnaire was sent to all miners who had been exposed to aluminium powder. A follow-up questionnaire was sent to 1,000 miners who were still alive. The prevalence of neurotoxic effects was 0.2% (1 of 500) in the first questionnaire and 0.1% (1 of 1000) in the follow-up questionnaire. The prevalence of neurotoxic effects was similar in the two groups. The results suggest that exposure to aluminium powder is not associated with neurotoxic effects.\n",
      "BLEU: 0.42034989715751797, ROUGE-L: {'r': 0.5227272727272727, 'p': 0.6216216216216216, 'f': 0.5679012296052431}, Perplexity: 6.545057773590088, Cosine Similarity: 0.7292\n",
      "Reference Text: Ampullary tumor caused by metastatic renal cell carcinoma. In this paper we report the case of a renal cell carcinoma (RCC) metastatic to the ampullary region. The patient presented with severe anemia due to blood loss from the ampullary tumor 11 years after nephrectomy for the primary renal cancer. The diagnosis was established by means of endoscopy and biopsy. \n",
      "Generated Text: Ampullary tumor caused by metastatic renal cell carcinoma. In this paper we report the case of a renal cell carcinoma (RCC) metastatic to the ampullary region. The patient presented with severe anemia due to blood loss from the ampullary tumor 11 years after nephrectomy for the primary renal cancer. The ampullary tumor was removed and the patient's anemia was corrected. The ampullary tumor was diagnosed as a metastatic RCC. The ampullary tumor is a rare manifestation of RCC metastasis. The clinical presentation, diagnostic approach, and treatment are discussed.\n",
      "BLEU: 0.5688174823901995, ROUGE-L: {'r': 0.8695652173913043, 'p': 0.7017543859649122, 'f': 0.7766990241832407}, Perplexity: 3.9864954948425293, Cosine Similarity: 0.8952\n",
      "Reference Text: Photochemotherapy improves chronic cutaneous graft-versus-host disease. We have used oral psoralen photochemotherapy (PUVA) to treat four patients with chronic graft-versus-host disease of the skin, oral mucosa, and liver, who had responded only partially to long-term immunosuppressive therapy (prednisolone, cyclosporine, azathioprine). PUVA therapy was delivered to the entire skin but not to the oral mucosa, and immunosuppressive therapy was continued in all patients. Two patients' skin lesions improved considerably; the oral lesions healed and did not recur in one. Immunosuppressive therapy could be reduced in these two patients. One patient with sicca signs did not improve. One patient had to interrupt PUVA therapy because of side effects attributed to 8-methoxypsoralen (nausea and vomiting). No flare of acute cutaneous graft-versus-host disease was noted during PUVA therapy. Chronic graft-versus-host disease of the liver did not improve in any patient. \n",
      "Generated Text: Photochemotherapy improves chronic cutaneous graft-versus-host disease. We have used oral psoralen photochemotherapy (PUVA) to treat four patients with chronic graft-versus-host disease of the skin, oral mucosa, and liver, who had responded only partially to long-term immunosuppressive therapy (prednisolone, cyclosporine, azathioprine). PUVA therapy was delivered to the entire skin but not the liver or mucosa. After 6 weeks of therapy, all patients had complete regression of the skin lesions. Two patients also had complete resolution of the oral mucosal lesions. One patient had complete resolution of the liver lesions. The skin lesions responded to PUVA therapy in a similar manner to those lesions that had responded to long-term immunosuppressive therapy. The liver lesions did not respond to PUVA therapy. The oral mucosal lesions did not respond to PUVA therapy. PUVA therapy is effective in treating chronic graft-versus-host disease.\n",
      "BLEU: 0.4298579675943814, ROUGE-L: {'r': 0.6097560975609756, 'p': 0.704225352112676, 'f': 0.6535947662676748}, Perplexity: 3.714444398880005, Cosine Similarity: 0.8297\n",
      "Reference Text: Neuropsychological performance in medicated and unmedicated patients with Tourette's disorder. OBJECTIVE: To date, there have been no formal investigations of neuropsychological performance in patients with Tourette's disorder who are taking psychotropic medications. The authors conducted this study to provide such information. METHOD: They examined the neuropsychological performance of 96 patients 6-18 years old who met DSM-III-R criteria for Tourette's disorder; 51 of these patients were taking neuroleptic medications and 45 were not. The groups were well matched with regard to age, sex, education, and duration of symptoms. Each group was given a complete neuropsychological test battery as well as instruments rating symptoms of Tourette's disorder, obsessive-compulsive characteristics, and other behavioral disturbances. RESULTS: The patients taking medications did not differ from those not taking medications on any of the neuropsychological, intellectual, or educational measures. In addition, the groups did not differ with regard to level of Tourette's disorder symptoms. CONCLUSIONS: The results of this investigation suggest that patients with Tourette's disorder who do not experience intolerable side effects from neuroleptic medications are able to perform on educational, intellectual, and neuropsychological tests at a level comparable to that of unmedicated patients. These results have positive implications for patients with Tourette's disorder who respond to neuroleptic medications. \n",
      "Generated Text: Neuropsychological performance in medicated and unmedicated patients with Tourette's disorder. OBJECTIVE: To date, there have been no formal investigations of neuropsychological performance in patients with Tourette's disorder who are taking psychotropic medications. The authors conducted this study to provide such information. METHOD: They examined the neuropsychological performance of 96 patients with Tourette's disorder who were taking medication and 96 patients who were not taking medication. They administered the Mini-Mental State Examination (MMSE) and the Wechsler Memory Scale (WMS). RESULTS: There were significant differences between the groups on the MMSE and WMS, with the unmedicated group performing significantly better than the medicated group. CONCLUSIONS: This study suggests that there may be a relationship between medication and neuropsychological performance in patients with Tourette's disorder.\n",
      "BLEU: 0.250330007828988, ROUGE-L: {'r': 0.41379310344827586, 'p': 0.6486486486486487, 'f': 0.5052631531390582}, Perplexity: 2.8622305393218994, Cosine Similarity: 0.7522\n",
      "Reference Text: Pregnancy-induced hypertension and acute fatty liver of pregnancy: atypical presentations. Severe pregnancy-induced hypertension and markedly elevated levels of serum alkaline phosphatase developed in a 29-year-old-woman in whom one pregnancy resulted in intrauterine death. Acute fatty liver of pregnancy developed with good fetal outcome in the next pregnancy. This case suggests that pregnancy-induced hypertension and acute fatty liver of pregnancy are part of a clinical spectrum. Moreover, classic abnormalities of liver function tests need not be present in acute fatty liver of pregnancy. \n",
      "Generated Text: Pregnancy-induced hypertension and acute fatty liver of pregnancy: atypical presentations. Severe pregnancy-induced hypertension and markedly elevated levels of serum alkaline phosphatase developed in a 29-year-old-woman in whom one pregnancy resulted in intrauterine death. Acute fatty liver of pregnancy developed with good fetal outcome in the next pregnancy. This case suggests that pregnancy-induced hypertension may present with an atypical pattern of disease.\n",
      "BLEU: 0.6191203307449329, ROUGE-L: {'r': 0.7547169811320755, 'p': 0.9090909090909091, 'f': 0.8247422630842812}, Perplexity: 7.80150032043457, Cosine Similarity: 0.9253\n",
      "Reference Text: PTCA of gastroepiploic bypass. A technique for percutaneous transluminal coronary angioplasty (PTCA) of gastroepiploic bypass is described using standard PTCA devices. Severe spasm of gastroepiploic bypass occurred. Modification of guide catheter position is suggested to avoid inducing gastroepiploic bypass spasm. \n",
      "Generated Text: PTCA of gastroepiploic bypass. A technique for percutaneous transluminal coronary angioplasty (PTCA) of gastroepiploic bypass is described using standard PTCA devices. Severe spasm of gastroepiploic bypass occurred. Modification of guide catheter position is suggested to avoid inducing gastroepiploic bypass spasm.\n",
      "BLEU: 1.0, ROUGE-L: {'r': 0.9655172413793104, 'p': 1.0, 'f': 0.9824561353524162}, Perplexity: 8.228212356567383, Cosine Similarity: 1.0000\n",
      "Reference Text: Dental extraction for patients on oral anticoagulant therapy. Dental extraction in patients receiving long-term oral anticoagulant therapy is a controversial issue. Continuation of anticoagulation exposes the patient to serious hemorrhage, whereas cessation of therapy increases the risk of thromboembolism. Forty patients treated by coumarin underwent 63 tooth extractions, without a change in the therapeutic protocol of anticoagulation. The biologic adhesive Beriplast was used successfully to achieve local hemostasis at the site of the surgical wound. Apart from one patient who had mild oozing, there were no incidences of postsurgical hemorrhage. \n",
      "Generated Text: Dental extraction for patients on oral anticoagulant therapy. Dental extraction in patients receiving long-term oral anticoagulant therapy is a controversial issue. Continuation of anticoagulation exposes the patient to serious hemorrhage, whereas cessation of therapy increases the risk of thromboembolism. Forty patients treated by coumarin underwent 63 tooth extractions, without a significant increase in the risk of thromboembolism. All patients were maintained on anticoagulation with heparin, and the coumarin was discontinued 2 weeks before tooth extraction. The risk of bleeding during tooth extraction was evaluated by the use of a bleeding score and the use of prophylactic anticoagulation. The bleeding score was used to assess the risk of bleeding before tooth extraction. The bleeding score was calculated from the number of teeth, the number of teeth extracted, and the duration of tooth extraction. The risk of bleeding was assessed by comparing the bleeding score before and after tooth extraction. The bleeding score was used to assess the risk of bleeding before tooth extraction. The bleeding score was calculated from the number of teeth, the number of teeth extracted, and the duration of tooth extraction. The risk of bleeding was assessed by comparing the bleeding score before and after tooth extraction. The bleeding score was used to assess the risk of bleeding before tooth extraction. The bleeding score was calculated from the number of teeth, the number of teeth extracted, and the duration of tooth extraction. The risk of bleeding was assessed by comparing the bleeding score before and after tooth extraction. The bleeding score was used to assess the risk of bleeding before tooth extraction. The bleeding score was calculated from the number of teeth, the number of teeth extracted, and the duration of tooth extraction. The risk of bleeding was assessed by comparing the bleeding score before and after tooth extraction. The bleeding score was used to assess the risk of bleeding before tooth extraction. The bleeding score was calculated from the number of teeth, the number of teeth extracted, and the duration of tooth extraction. The risk of bleeding was assessed by comparing the bleeding score before and after tooth extraction. The bleeding score was used to assess the risk of bleeding before tooth extraction. The bleeding score was calculated from the number of teeth, the number of teeth extracted, and the duration of tooth extraction. The risk of bleeding was assessed by comparing the bleeding score before and after tooth extraction. The bleeding score was used to assess the risk of bleeding before tooth extraction. The bleeding score was\n",
      "BLEU: 0.12478149382364075, ROUGE-L: {'r': 0.6231884057971014, 'p': 0.6142857142857143, 'f': 0.6187050309714819}, Perplexity: 1.9012775421142578, Cosine Similarity: 0.6079\n",
      "Reference Text: Ph-negative chronic myeloid leukemia: molecular analysis of ABL insertion into M-BCR on chromosome 22. Leukemic cells from a patient with Ph-negative chronic myeloid leukemia (CML) had a normal karyotype. M-BCR was rearranged and chromosome in situ hybridization showed an ABL insertion between 5' and 3' M-BCR on an apparently normal chromosome 22. The association of 5' BCR and 3' ABL at the 5' junction of the chromosome 9 insert was typical of that found for the BCR-ABL fusion gene in other patients with the standard t(9;22) and CML. With an M-bcr-3' probe, we cloned and characterized a 3' junction fragment. Field inversion gel electrophoresis and chromosome in situ hybridization studies using a probe isolated from genomic DNA 5' of the junction showed that 3' M-BCR was joined to a region of chromosome 9q34 rich in repetitive sequences and lying some distance 3' of ABL. The chromosome 9 insert was at least 329 kilobases long and included 3' ABL and a larger portion of chromosome 9q34. Our results allowed us to exclude transposon- or retroviral-mediated insertion of ABL into chromosome 22. Instead, we favored a two-translocation model in which a second translocation reconstituted a standard t(9;22)(q34;q11) but left the chromosome 9 insert, including 3' ABL, in chromosome 22. \n",
      "Generated Text: Ph-negative chronic myeloid leukemia: molecular analysis of ABL insertion into M-BCR on chromosome 22. Leukemic cells from a patient with Ph-negative chronic myeloid leukemia (CML) had a normal karyotype. M-BCR was rearranged and chromosome in situ hybridization showed an ABL insertion between 5' and 3' M-BCR on an apparently normal chromosome 22. The insertion was mapped to a 5.3-kb region of chromosome 22, which includes the 5' end of the M-BCR gene. The 5' M-BCR gene was not disrupted by the ABL insertion. The ABL gene was mapped to chromosome 22 by fluorescence in situ hybridization using a 5.3-kb probe. The ABL gene was amplified from leukemic cells by polymerase chain reaction. The ABL gene is not rearranged in Ph-negative CML. The ABL gene is a candidate for the 5' end of the M-BCR gene.\n",
      "BLEU: 0.2732624642901898, ROUGE-L: {'r': 0.39473684210526316, 'p': 0.703125, 'f': 0.5056179729226108}, Perplexity: 4.198660373687744, Cosine Similarity: 0.7608\n",
      "Reference Text: Extraperitoneal endarterectomy for iliofemoral occlusive disease. Sixty patients with iliofemoral occlusive disease were treated by autogenous anatomic reconstruction by endarterectomy. Endarterectomy was performed extra-peritoneally by the eversion technique. The operative technique and its advantages and disadvantages are discussed. Six patients had postoperative complications of acute anastomotic hemorrhage (two patients), would hematoma (two patients), and atelectasis (two patients). Sixty patients discharged with patient arterial reconstruction were followed up from 5 months to 17 1/2 years, with a mean follow-up of 53 months. There were no other vascular complications. Seventy limbs were at risk during this period, with an accumulative patency rate of 80.4% at 5 years and 71.4% at 10 years. There were 11 occlusions of the external iliac artery and one stenosis of the common femoral artery. Failures occurred mainly in the external iliac artery, which appears to be the limiting factor in the continued patency of endarterectomy. There were 18 deaths (30%). Nine deaths were attributed to the complications of arteriosclerosis. \n",
      "Generated Text: Extraperitoneal endarterectomy for iliofemoral occlusive disease. Sixty patients with iliofemoral occlusive disease were treated by autogenous anatomic reconstruction by endarterectomy. Endarterectomy was performed extra-peritoneally by the eversion technique. The operative technique and its advantages and disadvantages are discussed. Six patients had postoperative complications of acute anastomotic hemorrhage (two patients), would have been treated by open endarterectomy, and were treated by endarterectomy. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six patients. The procedure was successful in all six\n",
      "BLEU: 0.12096588734442154, ROUGE-L: {'r': 0.3925233644859813, 'p': 0.84, 'f': 0.5350318427928111}, Perplexity: 1.6264711618423462, Cosine Similarity: 0.3518\n",
      "Reference Text: Specific supersensitivity of the mesenteric vascular bed of Dahl salt-sensitive rats. Dahl salt-sensitive (DS) and salt-resistant (DR) rats were maintained on a diet containing normal (0.45%) or high (7%) salt for 5 days. The DS rats had slightly higher systolic blood pressures than DR rats, although a high salt diet failed to significantly elevate pressure in either group when compared with their appropriate (low salt diet) controls. The sensitivity of the isolated, perfused mesenteric vasculature from DS rats fed a high salt diet to nerve stimulation was greater when compared with all other groups in the presence or absence of cocaine (1 microM). A similar difference in sensitivity between high salt DS rats and high salt DR rats to bolus injections of norepinephrine was observed only in the presence of cocaine. The change in sensitivity was characterized by a leftward shift of the dose-response curve without a change in maximum response. No difference in sensitivity between the high salt DS group and any other treatment group was observed in response to the pressor agents KCl, angiotensin II, 5-hydroxytryptamine or the depressor agent acetylcholine. These data indicate that DS rats on a short-term, high salt diet possess a significant and specific elevation in sensitivity to nerve stimulation and norepinephrine in the absence of an increase in blood pressure. Differences in the effectiveness of cocaine among the groups suggest that differences may exist in neuronal uptake (uptake 1). \n",
      "Generated Text: Specific supersensitivity of the mesenteric vascular bed of Dahl salt-sensitive rats. Dahl salt-sensitive (DS) and salt-resistant (DR) rats were maintained on a diet containing normal (0.45%) or high (7%) salt for 5 days. The DS rats had slightly higher systolic blood pressures than DR rats, although a high salt diet did not cause hypertension in either strain. The vascular bed of the mesenteric artery of the DS rats was 2.5-fold more sensitive to the vasoconstrictor effects of angiotensin II than that of the DR rats. The vasodilator effect of bradykinin was also 2.5-fold greater in the DS rats. The DS rats had higher blood pressures, but the difference was not significant. The sensitivity of the mesenteric vascular bed of DS rats to the vasoconstrictor effects of angiotensin II was not related to the sensitivity of the mesenteric vascular bed to the vasodilator effect of bradykinin. The sensitivity of the mesenteric vascular bed of the DS rats to the vasoconstrictor effects of angiotensin II was not related to the sensitivity of the mesenteric vascular bed to the vasodilator effect of bradykinin.\n",
      "BLEU: 0.25284075763727354, ROUGE-L: {'r': 0.38461538461538464, 'p': 0.6944444444444444, 'f': 0.4950495003627096}, Perplexity: 2.6176154613494873, Cosine Similarity: 0.7275\n",
      "Reference Text: Extramedullary blast crisis in a patient with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic remission. Treatment of Philadelphia (Ph) chromosome-positive chronic myelogenous leukemia (CML) with recombinant interferon-alpha (IFN-A) results in complete disappearance of the Ph chromosome in about 10% to 15% of patients in early chronic phase. This group has a long survival and very low incidence of blast crisis. The first known case is reported of extramedullary blastic transformation in a patient with medullary complete cytogenetic response (0% Ph-positive metaphases) to IFN-A. Four episodes of extramedullary blast crisis have occurred in this patient. The first three episodes were lymphoid by morphology and cytochemical stains. Molecular analysis confirmed breakpoint cluster region rearrangement. The most recent transformation was myeloid in nature and involved bone and pulmonary parenchyma. The patient is currently undergoing a second autologous transplantation with stored bone marrow that is Ph negative. The patient has survived more than 18 months since the first episode of blast crisis, and the bone marrow is normal. \n",
      "Generated Text: Extramedullary blast crisis in a patient with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic remission. Treatment of Philadelphia (Ph) chromosome-positive chronic myelogenous leukemia (CML) with recombinant interferon-alpha (IFN-A) results in complete disappearance of the Ph chromosome in about 10% to 15% of patients in early chronic phase. This group of patients has a significantly increased risk of developing extramedullary blast crisis (EMBC). We report a case of EMBC in a patient with Ph-positive CML in complete cytogenetic remission (CCR) after IFN-A treatment. The patient was a 28-year-old man with Ph-positive CML in CCR. He was treated with IFN-A for 3 months, but the response was not sustained. The patient developed EMBC 4 months after the cessation of IFN-A. The patient received a second course of IFN-A, which resulted in complete remission. We believe that the EMBC in this patient was related to the IFN-A therapy, since the complete response to IFN-A was associated with a complete remission of the EMBC. The presence of the Ph chromosome in the bone marrow and peripheral blood of this patient before IFN-A treatment suggests that the Ph chromosome may play a role in the development of EMBC in Ph-positive CML.\n",
      "BLEU: 0.3154667413753803, ROUGE-L: {'r': 0.49523809523809526, 'p': 0.5416666666666666, 'f': 0.5174129303334077}, Perplexity: 2.823133707046509, Cosine Similarity: 0.7950\n",
      "Reference Text: Occult vascular malformations of the optic chiasm: magnetic resonance imaging diagnosis and surgical laser resection. Angiographically occult vascular malformations of the optic nerve and chiasm are extremely rare. Before the advent of magnetic resonance imaging (MRI), it was difficult to diagnose these lesions preoperatively. We report MRI scan findings of optic chiasm cavernous angiomas in two patients with chiasmal syndrome. MRI was useful in localizing the vascular malformation and delineating its characteristics, especially chronic hemorrhage. One patient underwent biopsy of the lesion. The other patient underwent complete microsurgical resection of the malformation with the carbon dioxide laser with preservation of vision. Occult vascular malformations of the optic nerve and chiasm may be a more common cause of visual deterioration than previously recognized. The MRI scan is the imaging modality of choice for diagnosing and following these lesions. In certain patients, these vascular malformations may be amenable to complete surgical removal with stabilization or improvement of visual function. \n",
      "Generated Text: Occult vascular malformations of the optic chiasm: magnetic resonance imaging diagnosis and surgical laser resection. Angiographically occult vascular malformations of the optic nerve and chiasm are extremely rare. Before the advent of magnetic resonance imaging (MRI), it was difficult to diagnose these lesions preoperatively. We report MRI scan findings of 3 patients with vascular malformations of the optic chiasm, and the surgical management of these lesions. A 27-year-old woman with a 6-month history of double vision and right-sided hemianopsia had a MRI scan of the brain that showed a large lesion in the right optic chiasm. The lesion was a well-circumscribed, hyperintense lesion on T1-weighted images and was isointense on T2-weighted images. It was isointense on T1-weighted images and hyperintense on T2-weighted images on gadolinium-enhanced scans. A 23-year-old woman with a 1-year history of headache and double vision had a MRI scan of the brain that showed a well-circumscribed, hyperintense lesion in the right optic chiasm. The lesion was isointense on T1-weighted images and hyperintense on T2-weighted images on gadolinium-enhanced scans. A 20-year-old man with a 6-month history of double vision had a MRI scan of the brain that showed a well-circumscribed, hyperintense lesion in the right optic chiasm. The lesion was isointense on T1-weighted images and hyperintense on T2-weighted images on gadolinium-enhanced scans. All 3 lesions were treated by laser resection. In 1 patient, the lesion was resected by a combination of laser and electrocautery. In the other 2 patients, the lesions were resected by laser alone. We conclude that MRI is useful in the diagnosis of vascular malformations of the optic chiasm. Laser resection is an effective treatment for these lesions.\n",
      "BLEU: 0.2280445743939422, ROUGE-L: {'r': 0.5263157894736842, 'p': 0.5050505050505051, 'f': 0.5154639125278989}, Perplexity: 2.2310497760772705, Cosine Similarity: 0.7334\n",
      "Reference Text: Estimation of myocardial infarct size with ultrasonic tissue characterization. BACKGROUND. Ultrasonic tissue characterization (UTC) can distinguish normal from infarcted myocardium. Infarcted myocardium shows an increase in integrated backscatter and loss of cardiac cycle-dependent variation in backscatter. The cyclic variation of backscatter is closely related to regional myocardial contractile function; the latter is a marker of myocardial ischemia. The present study was designed to test the hypothesis that intramural cyclic variation of backscatter can map and estimate infarct size. METHODS AND RESULTS. Transmural myocardial infarction was produced in 12 anesthetized, open-chest dogs by total occlusion of the left anterior descending coronary artery for 4 hours. A real-time ultrasonic tissue characterization instrument, which graphically displays integrated backscatter Rayleigh 5, cardiac cycle-dependent variation, and patterns of cyclic variation in backscatter, was used to map infarct size and area at risk of infarction. Staining with 2,3,4-triphenyltetrazolium chloride (TTC) and Patent Blue Dye was used to estimate infarct size and the area at risk, respectively. The ratio of infarct size to area at risk of infarction determined with UTC correlated well with that determined with TCC (r = 0.862, y = 23.7 +/- 0.792x). Correlation coefficients for infarct size and area at risk were also good (r = 0.736, y = 12.3 +/- 737x for infarct size and r = 0.714, y = 5.80 +/- 1.012x for area at risk). However, UTC underestimated both infarct size and area at risk. CONCLUSIONS. Ultrasonic tissue characterization may provide a reliable, noninvasive method to estimate myocardial infarct size. \n",
      "Generated Text: Estimation of myocardial infarct size with ultrasonic tissue characterization. BACKGROUND. Ultrasonic tissue characterization (UTC) can distinguish normal from infarcted myocardium. Infarcted myocardium shows an increase in integrated backscatter and loss of cardiac cycle-dependent variation in backscatter. The cyclic variation of backscatter is closely related to regional myocardial contractile function; the loss of the cyclic variation of backscatter is believed to be due to loss of contractile function. We evaluated the ability of UTC to estimate infarct size and to determine whether infarct size is related to the cyclic variation of backscatter. METHODS. Infarct size was determined in 10 dogs by infusing 3.5% intralipid into the left ventricle and measuring infarct size by two-dimensional echocardiography. Infarct size was determined by infusing 3.5% intralipid into the left ventricle and measuring infarct size by two-dimensional echocardiography. Infarct size was determined in 10 dogs by infusing 3.5% intralipid into the left ventricle and measuring infarct size by two-dimensional echocardiography. Infarct size was determined in 10 dogs by infusing 3.5% intralipid into the left ventricle and measuring infarct size by two-dimensional echocardiography. Infarct size was determined in 10 dogs by infusing 3.5% intralipid into the left ventricle and measuring infarct size by two-dimensional echocardiography. Infarct size was determined in 10 dogs by infusing 3.5% intralipid into the left ventricle and measuring infarct size by two-dimensional echocardiography. Infarct size was determined in 10 dogs by infusing 3.5% intralipid into the left ventricle and measuring infarct size by two-dimensional echocardiography. Infarct size was determined in 10 dogs by infusing 3.5% intralipid into the left ventricle and measuring infarct size by two-dimensional echocardiography. Infarct size was determined in 10 dogs by infusing 3.5% intralipid into the left ventricle and measuring infarct size by two-dimensional ech\n",
      "BLEU: 0.227874306517111, ROUGE-L: {'r': 0.34532374100719426, 'p': 0.6956521739130435, 'f': 0.4615384571047523}, Perplexity: 1.6919772624969482, Cosine Similarity: 0.6015\n",
      "Reference Text: Temporal bone findings in two cases of head injury. Temporal bone findings in two cases of head injury are reported. In one patient, longitudinal fractures occurred in both temporal bones, and extended to the middle ear bilaterally. Bleeding was seen in the tympanic cavity, mastoid air cells, internal auditory meatus and facial nerve canal. Bleeding was observed in the scala tympani, cochlear aqueduct and endolymphatic sac, but there were no fractures. In the other patient, bleeding was seen in the internal auditory meatus and facial nerve canal. In the right ear, endolymphatic hydrops was observed in all turns of the cochlea. \n",
      "Generated Text: Temporal bone findings in two cases of head injury. Temporal bone findings in two cases of head injury are reported. In one patient, longitudinal fractures occurred in both temporal bones, and extended to the middle ear bilaterally. Bleeding was seen in the tympanic cavity, mastoid air cells, internal auditory meatus, and petrous apex. In the other patient, a fracture of the petrous temporal bone was seen. This patient had a subdural hematoma with a petrous temporal bone fracture.\n",
      "BLEU: 0.4975844445969048, ROUGE-L: {'r': 0.6229508196721312, 'p': 0.7755102040816326, 'f': 0.6909090859685951}, Perplexity: 5.364613056182861, Cosine Similarity: 0.8171\n",
      "Reference Text: Medical management of acute traumatic rupture of the aorta. Surgical reconstruction is the treatment for acute traumatic aortic rupture and should be accomplished immediately in most patients. In patients in whom concomitant injuries or the development of life-threatening complications preclude safe and successful aortic reconstruction, pharmacological intervention to reduce the risk of free aortic rupture may be considered. Surgical reconstruction can then be more safely performed under controlled elective circumstances. \n",
      "Generated Text: Medical management of acute traumatic rupture of the aorta. Surgical reconstruction is the treatment for acute traumatic aortic rupture and should be accomplished immediately in most patients. In patients in whom concomitant injuries or the development of life-threatening complications preclude safe and successful aortic reconstruction, pharmacological intervention to reduce the risk of aortic rupture should be considered. We present a case of a patient with a traumatic aortic rupture in whom the patient was treated with pharmacological intervention and who survived. The patient was treated with the use of an intravenous infusion of a combination of antifibrinolytic agents, including tranexamic acid, and platelet inhibitors, including aspirin. The patient's condition improved and he was discharged from the hospital after 10 days of treatment. The patient was followed for 18 months and was free of recurrent episodes of aortic rupture. In patients with aortic rupture, pharmacological intervention should be considered in the treatment of the patient.\n",
      "BLEU: 0.3435257647928986, ROUGE-L: {'r': 0.7884615384615384, 'p': 0.5061728395061729, 'f': 0.6165413486211772}, Perplexity: 4.741035461425781, Cosine Similarity: 0.7881\n",
      "Reference Text: Thigh muscle function after partial tear of the medial ligament compartment of the knee. The purpose of the study was to assess the isokinetic and isometric strength and power profile of the knees of 48 patients who had a previous second-degree sprain (partial tear) of the medial ligament compartment, the most common knee ligament injury in sports. The CYBEX II isokinetic dynamometer was used in the measurements. On an average of 8 yr after the injury, the mean strength deficit of the injured knees was minimal: 4 +/- 5% (range 0-28%) in extension and 2 +/- 4% (0-20%) in flexion. The average strength score (max. 100 points) was 90 +/- 11 (56-100), representing an excellent classification. In hamstrings, the relative strength deficit increased significantly with a higher speed of isokinetic movement (P less than 0.05). Compared with the strength parameters (peak torques), the other functional parameters of the injured knees (total work, average power, and peak torque acceleration energy) showed some but not significantly greater deficits (hamstrings 9-11%, quadriceps 6-8%). In conclusion, the general thigh muscle function in knees with old second-degree sprain of the medial ligament compartment appears good and acceptable, but the strength deficits are systematically greater in higher speeds of isokinetic movement. Therefore, rehabilitation utilizing high speed extension and flexion exercises is recommended. \n",
      "Generated Text: Thigh muscle function after partial tear of the medial ligament compartment of the knee. The purpose of the study was to assess the isokinetic and isometric strength and power profile of the knees of 48 patients who had a previous second-degree sprain (partial tear) of the medial ligament compartment, the function of which was believed to be normal. The isokinetic and isometric strength and power of the knee were assessed using a 12 degree knee flexion/extension angle and 20 degree knee extension angle. The results were compared with the results of 49 patients who had no previous injury to the medial ligament compartment. The results of the present study showed that the isokinetic strength and power of the knee was significantly lower than that of the control group. The isokinetic strength and power of the knee were significantly lower than those of the control group at all angles of knee flexion and extension. The isometric strength and power of the knee were significantly lower than those of the control group at all angles of knee flexion and extension. The results of the present study suggest that the function of the medial ligament compartment was impaired.\n",
      "BLEU: 0.2823912234524748, ROUGE-L: {'r': 0.3053435114503817, 'p': 0.5714285714285714, 'f': 0.3980099457092646}, Perplexity: 3.52742075920105, Cosine Similarity: 0.8385\n",
      "Reference Text: Vagus nerve stimulation in humans: neurophysiological studies and electrophysiological monitoring. Evidence from studies of experimental animals indicates that electrical stimulation of the vagus nerve alters behavioral and electrographic seizure activity. We report on effects of electrical stimulation of the vagus nerve in five patients with medically intractable seizures as part of a clinical trial of chronic vagal stimulation for control of epilepsy. The mechanism of action of the vagal antiepileptic effect is unknown, and it is hoped that analysis of electrophysiological effects of vagal nerve stimulation will help elucidate which brain areas are affected. Stimulation of the left vagus nerve in the neck was accomplished with a programmable implanted stimulator. Effects of stimulus amplitude, duration, and rate were studied. Noncephalic reference recording of the vagus-nerve-evoked potential showed some unusual properties: a scalp negative component occurred with latency of 12 ms, very high amplitude (up to 60 microV), and widespread scalp distribution. Field distribution studies indicate that this potential is generated in the neck, in the region of the stimulating electrodes. Muscle paralysis confirms this observation. Stimulation at various frequencies had no noticeable effect on electroencephalographic (EEG) activity regardless of whether the patient was under general anesthesia, awake, or asleep. \n",
      "Generated Text: Vagus nerve stimulation in humans: neurophysiological studies and electrophysiological monitoring. Evidence from studies of experimental animals indicates that electrical stimulation of the vagus nerve alters behavioral and electrographic seizure activity. We report on effects of electrical stimulation of the vagus nerve in five patients with medically intractable seizures as part of a larger study of the effects of vagus nerve stimulation in humans. The patients were studied for 2 to 5 months, during which time the vagus nerve was stimulated for periods ranging from 1 to 10 hours per day, three to five times per week. In all patients, electrical stimulation of the vagus nerve altered the electrographic pattern of seizure activity. In three patients, the electrographic pattern of seizure activity changed from a pattern of generalized tonic-clonic seizures to a pattern of partial seizures. In one patient, the electrographic pattern of seizure activity changed from a pattern of generalized tonic-clonic seizures to a pattern of partial seizures, and in one patient, the electrographic pattern of seizure activity changed from a pattern of partial seizures to a pattern of generalized tonic-clonic seizures. In the fourth patient, the electrographic pattern of seizure activity changed from a pattern of generalized tonic-clonic seizures to a pattern of partial seizures. In the fifth patient, the electrographic pattern of seizure activity changed from a pattern of partial seizures to a pattern of generalized tonic-clonic seizures. We conclude that electrical stimulation of the vagus nerve in humans alters the electrographic pattern of seizure activity. The mechanism of this effect is unknown, but may be related to the effects of vagus nerve stimulation in experimental animals.\n",
      "BLEU: 0.2350113570764473, ROUGE-L: {'r': 0.3684210526315789, 'p': 0.5568181818181818, 'f': 0.44343890923445467}, Perplexity: 2.4535763263702393, Cosine Similarity: 0.7475\n",
      "Reference Text: Effects of inflammatory mediators on the responsiveness of isolated human airways to methacholine. Several studies have suggested that in asthmatics the quantities of inflammatory mediators such as histamine, thromboxane A2 (TxA2), prostaglandin D2 (PGD2), prostaglandin F2 alpha (PGF2 alpha), and leukotriene C4 (LTC4) that are present in the airway lumen are related to the degree of bronchial responsiveness to inhaled methacholine (MCh). Therefore, we studied the effect of these mediators on the cholinergic responsiveness of isolated human airway segments. Lung tissue collected at thoracotomy from 30 patients was studied. Dose-response curves to MCh were obtained from bronchial segments before, during, and after incubation with either a subthreshold or a threshold concentration of histamine (10(-10) or 10(-8) M), the stable TxA2 analogue U46619 (10(-11) or 10(-9) M), PGD2 (5 x 10(-9) or 5 x 10(-7) M), PGF2 alpha (10(-9) or 10(-7) M), or LTC4 (10(-11) or 10(-9) M). With the exception of LTC4, the presence of any of these mediators at either concentration increased the sensitivity to MCh by a factor of 1.1 to 2 (p less than 0.05, ANOVA). This increase did not depend on the dose of the mediator (p greater than 0.05, ANOVA). These data indicate that mediator-induced muscle hypersensitivity can explain a small part of the leftward shift of the dose-response curve to inhaled MCh as observed in asthma. \n",
      "Generated Text: Effects of inflammatory mediators on the responsiveness of isolated human airways to methacholine. Several studies have suggested that in asthmatics the quantities of inflammatory mediators such as histamine, thromboxane A2 (TxA2), prostaglandin D2 (PGD2), prostaglandin F2 alpha (PGF2 alpha), and leukotriene C4 (LTC4) that are present in the airway lumen are increased. These mediators may play a role in the development of airway hyperresponsiveness (AHR) and bronchial hyperreactivity (BHR). To evaluate the effects of these mediators on the responsiveness of isolated human airways to methacholine, we measured the effect of 1) methacholine, 2) PGD2, 3) PGF2 alpha, 4) LTC4, and 5) histamine on the responsiveness of isolated human bronchial mucosa to methacholine, and 6) the effect of PGD2, PGF2 alpha, LTC4, and histamine on the responsiveness of isolated human bronchial mucosa to methacholine. The mucosal response to methacholine was assessed in 18 asthmatic subjects and 13 normal control subjects. PGD2 (0.1-1000 ng/ml) and PGF2 alpha (0.1-1000 ng/ml) increased the responsiveness of isolated human bronchial mucosa to methacholine. LTC4 (0.1-1000 ng/ml) and histamine (0.1-100 ng/ml) also increased the responsiveness of isolated human bronchial mucosa to methacholine. In contrast, the responsiveness of isolated human bronchial mucosa to methacholine was not significantly affected by PGD2 (0.1-1000 ng/ml), PGF2 alpha (0.1-1000 ng/ml), LTC4 (0.1-1000 ng/ml), and histamine (0.1-100 ng/ml). These results suggest that the responsiveness of isolated human bronchial mucosa to methacholine is not affected by the presence of PGD2, PGF2 alpha, LTC4, and histamine. The results also suggest that the effects of PGD2, PGF2 alpha, LTC4, and histamine on the responsiveness of isolated human bronchial mucosa to\n",
      "BLEU: 0.2550981723133359, ROUGE-L: {'r': 0.381294964028777, 'p': 0.5196078431372549, 'f': 0.4398340200141183}, Perplexity: 1.8402931690216064, Cosine Similarity: 0.6834\n",
      "Reference Text: Hemodynamic effects of H2-receptor antagonists. Histamine H2-receptor antagonists (H2RAs) often are administered to intensive care unit patients in an attempt to reduce gastric acidity and to prevent stress-related mucosal damage. These agents have an extremely low overall incidence and severity of adverse reactions; however, hemodynamically significant hypotension has been noted. Clinical studies with rapidly administered intravenous cimetidine in critically ill patients have demonstrated a depression in blood pressure in up to 75 percent of patients. Ranitidine, also studied in this setting, does not appear to induce similar hemodynamic changes. The newer H2RAs, famotidine and nizatidine, have not been evaluated in critically ill patients. \n",
      "Generated Text: Hemodynamic effects of H2-receptor antagonists. Histamine H2-receptor antagonists (H2RAs) often are administered to intensive care unit patients in an attempt to reduce gastric acidity and to prevent stress-related mucosal damage. These agents have an extremely low overall incidence and severity of adverse reactions; however, hemodynamically significant hypotension has been noted. The incidence of hypotension appears to be related to the dose of H2RA used. The hypotensive effect of H2RAs may be related to a direct pressor effect on the renal vasculature. H2RAs also may have a direct effect on the myocardium. The use of H2RAs in the intensive care unit should be considered with caution.\n",
      "BLEU: 0.48829444995021143, ROUGE-L: {'r': 0.5897435897435898, 'p': 0.6764705882352942, 'f': 0.6301369813248265}, Perplexity: 4.755039691925049, Cosine Similarity: 0.6496\n",
      "Reference Text: Catheterization of coronary artery bypass graft from the descending aorta. The increasing frequency of reoperation for coronary artery disease has led to the use of a variety of grafts. This report describes the catheter technique for selective opacification of a saphenous vein graft from the descending thoracic aorta to the posterior coronary circulation. \n",
      "Generated Text: Catheterization of coronary artery bypass graft from the descending aorta. The increasing frequency of reoperation for coronary artery disease has led to the use of a variety of grafts. This report describes the catheter technique for selective opacification of a saphenous vein graft from the descending thoracic aorta to the left anterior descending coronary artery. The technique is described, and the results of a series of 12 grafts are discussed. The procedure is safe and effective in the majority of cases. This procedure provides an alternative to the conventional open surgical approach.\n",
      "BLEU: 0.5384692457118216, ROUGE-L: {'r': 0.9166666666666666, 'p': 0.5892857142857143, 'f': 0.717391299584121}, Perplexity: 5.2904205322265625, Cosine Similarity: 0.9095\n",
      "Reference Text: Anaplastic carcinoma presenting with cervical lymphadenopathy. We describe 50 patients with anaplastic carcinoma presenting with a mass in the neck. The diagnosis of anaplastic carcinoma was confirmed by immunocytochemistry to exclude very poorly differentiated squamous carcinomas, amelanotic melanoma, and non-Hodgkin's lymphoma. The primary site was established immediately in 26 patients (25 in the head and neck; 1 in the lung); a further 4 had radiological evidence of a primary tumour in the lung. The primary site was established later in 1 patient, in the ethmoid sinuses. In 20 patients the primary site was never established. The commonest primary site was the nasopharynx. The basic treatment policy was radiotherapy, although 20% of patients with a known primary tumour, and 50% of those without, were untreated. The 2-year survival was about 30% in both groups, and did not differ significantly. Prognostic factors for survival were age, performance status, and T status of the primary tumour. Sex, node status, node level, and laterality of nodes, were not. \n",
      "Generated Text: Anaplastic carcinoma presenting with cervical lymphadenopathy. We describe 50 patients with anaplastic carcinoma presenting with a mass in the neck. The diagnosis of anaplastic carcinoma was confirmed by immunocytochemistry to exclude very poorly differentiated squamous carcinomas, amelanotic melanoma, and non-Hodgkin's lymphoma. The primary site was established immediately in 26 patients. The most common primary site was the head and neck, followed by the upper respiratory tract. The cervical lymph nodes were involved in 23 patients. In 12 patients, the lymph nodes were clinically and pathologically negative. In 17 patients, the lymph nodes were clinically positive but pathologically negative. In 11 patients, the lymph nodes were clinically and pathologically positive. The median survival time for the 50 patients was 5.4 months (range 0.4 to 25.7 months). The most common sites of distant metastasis were the lung, bone, liver, and brain. The median survival time for the patients with clinically and pathologically negative lymph nodes was 11.4 months (range 0.4 to 25.7 months), compared with 6.5 months (range 0.4 to 14.7 months) for the patients with clinically and pathologically positive lymph nodes. The median survival time for the patients with clinically and pathologically negative lymph nodes was 9.3 months (range 0.4 to 25.7 months), compared with 5.3 months (range 0.4 to 14.7 months) for the patients with clinically and pathologically positive lymph nodes. The 5-year survival rate for patients with clinically and pathologically negative lymph nodes was 44.5% (range 0.4 to 100%), compared with 0% (range 0 to 100%) for the patients with clinically and pathologically positive lymph nodes. The 5-year survival rate for patients with clinically and pathologically negative lymph nodes was 44.5% (range 0.4 to 100%), compared with 0% (range 0 to 100%) for the patients with clinically and pathologically positive lymph nodes. The 5-year survival rate for patients with clinically and pathologically negative lymph nodes was 44.5% (range 0.4 to 100%), compared with 0% (range 0 to 100%) for the patients with clinically and\n",
      "BLEU: 0.17767172832904943, ROUGE-L: {'r': 0.46938775510204084, 'p': 0.4842105263157895, 'f': 0.47668393282504234}, Perplexity: 2.0865535736083984, Cosine Similarity: 0.6158\n",
      "Reference Text: Transcranial electrical motor evoked potentials as a prognostic indicator for motor recovery in stroke patients. Transcranial electrical motor evoked potentials (MEP) were examined in 33 patients within three days after stroke. Normal values for MEP and motor central conduction time (CCT) were obtained in 46 healthy controls whose MEPs were evaluated during slight voluntary muscle contraction and at rest. Two months later 23 patients were re-examined clinically and electrophysiologically. Motor function change was correlated with MEP results. Two months after stroke the patients with normal or prolonged CCT had an improved motor function compared with those with absent CCT. MEP may be a valuable prognostic indicator in the acute stage of paralytic stroke for recovery of motor function. \n",
      "Generated Text: Transcranial electrical motor evoked potentials as a prognostic indicator for motor recovery in stroke patients. Transcranial electrical motor evoked potentials (MEP) were examined in 33 patients within three days after stroke. Normal values for MEP and motor central conduction time (CCT) were obtained in 46 healthy controls whose MEPs were recorded by using a bipolar electrode placed on the middle of the median nerve at the wrist. MEP amplitudes were recorded in 31 patients with a stroke of the dominant hemisphere and in 2 patients with a stroke of the nondominant hemisphere. MEP amplitudes were measured in 4 groups of patients: (1) patients with a stroke of the dominant hemisphere, (2) patients with a stroke of the nondominant hemisphere, (3) patients with a stroke of the dominant hemisphere with a normal CCT, and (4) patients with a stroke of the nondominant hemisphere with a normal CCT. The patients with a stroke of the dominant hemisphere had significantly lower MEP amplitudes than the other 3 groups of patients. The patients with a stroke of the nondominant hemisphere had significantly lower MEP amplitudes than the other 3 groups of patients. The patients with a stroke of the dominant hemisphere with a normal CCT had significantly lower MEP amplitudes than the patients with a stroke of the nondominant hemisphere with a normal CCT. The patients with a stroke of the dominant hemisphere had a significantly lower MEP amplitude than the patients with a stroke of the nondominant hemisphere. The patients with a stroke of the dominant hemisphere had a significantly lower MEP amplitude than the patients with a stroke of the nondominant hemisphere with a normal CCT. The results suggest that the MEP amplitude may be useful as a prognostic indicator for motor recovery in stroke patients.\n",
      "BLEU: 0.19260629685824004, ROUGE-L: {'r': 0.5974025974025974, 'p': 0.5542168674698795, 'f': 0.5749999950070313}, Perplexity: 2.2317676544189453, Cosine Similarity: 0.5910\n",
      "Reference Text: Factors determining improvement in left ventricular function after reperfusion therapy for acute myocardial infarction: primacy of baseline ejection fraction. Improvement in left ventricular ejection fraction is a measure of salvage of ischemic myocardium after reperfusion therapy for acute myocardial infarction. The degree of improvement in left ventricular ejection fraction may be influenced by many factors. Therefore, 137 patients in whom paired radionuclide angiograms were obtained within 24 h of acute infarction and before hospital discharge were retrospectively evaluated to determine which factors most affect improvement in ejection fraction. Only baseline ejection fraction correlated significantly with improvement in ejection fraction by both univariate analysis (ejection fraction as a continuous variable; p less than 0.001; ejection fraction as a categorical variable, less than or equal to 45% versus greater than 45%, p less than 0.0001) and multivariate analysis (p less than 0.0001). Reperfusion status (patent versus occluded infarct artery) and extent of coronary artery disease (one, two or three vessel) were significant factors by multivariate but not by univariate analysis. Location of infarction, treatment modality and time to treatment did not correlate with change in ejection fraction by either statistical technique. Thus, of those factors tested, baseline left ventricular ejection fraction is the most potent predictor of improvement in ventricular function after acute infarction. Knowledge of baseline ejection fraction may be helpful in deciding whether to treat some patients with equivocal indications or contraindications for reperfusion therapy. Clinical trials of reperfusion strategies should stratify patients on the basis of baseline ejection fraction if ejection fraction is to be used as an end point for myocardial salvage. \n",
      "Generated Text: Factors determining improvement in left ventricular function after reperfusion therapy for acute myocardial infarction: primacy of baseline ejection fraction. Improvement in left ventricular ejection fraction is a measure of salvage of ischemic myocardium after reperfusion therapy for acute myocardial infarction. The degree of improvement in left ventricular ejection fraction may be related to the initial left ventricular function. We studied the relationship between the initial left ventricular function and improvement in left ventricular function after reperfusion therapy in 100 consecutive patients with acute myocardial infarction. The initial left ventricular ejection fraction was 50.3 +/- 11.3% (mean +/- SD). The initial left ventricular function was worse in patients with a history of congestive heart failure (59.7 +/- 11.4% vs 52.3 +/- 10.8%, P = 0.003) and in patients with a history of angina pectoris (57.1 +/- 10.6% vs 52.5 +/- 11.3%, P = 0.003) than in patients without these risk factors. After reperfusion therapy, improvement in left ventricular function was associated with improvement in left ventricular ejection fraction. The initial left ventricular function was significantly related to improvement in left ventricular ejection fraction. The degree of improvement in left ventricular function was related to the initial left ventricular function. In patients with a history of congestive heart failure and angina pectoris, the initial left ventricular function was worse than in patients without these risk factors. Patients with a history of congestive heart failure and angina pectoris had a lower initial left ventricular function than patients without these risk factors. Improvement in left ventricular function was related to improvement in left ventricular function. The initial left ventricular function was the most important determinant of improvement in left ventricular function after reperfusion therapy for acute myocardial infarction.\n",
      "BLEU: 0.23004536678068824, ROUGE-L: {'r': 0.2907801418439716, 'p': 0.44565217391304346, 'f': 0.3519313256932344}, Perplexity: 2.166227340698242, Cosine Similarity: 0.6124\n",
      "Reference Text: Vascular renin and hypertension. Uptake versus synthesis. Conventional radioimmunoassay techniques demonstrated in the aortic wall a renin-like activity which is derived from plasma but has a longer half-life than plasma renin. Blood pressure elevation after renin injection into nephrectomized rats correlates better with aortic renin than with plasma renin. Vascular and other extrarenal tissue can also synthesize renin. Using a ribonuclease protection technique for the detection of renin messenger RNA we have been able to demonstrate that a wide variety of extrarenal tissues contain the renin message. In at least two of these, the brain and the liver, renin messenger RNA levels are unaffected by changes in dietary salt or by changes in systemic blood pressure. Functional studies using isolated human resistance vessels also demonstrate the presence of renin-like activity by a contractile response to added renin substrate. It is suggested that extrarenal tissues therefore contain renin-like activity derived both from uptake and from local synthesis. These systems may be regulated in different ways and may carry out different functions. \n",
      "Generated Text: Vascular renin and hypertension. Uptake versus synthesis. Conventional radioimmunoassay techniques demonstrated in the aortic wall a renin-like activity which is derived from plasma but has a longer half-life than plasma renin. Blood pressure elevation after renin injection into nephrectomized rats correlates better with aortic renin than with plasma renin. Vascular renin synthesis, as measured by 3H-leucine incorporation, is decreased in nephrectomized rats. These findings suggest that vascular renin synthesis is not the major determinant of vascular renin activity.\n",
      "BLEU: 0.20396788238112726, ROUGE-L: {'r': 0.38392857142857145, 'p': 0.7818181818181819, 'f': 0.5149700554627273}, Perplexity: 7.692223072052002, Cosine Similarity: 0.7700\n",
      "Reference Text: Stapling or suturing for anastomoses of the left side of the large intestine. Two hundred and fifty patients undergoing elective surgical treatment involving anastomoses of the left side of the colon or colon and rectum have been studied in a randomized trial in which the EEA (U. S. Surgical Corp.) circular stapler has been compared with single layer sutured anastomoses. Only patients in whom either technique was feasible were included in the analysis. The operative techniques were largely standardized. Patients were studied by means of a limited barium enema on the ninth or tenth postoperative day. The data have been analyzed for leakage rate (clinical and roentgenologic), other complications and degree of experience of the surgeon. Eleven patients were excluded from the analysis because the selected technique could not be carried out; of these, eight were in the stapled group in which it was possible to perform a sutured anastomosis. There were no instances in which it was possible to staple but not possible to suture. The remaining three exclusions were patients in whom either a coloanal anastomosis or a Hartmann procedure was performed. There was no over-all difference in the leakage rate--roentgenologic, clinical or total--between the two groups. However, when analyzed by the surgeon, the clinical leakage rate for surgeons in training was greater for sutured anastomoses than for stapled anastomoses (p = 0.053). Thus, it appears that the benefits of experience are more pronounced for sutured anastomoses but that, in experienced hands, neither technique is superior. \n",
      "Generated Text: Stapling or suturing for anastomoses of the left side of the large intestine. Two hundred and fifty patients undergoing elective surgical treatment involving anastomoses of the left side of the colon or colon and rectum have been studied in a randomized trial in which the EEA (U. S. Surgical Corp.) stapling device was used for anastomoses. The results of the study were similar to those obtained in a previous trial in which the U. S. Surgical Corp. stapling device was used. The EEA stapling device is more reliable than the U. S. Surgical Corp. stapling device, but the two devices are equally effective. The EEA stapling device is less expensive and less time-consuming than the U. S. Surgical Corp. stapling device. The U. S. Surgical Corp. stapling device is a useful and reliable device for anastomoses of the left side of the colon and rectum.\n",
      "BLEU: 0.19189686215908597, ROUGE-L: {'r': 0.3103448275862069, 'p': 0.6818181818181818, 'f': 0.4265402800610948}, Perplexity: 3.723820447921753, Cosine Similarity: 0.7036\n",
      "Reference Text: Extensive peripheral retinectomy combined with posterior 360 degrees retinotomy for retinal reattachment in advanced proliferative vitreoretinopathy cases. Posterior 360 degrees retinotomy in conjunction with extensive peripheral retinectomy was necessary for retinal reattachment in 18 eyes. A visual acuity of 20/400 or better was achieved in 22% of the patients; in patients with rubeosis, regression was found in 89%. Of the hypotonus eyes, preoperatively 78% were normotensive postoperatively after removal of anterior proliferative vitreoretinopathy (PVR) covering ciliary epithelium. The major intraoperative complication was hemorrhage, which could be readily controlled. Recurrent retinal detachment (RD) occurred in 39% and reproliferation in 50% of the patients. \n",
      "Generated Text: Extensive peripheral retinectomy combined with posterior 360 degrees retinotomy for retinal reattachment in advanced proliferative vitreoretinopathy cases. Posterior 360 degrees retinotomy in conjunction with extensive peripheral retinectomy was necessary for retinal reattachment in 18 eyes. A visual acuity of 20/400 or better was achieved in 22% of the patients; in the remaining 78%, a visual acuity of 20/200 or better was achieved. The surgical technique of retinectomy and retinotomy was described. Posterior 360 degrees retinotomy was performed in 14 eyes. In 2 eyes, 1 with a vitreous hemorrhage and 1 with a postoperative macular hemorrhage, the posterior 360 degrees retinotomy was performed at the time of retinectomy. In 2 eyes, 1 with a postoperative macular hemorrhage and 1 with a vitreous hemorrhage, the posterior 360 degrees retinotomy was performed at the time of retinotomy. In 2 eyes, 1 with a postoperative macular hemorrhage and 1 with a vitreous hemorrhage, the posterior 360 degrees retinotomy was performed at the time of retinectomy. In 2 eyes, 1 with a postoperative macular hemorrhage and 1 with a vitreous hemorrhage, the posterior 360 degrees retinotomy was performed at the time of retinectomy. In 2 eyes, 1 with a postoperative macular hemorrhage and 1 with a vitreous hemorrhage, the posterior 360 degrees retinotomy was performed at the time of retinectomy. In 2 eyes, 1 with a postoperative macular hemorrhage and 1 with a vitreous hemorrhage, the posterior 360 degrees retinotomy was performed at the time of retinectomy. In 2 eyes, 1 with a postoperative macular hemorrhage and 1 with a vitreous hemorrhage, the posterior 360 degrees retinotomy was performed at the time of retinectomy. In 2 eyes, 1 with a postoperative macular hemorrhage and 1 with a vitreous hemorrhage, the posterior 360 degrees retinotomy was performed at the time of retinectomy. In 2 eyes, 1 with a postoperative macular hemorrhage and 1\n",
      "BLEU: 0.16748403294791522, ROUGE-L: {'r': 0.527027027027027, 'p': 0.6842105263157895, 'f': 0.5954198424124468}, Perplexity: 1.7333213090896606, Cosine Similarity: 0.6849\n",
      "Reference Text: Pneumococcal pneumonia in a rat model of cirrhosis: effects of cirrhosis on pulmonary defense mechanisms against Streptococcus pneumoniae. To study alterations in host defense mechanisms that enhance pneumococcal virulence, a model of Streptococcus pneumoniae pneumonia was developed in cirrhotic rats. Cirrhosis, with or without ascites, was produced in rats by intragastric administration of carbon tetrachloride (CCl4). Histopathologic and laboratory studies demonstrated that CCl4-induced cirrhosis was similar to alcoholic cirrhosis in humans. Cirrhotic rats were more susceptible to type 3 pneumococcal pneumonia induced by intratracheal challenge than controls, and the presence of ascites was associated with the lowest LD50. More cirrhotic rats with ascites had bacteremia and elevated levels of circulating capsular antigen after challenge compared with cirrhotic rats without ascites or controls. Pulmonary clearance of pneumococci was markedly reduced in rats with cirrhosis and ascites and was associated with reduced serum complement levels. This model may be useful in further studies of the pathogenesis and therapy of pneumococcal infections in the compromised host. \n",
      "Generated Text: Pneumococcal pneumonia in a rat model of cirrhosis: effects of cirrhosis on pulmonary defense mechanisms against Streptococcus pneumoniae. To study alterations in host defense mechanisms that enhance pneumococcal virulence, a model of Streptococcus pneumoniae pneumonia was developed in cirrhotic rats. Cirrhosis, with or without ascites, was produced in rats by partial hepatectomy. After 4 weeks, the animals were infected intratracheally with 5 x 10(5) S. pneumoniae. The animals were killed at 4, 8, and 12 days after infection. Cirrhosis and ascites did not affect the mortality rate or the pulmonary histologic changes. However, in cirrhotic rats, the number of neutrophils in the alveolar exudate was significantly increased at 4 days after infection. The pulmonary neutrophil count increased from 0.2 +/- 0.1 at 4 days to 1.6 +/- 0.5 at 8 days and 2.1 +/- 0.5 at 12 days after infection. The number of neutrophils in the bronchoalveolar lavage fluid was not significantly altered by cirrhosis or ascites. In addition, the number of alveolar macrophages and the number of alveolar macrophages with intracellular bacteria were not significantly altered by cirrhosis or ascites. The pulmonary neutrophil count was significantly correlated with the number of bacteria in the alveolar exudate at 4 and 8 days after infection. The number of bacteria in the alveolar exudate was significantly correlated with the number of neutrophils in the alveolar exudate at 4 days after infection. These results indicate that the pulmonary neutrophil count is an early indicator of pneumococcal virulence in cirrhotic rats. The pulmonary neutrophil count is also correlated with the number of bacteria in the alveolar exudate. These findings suggest that neutrophil activation is an early event in the pathogenesis of pneumococcal pneumonia in cirrhotic rats.\n",
      "BLEU: 0.20872434266611495, ROUGE-L: {'r': 0.4479166666666667, 'p': 0.38738738738738737, 'f': 0.4154589322243227}, Perplexity: 2.308642625808716, Cosine Similarity: 0.6593\n",
      "Reference Text: Latent sensitisation to respiratory syncytial virus during acute bronchiolitis and lung function after recovery. To determine whether latent sensitivity to respiratory syncytial virus antigen(s) occurs after infection, 27 infants with acute bronchiolitis were studied and compared with 15 hospital controls. Blood was collected for whole blood challenge, and histamine release was measured by a high performance liquid chromatography technique with fluorometric detection. There was a significantly greater histamine release to respiratory syncytial virus antigen(s) in those with bronchiolitis than in controls, expressed either in amount (median 154 nmol/l compared with 104 nmol/l) or percentage release (median 20% compared with 3%). There was a significant difference between index and control groups in terms of individual histamine responses. These findings strongly suggest that infants develop latent sensitivity to respiratory syncytial virus antigen(s) during the course of acute bronchiolitis. Serial lung function tests were performed in 15 infants. All infants had abnormalities of lung function at some stage, but the small numbers of subjects precluded comparison between 'sensitised' and 'non-sensitised' infants. Further study is indicated to define the relation of latent sensitisation and subsequent bronchial hyper-responsiveness after respiratory syncytial virus infection in infants. \n",
      "Generated Text: Latent sensitisation to respiratory syncytial virus during acute bronchiolitis and lung function after recovery. To determine whether latent sensitivity to respiratory syncytial virus antigen(s) occurs after infection, 27 infants with acute bronchiolitis were studied and compared with 15 hospital controls. Blood was collected for whole blood challenge, and histamine release and T-cell proliferation were measured. In the bronchiolitis group, there was a significantly increased whole blood challenge response to respiratory syncytial virus antigen, but no significant increase in histamine release or T-cell proliferation. The bronchiolitis group also had a significantly lower forced expiratory volume in 1 s at 3 months of age than the control group. These findings suggest that latent sensitisation to respiratory syncytial virus occurs after acute bronchiolitis but that this does not influence the subsequent course of the disease.\n",
      "BLEU: 0.30553102865406484, ROUGE-L: {'r': 0.48695652173913045, 'p': 0.6436781609195402, 'f': 0.5544554406406236}, Perplexity: 4.421627521514893, Cosine Similarity: 0.7906\n",
      "Reference Text: A 47-kDa human nuclear protein recognized by antikinetochore autoimmune sera is homologous with the protein encoded by RCC1, a gene implicated in onset of chromosome condensation. Several autoimmune sera from patients with Raynaud phenomenon decorated mammalian kinetochores and bound to a 47-kDa protein on immunoblots of nuclear lysates. Antibody affinity-purified from immunoblots of the 47-kDa band recognized kinetochores, but due to crossreaction with an 18-kDa protein, localization remains elusive. We used one of these sera to purify the antigen from HeLa cells synchronized in mitosis as a noncovalent complex with a 25-kDa protein. The antigen was released from DNA by intercalation with 25 mM chloroquine. Ion-exchange chromatography yielded the pure complex with an apparent molecular size of 68 kDa, which was separated into its components by gel filtration in 6 M guanidinium chloride. Upon two-dimensional gel electrophoresis the 47-kDa protein gave two main spots of pI 6.6 and 6.7, respectively. Posttranslational modification is indicated by additional antigenic spots, by lack of a free alpha-amino group, and by chromatographic behavior of peptides on reversed-phase chromatography. The amino acid sequence for 205 residues of the 47-kDa protein has been established. This sequence is highly homologous with the translated reading frame of RCC1, a gene reportedly involved in regulating onset of mammalian chromosome condensation. \n",
      "Generated Text: A 47-kDa human nuclear protein recognized by antikinetochore autoimmune sera is homologous with the protein encoded by RCC1, a gene implicated in onset of chromosome condensation. Several autoimmune sera from patients with Raynaud phenomenon decorated mammalian kinetochores and bound to a 47-kDa protein on immunoblots of nuclear lysates. Antibody affinity-purified from the sera reacted with the 47-kDa protein in immunoblots of nuclear extracts. The 47-kDa protein was identified as RCC1 by immunoblotting of nuclear extracts with RCC1-specific monoclonal antibodies. The 47-kDa protein was also identified by immunoblotting of nuclear extracts with a monoclonal antibody specific for the RCC1 protein. The 47-kDa protein was not detected in nuclear extracts of normal human and mouse tissues. The 47-kDa protein was identified as a nuclear protein by immunoblotting of nuclear extracts with a monoclonal antibody specific for the RCC1 protein. The 47-kDa protein was not detected in nuclear extracts of normal human and mouse tissues. The 47-kDa protein was identified as a nuclear protein by immunoblotting of nuclear extracts with a monoclonal antibody specific for the RCC1 protein. The 47-kDa protein was not detected in nuclear extracts of normal human and mouse tissues. The 47-kDa protein was identified as a nuclear protein by immunoblotting of nuclear extracts with a monoclonal antibody specific for the RCC1 protein. The 47-kDa protein was not detected in nuclear extracts of normal human and mouse tissues. The 47-kDa protein was identified as a nuclear protein by immunoblotting of nuclear extracts with a monoclonal antibody specific for the RCC1 protein. The 47-kDa protein was not detected in nuclear extracts of normal human and mouse tissues. The 47-kDa protein was identified as a nuclear protein by immunoblotting of nuclear extracts with a monoclonal antibody specific for the RCC1 protein. The 47-kDa protein was not detected in nuclear extracts of normal human and mouse tissues. The 47-kDa protein was identified as a nuclear protein by immunoblotting of nuclear extracts with a monoclonal antibody specific for the RCC1 protein. The 47-kDa protein was not detected in nuclear extracts of normal human and mouse tissues. The 47-kDa protein was identified as a nuclear\n",
      "BLEU: 0.1748308463409726, ROUGE-L: {'r': 0.31851851851851853, 'p': 0.7166666666666667, 'f': 0.44102563676528606}, Perplexity: 1.871683120727539, Cosine Similarity: 0.6898\n",
      "Reference Text: Antenatal phenobarbital for the prevention of periventricular and intraventricular hemorrhage: a double-blind, randomized, placebo-controlled, multihospital trial. To determine whether the neuroprotective properties of phenobarbital would alter the incidence and severity of intracranial hemorrhage in premature infants, we randomly assigned 110 women at less than 31 weeks of gestation to receive 10 mg/kg phenobarbital or placebo in a blinded fashion before delivery. Infants were examined postnatally with real-time ultrasonography for evidence of intracranial hemorrhage. Maternal demographics, pregnancy complications, antenatal management, and route of delivery did not differ between the phenobarbital group (n = 50) and the placebo group (n = 60). The total incidence of periventricular-intraventricular hemorrhage did not differ between the phenobarbital-treated (n = 54) and the placebo-treated (n = 67) infants. However, the frequency of grade 3 and grade 4 hemorrhages was 15% (10 infants) in the placebo group and 3.7% (2 infants) in the phenobarbital group (p less than 0.05). There were no differences in the severity of associated conditions in the babies to explain the difference in the incidence of severe hemorrhage between the study groups. We conclude that antenatal administration of phenobarbital appears to be effective in decreasing the severity of periventricular-intraventricular hemorrhage in infants delivered at less than 31 weeks of gestation. \n",
      "Generated Text: Antenatal phenobarbital for the prevention of periventricular and intraventricular hemorrhage: a double-blind, randomized, placebo-controlled, multihospital trial. To determine whether the neuroprotective properties of phenobarbital would alter the incidence and severity of intracranial hemorrhage in premature infants, we randomly assigned 110 women at less than 31 weeks of gestation to receive phenobarbital (60 mg/kg) or placebo in the early postpartum period. A total of 49 women (44%) received phenobarbital. The incidence of periventricular and intraventricular hemorrhage was 25% (13/52) in the phenobarbital group and 28% (14/50) in the placebo group (P =.72). The incidence of periventricular and intraventricular hemorrhage was 26% (13/50) in the 2nd group and 28% (14/50) in the 3rd group (P =.83). The incidence of periventricular and intraventricular hemorrhage in the 4th group was 25% (13/52) (P =.83). The incidence of periventricular and intraventricular hemorrhage in the 5th group was 24% (12/50) (P =.87). The incidence of periventricular and intraventricular hemorrhage in the 6th group was 24% (12/50) (P =.87). In conclusion, the use of phenobarbital to prevent periventricular and intraventricular hemorrhage in premature infants did not alter the incidence of periventricular and intraventricular hemorrhage.\n",
      "BLEU: 0.3174240746619434, ROUGE-L: {'r': 0.44537815126050423, 'p': 0.6385542168674698, 'f': 0.5247524704063328}, Perplexity: 2.202688694000244, Cosine Similarity: 0.8603\n",
      "Reference Text: Prediction of outcome in acute pancreatitis: a comparative study of APACHE II, clinical assessment and multiple factor scoring systems. The APACHE II severity of disease classification system has been examined prospectively in 160 patients with acute pancreatitis. Using clinical and simple laboratory data APACHE II was able to provide useful discrimination between uncomplicated, complicated and fatal attacks within a few hours of admission. Peak APACHE II scores (recorded during the first 3 days) had a prognostic accuracy similar to the multiple factor scoring systems, but then incurred a similar delay. Patients could be graded according to their risk of death or of developing a major complication; no deaths occurred in patients with a peak APACHE II score less than 10. APACHE II can be repeated daily, uncomplicated attacks demonstrating falling scores in association with clinical improvement, in contrast to the rising scores associated with clinical deterioration in those dying early. APACHE II appears to reflect any continuing disease activity and may prove a useful means of monitoring the course of the illness and response to therapy. \n",
      "Generated Text: Prediction of outcome in acute pancreatitis: a comparative study of APACHE II, clinical assessment and multiple factor scoring systems. The APACHE II severity of disease classification system has been examined prospectively in 160 patients with acute pancreatitis. Using clinical and simple laboratory data APACHE II was able to provide useful prognostic information. In addition, the APACHE II score correlated with the results of the clinical assessment of severity. A multiple factor scoring system (MFS) was developed from a literature review of 25 studies of prognostic scoring systems in acute pancreatitis. The MFS was then tested in 160 patients with acute pancreatitis and compared with APACHE II and the clinical assessment of severity. The MFS was a better predictor of outcome than either APACHE II or the clinical assessment. The MFS was superior to APACHE II in predicting mortality. The MFS is a simple scoring system which may be useful in predicting outcome in acute pancreatitis.\n",
      "BLEU: 0.3412857131500155, ROUGE-L: {'r': 0.37606837606837606, 'p': 0.6027397260273972, 'f': 0.4631578900049862}, Perplexity: 3.8833746910095215, Cosine Similarity: 0.7987\n",
      "Reference Text: Efficacy of nimodipine in cerebral ischemia or hemorrhage. Our studies showed that in an appropriate dose, nimodipine increased local cerebral blood flow with no corresponding increase in local metabolism. Nimodipine treatment given before experimental ischemic insult, resulting from either vascular occlusion or intracranial hemorrhage or after subarachnoid hemorrhage, maintained or improved blood flow and minimized the severity of subsequent brain damage. Lack of benefit from nimodipine treatment after the insult may occur because the inexorable progression of events leading to ischemic neuronal damage, once initiated, cannot be arrested. On the other hand, pharmacokinetic factors may be important, and post-treatment efficacy may depend on administration protocols that achieve an adequate concentration in ischemic tissue sufficiently soon after an insult. Our findings are compatible with the benefit of nimodipine being due to an improvement in blood flow that reduces the severity of ischemia. However, they do not exclude the possibility that treatment may minimize the accumulation of calcium in damaged cells as a result of \"cytoprotective\" effects. \n",
      "Generated Text: Efficacy of nimodipine in cerebral ischemia or hemorrhage. Our studies showed that in an appropriate dose, nimodipine increased local cerebral blood flow with no corresponding increase in local metabolism. Nimodipine treatment given before experimental ischemic insult, resulting from either vascular occlusion or intracranial hemorrhage or after subarachnoid hemorrhage, maintained or improved cerebral blood flow and oxygen metabolism in the treated brain. Nimodipine did not significantly alter regional cerebral blood flow or oxygen metabolism in the contralateral brain. Nimodipine did not increase the risk of cerebral hemorrhage in the treated brain. Nimodipine is a safe, effective, and selective vasodilator in the treatment of cerebral ischemia or hemorrhage. Nimodipine is not a cerebral vasodilator in the treatment of aneurysmal subarachnoid hemorrhage.\n",
      "BLEU: 0.3191947566872045, ROUGE-L: {'r': 0.42201834862385323, 'p': 0.7540983606557377, 'f': 0.5411764659868512}, Perplexity: 4.423405647277832, Cosine Similarity: 0.7304\n",
      "Reference Text: Reperfusion and readmission of oxygen. Pathophysiological relevance of oxygen-derived free radicals to arrhythmogenesis. We have examined the pathophysiological role of readmission of oxygen (and hence production of oxygen-derived free radicals) in the initiation of reperfusion-induced arrhythmias by separating, on a temporal basis, readmission flow from readmission of oxygen. Isolated rat hearts (n = 12/group) were subjected to 10 minutes of regional ischemia and 10 minutes of reperfusion. In controls reperfused with oxygenated solution (Po2 greater than 600 mm Hg), 92% of hearts developed ventricular fibrillation (VF) during the first 20 seconds of reperfusion, whereas in hearts reperfused with hypoxic solution (Po2 9.3-12.2 mm Hg), the incidence of VF was only 17% (p less than 0.05). Subsequent readmission of control solution (Po2 greater than 600 mm Hg) to the latter group led, within 20 seconds, to the appearance of VF in seven of the 10 hearts (70%) that had not previously fibrillated. To examine whether hypoxic reperfusion had prevented VF or merely delayed its onset, the studies were repeated in separate groups of hearts with the duration of hypoxic reperfusion extended to 5 minutes. In addition, to examine the partial pressure dependence of the relation, the Po2 in the reperfusion solution was set at one of five different levels: greater than 600, 150-192.7, 69-85.6, 9.2-14.8, or 0.0 mm Hg. It was found that hypoxia merely delayed VF onset by 20-40 seconds and did not significantly reduce the incidence of VF, which was 83%, 92%, 67%, 58%, and 58%, respectively. This indicated that readmission of oxygen is unnecessary for the initiation of VF during reperfusion. The hearts that reverted to sinus rhythm during the ensuing 5 minutes (n = 8, 4, 5, 9, and 8, respectively) were used to assess the arrhythmogenic consequences of readmission of oxygen. When control solution (Po2 greater than 600 mm Hg) was readmitted, new episodes of VF were elicited within 20 seconds in a manner that was inversely proportional to the preceding Po2 (p less than 0.05), the incidence of new episodes of VF being 0%, 0%, 40%, 67%, and 86%, respectively. The arrhythmogenic effect of readmission of oxygen was not the result of a sudden increase in heart rate, because a similar arrhythmogenic effect of readmission of oxygen was seen in separate groups of hearts that were paced (350 beats/min) throughout hypoxia and readmission of oxygen. In conclusion, readmission of flow and readmission of oxygen are independent determinants of reperfusion-induced arrhythmias.(ABSTRACT TRUNCATED AT 400 WORDS). \n",
      "Generated Text: Reperfusion and readmission of oxygen. Pathophysiological relevance of oxygen-derived free radicals to arrhythmogenesis. We have examined the pathophysiological role of readmission of oxygen (and hence production of oxygen-derived free radicals) in the initiation of reperfusion-induced arrhythmias by separating, on a temporal basis, readmission flow from readmission of oxygen. Isolated rat hearts were reperfused with 5 mM glucose and 20 mM lactate. The left ventricular pressure and left ventricular developed pressure (Pd) were measured continuously. Oxygenated and deoxygenated reperfusion flow were measured by laser Doppler flowmetry. Oxygen-derived free radicals were measured by xanthine oxidase and xanthine dehydrogenase. The left ventricular pressure and Pd were monitored for 120 minutes after reperfusion. Oxygen-derived free radicals were measured for 120 minutes after reperfusion. Oxygenated reperfusion flow was significantly higher than deoxygenated reperfusion flow. The left ventricular pressure and Pd were significantly higher during oxygenated reperfusion. The oxygen-derived free radical levels were significantly higher during oxygenated reperfusion. The oxygen-derived free radical levels were significantly higher during oxygenated reperfusion than during deoxygenated reperfusion. Oxygen-derived free radicals were measured in the left ventricle during oxygenated reperfusion and during deoxygenated reperfusion. The oxygen-derived free radical levels were significantly higher during oxygenated reperfusion than during deoxygenated reperfusion. Oxygen-derived free radicals were measured in the left ventricle during oxygenated reperfusion and during deoxygenated reperfusion. Oxygenated reperfusion resulted in a marked increase in the oxygen-derived free radical levels, which were significantly higher than during deoxygenated reperfusion. The results of these experiments indicate that the pathophysiological role of oxygen-derived free radicals in reperfusion-induced arrhythmias is not limited to the production of oxygen-derived free radicals during oxygenated reperfusion. Oxygenated reperfusion results in a marked increase in the oxygen-derived free radical levels, which are significantly higher than during deoxygenated reperfusion. The results of these experiments indicate that the pathophysiological role of oxygen-derived free radicals in reperfusion-induced arrhythmias is not limited to the production of oxygen-derived free radicals during oxygenated reperfusion. Oxygenated\n",
      "BLEU: 0.1523144252704725, ROUGE-L: {'r': 0.28292682926829266, 'p': 0.6304347826086957, 'f': 0.39057238629618296}, Perplexity: 2.5843505859375, Cosine Similarity: 0.5921\n",
      "Reference Text: Repetitive conservative surgery for recurrence of endometriosis. We evaluated the recovery of fertility and the relief of pain symptoms in a long-term follow-up of 42 women undergoing repetitive conservative surgery for recurrent endometriosis. The mean age of the patients was 31.1 +/- 4.3 years. At the time of their second operation the disease was stage IV in 14 women, stage III in 25, and stage I in three. After reoperation, the patients were followed for a mean period of 41.8 +/- 30.3 months. Pain symptoms returned in eight women, dysmenorrhea and deep dyspareunia in eight, and pelvic pain in seven. Eight of the 28 women (28.6%) who attempted to conceive achieved a total of 13 pregnancies. The corrected pregnancy rate was 35%, and the cumulative rate at 27 months was 30.7%. A third operation was necessary in six women after a mean period of 35 months. Conservative surgery is an effective therapeutic option for infertile patients with recurrent endometriosis. \n",
      "Generated Text: Repetitive conservative surgery for recurrence of endometriosis. We evaluated the recovery of fertility and the relief of pain symptoms in a long-term follow-up of 42 women undergoing repetitive conservative surgery for recurrent endometriosis. The mean age of the patients was 31.1 +/- 4.3 years. At the time of their second operation, 21 women had endometriosis of the ovaries and 21 had endometriosis of the uterus. The mean duration of the disease was 7.2 +/- 4.1 years. The mean duration of the first operation was 7.8 +/- 3.9 years. The mean follow-up period was 7.3 +/- 4.2 years. The mean duration of the second operation was 4.6 +/- 1.7 years. All patients were examined and treated for the presence of adnexal lesions during the second operation. The mean duration of follow-up after the second operation was 6.1 +/- 4.2 years. The mean number of operations was 1.8 +/- 0.8. The mean number of operations per patient was 2.4 +/- 0.9. The mean duration of the third operation was 2.8 +/- 1.4 years. The mean number of operations per patient was 1.6 +/- 0.7. The mean duration of follow-up after the third operation was 4.7 +/- 3.4 years. The mean number of operations per patient was 1.6 +/- 0.7. The mean duration of follow-up after the fourth operation was 4.7 +/- 3.5 years. The mean number of operations per patient was 1.4 +/- 0.6. The mean duration of follow-up after the fifth operation was 4.8 +/- 3.6 years. The mean number of operations per patient was 1.2 +/- 0.7. The mean duration of follow-up after the sixth operation was 4.9 +/- 4.0 years. The mean number of operations per patient was 1.1 +/- 0.7. The mean duration of follow-up after the seventh operation was 5.1 +/- 4.4 years. The mean number of operations per patient was 1.2 +/- 0.6. The mean duration of follow-up after the eighth operation was 5.3 +/- 4\n",
      "BLEU: 0.17771777287066023, ROUGE-L: {'r': 0.44660194174757284, 'p': 0.6052631578947368, 'f': 0.513966475560688}, Perplexity: 2.122638463973999, Cosine Similarity: 0.6826\n",
      "Reference Text: Dexamethasone increases plasma levels of albendazole. Therapy of neurocysticercosis with cysticidal drugs is frequently complicated by the exacerbation of symptoms that follows the inflammation triggered by the acute destruction of cysticerci. Treatment of such adverse reactions with dexamethasone is highly effective. However, it has been shown that dexamethasone lowers the plasma levels of praziquantel, thus reducing its cysticidal efficacy. We measured plasma levels of albendazole, another strong cysticidal drug, when dexamethasone was given simultaneously. We found that dexamethasone increased the plasma levels of albendazole by about 50% (P less than 0.002); hence, it seems that cysticercosis and the ensuing inflammation can be treated simultaneously with albendazole and dexamethasone without diminishing the efficacy of the cysticidal drug. \n",
      "Generated Text: Dexamethasone increases plasma levels of albendazole. Therapy of neurocysticercosis with cysticidal drugs is frequently complicated by the exacerbation of symptoms that follows the inflammation triggered by the acute destruction of cysticerci. Treatment of such adverse reactions with dexamethasone is highly effective. However, it has been shown that dexamethasone lowers the plasma levels of albendazole. This effect may be responsible for the failure of dexamethasone to relieve the adverse reactions.\n",
      "BLEU: 0.3948434304499648, ROUGE-L: {'r': 0.527027027027027, 'p': 0.8297872340425532, 'f': 0.6446280944225121}, Perplexity: 6.545154571533203, Cosine Similarity: 0.8774\n",
      "Reference Text: Severe hypertension after liver transplantation in alpha 1 antitrypsin deficiency. Five children with alpha 1 antitrypsin deficiency and terminal liver disease received liver grafts; all five became hypertensive and four developed hypertensive encephalopathy. There was evidence of renal disease preoperatively and renal biopsy specimens showed variable glomerulonephritic histology with IgA nephropathy in one, mesangial-proliferative changes in two, and mesangio-capillary glomerulonephritis type I in two. Four hypertensive episodes were preceded by a fall in creatinine clearance. The association of glomerulonephritis with alpha 1 antitrypsin deficiency in children is more common than has been recognised. Affected patients are prone to severe hypertension of probable renal origin after liver transplantation and the renal lesion may affect long term prognosis. \n",
      "Generated Text: Severe hypertension after liver transplantation in alpha 1 antitrypsin deficiency. Five children with alpha 1 antitrypsin deficiency and terminal liver disease received liver grafts; all five became hypertensive and four developed hypertensive encephalopathy. There was evidence of renal disease preoperatively and renal biopsy specimens showed variable glomerulonephritic histology with IgA nephropathy, focal glomerulosclerosis, and membranous glomerulopathy. The hypertensive encephalopathy was accompanied by a severe decrease in glomerular filtration rate, with a progressive increase in serum creatinine and blood urea nitrogen. The hypertensive encephalopathy resolved with the administration of angiotensin-converting enzyme inhibitors. The renal disease preoperatively was probably the cause of the hypertension. The hypertensive encephalopathy was probably due to a combination of the hypertensive state and the renal disease. Liver transplantation in these patients should be performed with caution, and the possibility of renal disease should be considered.\n",
      "We describe a case of hepatic adenoma in a 38-year-old woman with a 7-year history of hypertension. The patient was found to have a 3.5-cm hepatic adenoma by ultrasound and magnetic resonance imaging. The adenoma was removed laparoscopically and the patient was asymptomatic 2 months later. The adenoma was a solitary lesion in the right lobe of the liver. The patient had a 7-year history of hypertension and had been treated with antihypertensive medications. The patient had no other clinical manifestations of the disease. The patient had a 7-year history of hypertension. The patient had been treated with antihypertensive medications for 7 years before the development of the hepatic adenoma. She had no other clinical manifestations of the disease. The patient had a 7-year history of hypertension. The patient had been treated with antihypertensive medications for 7 years before the development of the hepatic adenoma. She had no other clinical manifestations of the disease. The patient had a 7-year history of hypertension. The patient had been treated with antihypertensive medications for 7 years before the development of the hepatic adenoma. She had no other clinical manifestations of the disease. The patient had a 7-year history of hypertension. The patient had been treated with antihypertensive medications for 7 years before\n",
      "BLEU: 0.15845058919385177, ROUGE-L: {'r': 0.5609756097560976, 'p': 0.37398373983739835, 'f': 0.44878048300487805}, Perplexity: 2.5470762252807617, Cosine Similarity: 0.4820\n",
      "Reference Text: The in vivo biologic effect of interleukin 2 and interferon alfa on natural immunity in patients with head and neck cancer. Given the association of deficient natural immunity with the risk of metastatic disease, the ability to activate natural killer cell function may have a therapeutic significance. The effect of continuous infusion of interleukin 2 plus intramuscular interferon alfa on natural immune status was, therefore, analyzed in eight patients with head and neck cancer. Also evaluated was the effect of interleukin 2-interferon alfa therapy on lymphokine-activated killer cell activity as well as total lymphocyte count, percent of lymphocyte subsets, and levels of both circulating immune complexes and antibody classes. Both the percent and absolute number of natural killer cells (ie, CD56+ CD3- lymphocytes) within peripheral blood as well as natural killer cell activity against K562 targets increased significantly with treatment. The remaining immune parameters were not significantly altered. The demonstrated capacity to modulate natural immune function supports the potential use of interleukin 2-containing regimens as a preventive measure against metastatic disease in patients with head and neck cancer. \n",
      "Generated Text: The in vivo biologic effect of interleukin 2 and interferon alfa on natural immunity in patients with head and neck cancer. Given the association of deficient natural immunity with the risk of metastatic disease, the ability to activate natural killer cell function may have a therapeutic significance. The effect of interleukin 2 (IL-2) and interferon alfa (IFN-alfa) on natural immunity was studied in patients with head and neck cancer. A total of 26 patients were treated with IL-2 and IFN-alfa. One patient died of infection. The remaining 25 patients received 3 x 10(6) IU IL-2 or 3 x 10(6) IU IFN-alfa weekly for 4 weeks. The number of circulating lymphocytes and natural killer (NK) cells was measured before and after treatment. There was no significant difference in the number of circulating lymphocytes or NK cells before and after treatment. The number of lymphocytes and NK cells was not correlated with the number of metastatic lesions or survival. In conclusion, these results suggest that IL-2 and IFN-alfa do not induce a significant increase in natural immunity in patients with head and neck cancer.\n",
      "BLEU: 0.37607660291367356, ROUGE-L: {'r': 0.45544554455445546, 'p': 0.5054945054945055, 'f': 0.4791666616802301}, Perplexity: 2.995457649230957, Cosine Similarity: 0.7880\n",
      "Reference Text: Catecholamine-induced cardiomyopathy in multiple endocrine neoplasia. A histologic, ultrastructural, and biochemical study. A catecholamine-induced dilated cardiomyopathy is reported in a patient with multiple endocrine neoplasia, type 3. A histologic and ultrastructural study has been undertaken in cardiac biopsy samples, together with determination of myocardial Ca++ and cellular membrane fatty acids. Contraction band necrosis of cardiocytes with supercontraction of sarcomeres progressing to myofibrolysis and increased levels of myocardial Ca++ have been found as morphologic and biochemical abnormalities, respectively. No lipoperoxidation of cellular membranes or an alpha-adrenergic mediated reduction of coronary supply could be recognized in the study. We indicate a receptor-mediated intracellular Ca++ overload as the main abnormality responsible for myocardial impairment. \n",
      "Generated Text: Catecholamine-induced cardiomyopathy in multiple endocrine neoplasia. A histologic, ultrastructural, and biochemical study. A catecholamine-induced dilated cardiomyopathy is reported in a patient with multiple endocrine neoplasia, type 3. A histologic and ultrastructural study has been undertaken in cardiac biopsy samples, together with determination of myocardial Ca++ and cellular membrane fatty acids. The patient was 43 years old and had been diagnosed with multiple endocrine neoplasia, type 3, 3 years previously. Cardiac biopsy showed diffuse interstitial fibrosis with an increased number of T-tubules and an increased number of mitochondria. The ultrastructural features were those of a dilated cardiomyopathy. The myocardial Ca++ was increased, and the fatty acid composition of the myocardial membrane was abnormal. The patient was treated with L-dopa and carvedilol. The cardiac symptoms disappeared after 2 months, but the patient died of a myocardial infarction 7 months after the initial diagnosis. The histologic and ultrastructural features of the cardiomyopathy in this patient are consistent with a catecholamine-induced dilated cardiomyopathy. The myocardial Ca++ and fatty acid composition of the membrane are consistent with the pathogenesis of this disease.\n",
      "BLEU: 0.3009686358408689, ROUGE-L: {'r': 0.5185185185185185, 'p': 0.4883720930232558, 'f': 0.50299400698053}, Perplexity: 3.604990005493164, Cosine Similarity: 0.7168\n",
      "Reference Text: Assessing the clinical effectiveness of preventive maneuvers: analytic principles and systematic methods in reviewing evidence and developing clinical practice recommendations. A report by the Canadian Task Force on the Periodic Health Examination. This paper examines a process for evaluating clinical effectiveness and developing recommendations in which systematic methods are used to review evidence from published clinical research and to reach sound conclusions about appropriate medical policy. The methodology addresses four important components of the analytic process: (1) the criteria that must be satisfied for a clinical practice to be considered effective; (2) proper methods for reviewing evidence from published clinical research to determine whether a clinical practice meets these criteria (including methods for performing comprehensive literature reviews, for judging the quality of individual studies, and for synthesizing or pooling the results of multiple studies); (3) theoretical and practical concerns in translating the results of the scientific review into sound clinical practice recommendations; and (4) the importance of documentation, guidelines, and other safeguards to minimize the effect the reviewers themselves have on the objectivity and consistency of the analytic methods. \n",
      "Generated Text: Assessing the clinical effectiveness of preventive maneuvers: analytic principles and systematic methods in reviewing evidence and developing clinical practice recommendations. A report by the Canadian Task Force on the Periodic Health Examination. This paper examines a process for evaluating clinical effectiveness and developing recommendations in which systematic methods are used to identify, analyze, and evaluate the evidence available. The report focuses on the development of clinical practice recommendations for the Canadian Task Force on the Periodic Health Examination. The recommendations are based on a systematic review of the literature. The review was undertaken in 1987 and 1988 and included a literature search of the English-language medical literature on the prevention of disease in adults and children. A total of 23 recommendations were developed, with 13 recommendations being based on the results of a systematic review of the literature. The review was conducted by a multidisciplinary group of Canadian experts in the field of preventive medicine and public health. The group identified a list of 20 recommendations that were derived from the literature review. The recommendations were developed with the following criteria in mind: (1) the recommendations should be based on the best available evidence; (2) the recommendations should be supported by the best available evidence; (3) the recommendations should be supported by the best available evidence and be consistent with current clinical practice; (4) the recommendations should be supported by the best available evidence and be consistent with current clinical practice and be supported by the best available evidence; and (5) the recommendations should be supported by the best available evidence and be consistent with current clinical practice and be supported by the best available evidence. The recommendations are based on the best available evidence and are supported by the best available evidence. The recommendations are supported by the best available evidence and are supported by the best available evidence. The recommendations are supported by the best available evidence and are supported by the best available evidence. The recommendations are supported by the best available evidence and are supported by the best available evidence. The recommendations are supported by the best available evidence and are supported by the best available evidence. The recommendations are supported by the best available evidence and are supported by the best available evidence. The recommendations are supported by the best available evidence and are supported by the best available evidence. The recommendations are supported by the best available evidence and are supported by the best available evidence. The recommendations are supported by the best available evidence and are supported by the best available evidence. The recommendations are supported by the best available evidence and are supported by the best available evidence.\n",
      "BLEU: 0.14019230742309507, ROUGE-L: {'r': 0.4537037037037037, 'p': 0.49, 'f': 0.47115384116124265}, Perplexity: 2.4074883460998535, Cosine Similarity: 0.6402\n",
      "Reference Text: Transient ischaemic attacks in young patients: a thromboembolic or migrainous manifestation? A 10 year follow up study of 46 patients. Forty six patients aged 18-39 years with transient ischaemic attacks (TIA) were studied; two thirds were women. Twenty five patients had attacks accompanied by headache, and seven gave a history of common migraine. Only four of 27 angiograms were abnormal; no operable carotid lesion was demonstrated. Over a mean follow up period of 10 years stroke or myocardial infarction (AMI) occurred in all four patients who presented major cerebrovascular risk factors, but in only two of the remaining 42 patients. Thus irrespective of age thromboembolic TIA is a harbinger of stroke or AMI. However, most TIAs under the age of 40 years are caused by a non-embolic benign vascular disorder. The clinical characteristics, long-term prognosis, and possible pathogenesis, for such attacks are often indistinguishable from those of classical migraine. In the absence of cardiovascular risk factors, arteriography does not provide much diagnostic and prognostic information. \n",
      "Generated Text: Transient ischaemic attacks in young patients: a thromboembolic or migrainous manifestation? A 10 year follow up study of 46 patients. Forty six patients aged 18-39 years with transient ischaemic attacks (TIA) were studied; two thirds were women. Twenty five patients had attacks accompanied by headache, and seven gave a history of migraine. Thromboembolic episodes were found in 24 of the 46 patients. One patient had two thromboembolic episodes. In 10 patients the attacks were preceded by migraine. The mean duration of the attacks was 3.3 months (range 1-12 months). All the patients were treated with anticoagulants. No patient was subsequently lost to follow up. The thromboembolic episodes were more frequent in the patients who had migrainous attacks than in those with headache alone (p < 0.001). The patients with migrainous attacks had a higher incidence of thromboembolic episodes than those with headache alone (p < 0.01). The patients with migrainous attacks had a higher incidence of recurrent attacks than those with headache alone (p < 0.001). The patients with migrainous attacks had a higher incidence of recurrent attacks than those with headache alone (p < 0.001). The patients with migrainous attacks had a higher incidence of recurrent attacks than those with headache alone (p < 0.001). The patients with migrainous attacks had a higher incidence of recurrent attacks than those with headache alone (p < 0.001). The patients with migrainous attacks had a higher incidence of recurrent attacks than those with headache alone (p < 0.001). The patients with migrainous attacks had a higher incidence of recurrent attacks than those with headache alone (p < 0.001). The patients with migrainous attacks had a higher incidence of recurrent attacks than those with headache alone (p < 0.001). The patients with migrainous attacks had a higher incidence of recurrent attacks than those with headache alone (p < 0.001). The patients with migrainous attacks had a higher incidence of recurrent attacks than those with headache alone (p < 0.001). The patients with migrainous attacks had a higher incidence of recurrent attacks than those with headache alone (p < 0.001). The patients with migrainous attacks had a higher incidence of\n",
      "BLEU: 0.1597040417025479, ROUGE-L: {'r': 0.425, 'p': 0.6071428571428571, 'f': 0.4999999951557094}, Perplexity: 1.907473087310791, Cosine Similarity: 0.5278\n",
      "Reference Text: Incidence of perioperative myocardial ischemia detected by different electrocardiographic systems To determine the extent to which different electrocardiographic systems account for differences in reported incidence of perioperative myocardial ischemia, the authors simultaneously recorded in 109 patients undergoing coronary artery bypass grafting (CABG) the V5 or modified CM5 lead on five ECG systems by means of a specially constructed common V5 lead. The systems included a Spacelabs Alpha 14 Model Series 3200 ECG Cardule at bandwidths of 0.05-125 Hz and 0.5-30 Hz (a typical operating room monitor), a Marquette Electronics MAC II ECG at 0.05-40 Hz and 0.05-100 Hz (a standard ECG), and a Del Mar Holter recorder at 0.1-100 Hz. Relative ST-segment position and incidence of new ischemia compared to the preoperative ECG were determined in 109 sets of preinduction traces and 877 sets of intraoperative traces. ST-segment position on the three recording systems conforming with the American Heart Association (AHA) low-frequency response recommendations (0.05 Hz) were similar. Compared to the standard ECG, ST-segment position on the Spacelabs at 0.5-30 Hz was consistently more negative. Displacement on the Holter was consistently less negative and less positive. By the 0.1-mV displacement criterion for diagnosis of myocardial ischemia on any one ECG system, 16.5% of patients on arrival and 32.1% of patients intraoperatively suffered new myocardial ischemia. Based on the operating room monitor, arrival and intraoperative ischemia were present in 15.6 and 27.5% of patients, respectively. Ischemia at the same periods was less frequent by the standard ECG system (5.5 and 12.8%, respectively) and least frequent by the Holter recorder (4.6 and 8.3%, respectively). \n",
      "Generated Text: Incidence of perioperative myocardial ischemia detected by different electrocardiographic systems To determine the extent to which different electrocardiographic systems account for differences in reported incidence of perioperative myocardial ischemia, the authors simultaneously recorded in 109 patients undergoing coronary artery bypass grafting (CABG) the V5 or modified CM5 lead on five occasions. The incidence of ischemic episodes was 0.9% (n = 1) for the V5 lead, 2.1% (n = 2) for the modified CM5 lead, and 0.9% (n = 1) for the standard 12-lead electrocardiogram. There was no difference in the incidence of ischemic episodes between the three systems. The incidence of ischemic episodes was significantly greater for the V5 lead than for the modified CM5 lead (P <.05). The incidence of ischemic episodes was not significantly different between the V5 lead and the standard 12-lead electrocardiogram. The authors conclude that the V5 lead is as sensitive as the modified CM5 lead in detecting perioperative myocardial ischemia. The standard 12-lead electrocardiogram is not a sensitive method of detecting perioperative myocardial ischemia.\n",
      "BLEU: 0.19596009692053207, ROUGE-L: {'r': 0.3141025641025641, 'p': 0.620253164556962, 'f': 0.41702127213254864}, Perplexity: 2.973747968673706, Cosine Similarity: 0.6218\n",
      "Reference Text: Crohn's disease in the city of Derby, 1951-85. An epidemiological survey of Crohn's disease in the city of Derby showed that the incidence of the condition increased from 0.7/10(5) per year between 1951 and 1955 to 6.67/10(5) per year between 1981 and 1985 but seemed to reach a plateau between 1976 and 1985. Large bowel Crohn's disease was more common in patients presenting aged 60-79 years than in those aged 20-39 years. The increase in incidence was not solely due to the detection of milder disease. There was no evidence that the Asian (Indian subcontinent) population of Derby was resistant to the development of Crohn's disease. \n",
      "Generated Text: Crohn's disease in the city of Derby, 1951-85. An epidemiological survey of Crohn's disease in the city of Derby showed that the incidence of the condition increased from 0.7/10(5) per year between 1951 and 1955 to 6.67/10(5) per year between 1981 and 1985 but seemed to reach a plateau between 1981 and 1985. The disease was most common in men aged 20-40 years. The most common sites of involvement were the ileocaecal region and the right lower quadrant. The most common symptoms were abdominal pain, diarrhoea and weight loss. The disease was not associated with any specific dietary or other environmental factors. The incidence of Crohn's disease in the city of Derby was similar to that in the general population of the West Midlands.\n",
      "BLEU: 0.4627771275262795, ROUGE-L: {'r': 0.6268656716417911, 'p': 0.5753424657534246, 'f': 0.5999999950091837}, Perplexity: 3.6557860374450684, Cosine Similarity: 0.8749\n",
      "Reference Text: Caffeine and cardiac arrhythmias. PURPOSE: To review the evidence supporting the belief that caffeine causes cardiac arrhythmias. DATA SOURCES: Studies published since 1982 identified through computerized searches of MEDLINE, TOXLINE, and Chemical Abstracts and a review of bibliographies of relevant articles on the subject of caffeine and cardiac arrhythmias. STUDY SELECTION: All clinical studies examining caffeine as a cause of cardiac arrhythmias and a selection of basic science experiments to illustrate caffeine's effects in vitro. DATA EXTRACTION: Study quality was assessed and all available clinical data pertaining to caffeine as a cause of arrhythmias were summarized. RESULTS OF DATA ANALYSIS: In one electrophysiologic study, caffeine was associated with an increased susceptibility to provoked cardiac arrhythmias. In five placebo-controlled trials, caffeine in doses up to 500 mg daily (equivalent to 5 to 6 cups of coffee) did not increase the frequency or severity of ventricular arrhythmias. One large epidemiologic study reported an increase in the frequency of ventricular extrasystoles in persons consuming 9 or more cups of coffee daily. CONCLUSION: Moderate ingestion of caffeine does not increase the frequency or severity of cardiac arrhythmias in normal persons, patients with ischemic heart disease, or those with pre-existing serious ventricular ectopy. \n",
      "Generated Text: Caffeine and cardiac arrhythmias. PURPOSE: To review the evidence supporting the belief that caffeine causes cardiac arrhythmias. DATA SOURCES: Studies published since 1982 identified through computerized searches of MEDLINE, TOXLINE, and Chemical Abstracts and a review of bibliographies of relevant articles on the subject of caffeine and cardiac arrhythmias. STUDY SELECTION: Studies were selected if they reported on caffeine and cardiac arrhythmias. DATA EXTRACTION: The studies were evaluated for study design, sample size, method of caffeine administration, caffeine dose, caffeine concentration, and caffeine effect on arrhythmias. DATA SYNTHESIS: Most studies have shown that caffeine causes arrhythmias, and the arrhythmias are dose dependent. The arrhythmias are of three types: bradycardia, tachycardia, and ventricular fibrillation. Caffeine causes tachycardia and ventricular fibrillation in doses of 100-200 mg/kg and bradycardia in doses of 100-200 mg/kg. Caffeine causes arrhythmias at concentrations of 0.5-2.5 mg/L. The caffeine-induced arrhythmias are of three types: 1) ventricular fibrillation, 2) sinus tachycardia, and 3) sinus bradycardia. Caffeine-induced arrhythmias are dose dependent and are caused by caffeine's effect on the heart's automaticity. CONCLUSIONS: Caffeine causes arrhythmias at doses of 100-200 mg/kg and at concentrations of 0.5-2.5 mg/L. The arrhythmias are of three types: 1) ventricular fibrillation, 2) sinus tachycardia, and 3) sinus bradycardia. Caffeine's effect on the heart's automaticity is dose dependent. Caffeine is the most potent arrhythmic agent known. Caffeine-induced arrhythmias are not associated with increased mortality. The arrhythmias are not associated with increased morbidity. Caffeine is not a causative agent for cardiac arrhythmias. Caffeine has no significant pharmacologic effects on the heart.\n",
      "BLEU: 0.23786201978991248, ROUGE-L: {'r': 0.42276422764227645, 'p': 0.45217391304347826, 'f': 0.43697478492161573}, Perplexity: 2.5503315925598145, Cosine Similarity: 0.7107\n",
      "Reference Text: The surgical treatment of atrial fibrillation. III. Development of a definitive surgical procedure. On the basis of the known electrophysiologic mechanisms of atrial fibrillation, multiple surgical procedures were designed and tested in dogs to determine the feasibility of developing a surgical cure for human atrial fibrillation. These experimental studies culminated in a surgical approach that effectively creates an electrical maze in the atrium. The atrial incisions prevent atrial reentry and allow sinus impulses to activate the entire atrial myocardium, thereby preserving atrial transport function postoperatively. Since September 1987, this surgical procedure has been applied in seven patients, five with paroxysmal atrial fibrillation of 2 to 9 years' duration and two with chronic atrial fibrillation of 3 and 10 years' duration. All seven patients have been cured of atrial fibrillation and none is receiving any postoperative antiarrhythmic medications. \n",
      "Generated Text: The surgical treatment of atrial fibrillation. III. Development of a definitive surgical procedure. On the basis of the known electrophysiologic mechanisms of atrial fibrillation, multiple surgical procedures were designed and tested in dogs to determine the feasibility of developing a surgical cure for human atrial fibrillation. These experimental studies culminated in the development of a surgical procedure for the treatment of atrial fibrillation. The procedure consists of a right atrial appendage occlusion, followed by an atrial septal ablation, and finally a left atrial appendage occlusion. The procedure is performed under local anesthesia, with minimal blood loss and minimal morbidity. The procedure was performed in 5 dogs with atrial fibrillation. All dogs had an electrical cardioversion to sinus rhythm. The procedure was successful in 4 dogs. The mean time from onset of atrial fibrillation to the completion of the procedure was 11.3 days. The mean time from the onset of atrial fibrillation to the onset of sinus rhythm was 16.5 days. The procedure was complicated in 1 dog by atrial septal rupture. The dog was successfully treated by left atrial appendage occlusion. The mean time from the onset of atrial fibrillation to the onset of sinus rhythm was 5 days. The mean time from the onset of atrial fibrillation to the completion of the procedure was 12.5 days. The procedure was complicated in 2 dogs by atrial septal rupture. The mean time from the onset of atrial fibrillation to the onset of sinus rhythm was 14 days. The mean time from the onset of atrial fibrillation to the completion of the procedure was 13 days. The mean time from the onset of atrial fibrillation to the onset of sinus rhythm was 13 days. The mean time from the onset of atrial fibrillation to the completion of the procedure was 11 days. The mean time from the onset of atrial fibrillation to the onset of sinus rhythm was 11 days. The mean time from the onset of atrial fibrillation to the onset of sinus rhythm was 11 days. The mean time from the onset of atrial fibrillation to the onset of sinus rhythm was 11 days. The mean time from the onset of atrial fibrillation to the onset of sinus rhythm was 11 days. The mean time from the onset of atrial fibrillation to the onset of sinus rhythm was 11\n",
      "BLEU: 0.15090712011371266, ROUGE-L: {'r': 0.4835164835164835, 'p': 0.4943820224719101, 'f': 0.48888888388950624}, Perplexity: 2.134943962097168, Cosine Similarity: 0.6684\n",
      "Average BLEU: 0.270683329879671\n",
      "Average ROUGE-L: 0.521058355600036\n",
      "Average Perplexity: 3.0425111663341524\n",
      "Average Cosine Similarity: 0.7037047400357728\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import torch\n",
    "from transformers import AutoTokenizer, AutoModelForCausalLM\n",
    "from nltk.translate.bleu_score import sentence_bleu\n",
    "from rouge import Rouge\n",
    "from sklearn.metrics.pairwise import cosine_similarity\n",
    "from sklearn.feature_extraction.text import CountVectorizer\n",
    "\n",
    "device = torch.device(\"cuda:7\" if torch.cuda.is_available() else \"cpu\")\n",
    "\n",
    "# Load model and tokenizer\n",
    "#tokenizer = AutoTokenizer.from_pretrained(\"gpt2\")\n",
    "#generator_model = AutoModelForCausalLM.from_pretrained(\"gpt2\").to(device)\n",
    "\n",
    "# Load the dataset\n",
    "train_df = pd.read_csv(\"medical_tc_test.csv\")\n",
    "texts = train_df[\"medical_abstract\"][:100].tolist()\n",
    "\n",
    "# Ensure tokenizer has a pad token\n",
    "if tokenizer.pad_token is None:\n",
    "    tokenizer.pad_token = tokenizer.eos_token\n",
    "\n",
    "# Create prompts from the first 50 words\n",
    "prompts = [' '.join(str(text).split()[:50]) for text in texts]\n",
    "\n",
    "def generate_long_text(model, tokenizer, prompt, max_length=300):    \n",
    "    input_ids = tokenizer(prompt, return_tensors=\"pt\").input_ids.to(device)\n",
    "    output_ids = model.generate(input_ids, max_length=max_length, num_return_sequences=1, pad_token_id=tokenizer.eos_token_id)\n",
    "    generated_text = tokenizer.decode(output_ids[0], skip_special_tokens=True)\n",
    "    return generated_text\n",
    "\n",
    "def calculate_perplexity(model, tokenizer, text):\n",
    "    input_ids = tokenizer(text, return_tensors=\"pt\").input_ids.to(device)\n",
    "    with torch.no_grad():\n",
    "        outputs = model(input_ids, labels=input_ids)\n",
    "        loss = outputs.loss\n",
    "    return torch.exp(loss).item()\n",
    "\n",
    "def evaluate_generated_texts(reference_text, generated_text):\n",
    "    reference_list = reference_text.split()\n",
    "    generated_list = generated_text.split()\n",
    "\n",
    "    # BLEU Score\n",
    "    bleu_score = sentence_bleu([reference_list], generated_list)\n",
    "\n",
    "    # ROUGE Scores\n",
    "    rouge = Rouge()\n",
    "    rouge_scores = rouge.get_scores(generated_text, reference_text)[0]\n",
    "    P = rouge_scores['rouge-l']['p']\n",
    "    R = rouge_scores['rouge-l']['r']\n",
    "    F1 = rouge_scores['rouge-l']['f']\n",
    "\n",
    "    # Cosine Similarity\n",
    "    vectorizer = CountVectorizer().fit_transform([reference_text, generated_text])\n",
    "    vectors = vectorizer.toarray()\n",
    "    cos_sim = cosine_similarity(vectors)[0][1]\n",
    "\n",
    "    return bleu_score, rouge_scores, P, R, F1, cos_sim\n",
    "\n",
    "# Evaluation Loop\n",
    "total_bleu, total_rougeL, total_perplexity, total_sim = 0, 0, 0, 0\n",
    "for i, prompt in enumerate(prompts):\n",
    "    reference_text = texts[i]\n",
    "    generated_text_str = generate_long_text(generator_model, tokenizer, prompt, max_length=500)\n",
    "    \n",
    "    print(f\"Reference Text: {reference_text}\")\n",
    "    print(f\"Generated Text: {generated_text_str}\")\n",
    "\n",
    "    bleu_score, rouge_scores, P, R, F1, cos_sim = evaluate_generated_texts(reference_text, generated_text_str)\n",
    "    perplexity = calculate_perplexity(generator_model, tokenizer, generated_text_str)\n",
    "\n",
    "    print(f\"BLEU: {bleu_score}, ROUGE-L: {rouge_scores['rouge-l']}, Perplexity: {perplexity}, Cosine Similarity: {cos_sim:.4f}\")\n",
    "    \n",
    "    # Accumulate scores\n",
    "    total_bleu += bleu_score\n",
    "    total_rougeL += rouge_scores['rouge-l']['f']\n",
    "    total_perplexity += perplexity\n",
    "    total_sim += cos_sim\n",
    "\n",
    "# Averages\n",
    "num_samples = len(prompts)\n",
    "print(\"Average BLEU:\", total_bleu / num_samples)\n",
    "print(\"Average ROUGE-L:\", total_rougeL / num_samples)\n",
    "print(\"Average Perplexity:\", total_perplexity / num_samples)\n",
    "print(\"Average Cosine Similarity:\", total_sim / num_samples)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "9a11d76d-b8eb-4387-b012-1f43ef738827",
   "metadata": {},
   "outputs": [],
   "source": [
    "torch.cuda.empty_cache()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "9ffe5682-3959-44f7-90ee-906604b0e925",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[LightGBM] [Info] Number of positive: 79, number of negative: 81\n",
      "[LightGBM] [Info] Auto-choosing row-wise multi-threading, the overhead of testing was 0.007552 seconds.\n",
      "You can set `force_row_wise=true` to remove the overhead.\n",
      "And if memory is not enough, you can set `force_col_wise=true`.\n",
      "[LightGBM] [Info] Total Bins 216\n",
      "[LightGBM] [Info] Number of data points in the train set: 160, number of used features: 4\n",
      "[LightGBM] [Info] [binary:BoostFromScore]: pavg=0.500000 -> initscore=0.000000\n",
      "[LightGBM] [Info] Start training from score 0.000000\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "Classification Report:\n",
      "              precision    recall  f1-score   support\n",
      "\n",
      "           0       0.44      0.42      0.43        19\n",
      "           1       0.50      0.52      0.51        21\n",
      "\n",
      "    accuracy                           0.48        40\n",
      "   macro avg       0.47      0.47      0.47        40\n",
      "weighted avg       0.47      0.47      0.47        40\n",
      "\n",
      "ROC-AUC: 0.43\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import numpy as np\n",
    "import pandas as pd\n",
    "import torch\n",
    "from transformers import AutoTokenizer, AutoModelForCausalLM\n",
    "from sklearn.model_selection import train_test_split\n",
    "from sklearn.metrics import classification_report, roc_auc_score, roc_curve\n",
    "from lightgbm import LGBMClassifier\n",
    "from scipy.stats import entropy\n",
    "from sklearn.preprocessing import MinMaxScaler\n",
    "import matplotlib.pyplot as plt\n",
    "\n",
    "# Set up device\n",
    "device = torch.device(\"cuda:7\" if torch.cuda.is_available() else \"cpu\")\n",
    "\n",
    "# Load datasets\n",
    "train_df = pd.read_csv(\"medical_tc_train.csv\")  # Adjust file name if necessary\n",
    "test_df = pd.read_csv(\"medical_tc_test.csv\")    # Adjust file name if necessary\n",
    "\n",
    "train_texts = train_df[\"medical_abstract\"][:100].tolist()\n",
    "test_texts = test_df[\"medical_abstract\"][:100].tolist()\n",
    "\n",
    "# Function to calculate perplexity\n",
    "def calculate_perplexity(model, tokenizer, text, device):\n",
    "    input_ids = tokenizer(text, return_tensors=\"pt\", padding=True, truncation=True).input_ids.to(device)\n",
    "    with torch.no_grad():\n",
    "        outputs = model(input_ids, labels=input_ids)\n",
    "        loss = outputs.loss\n",
    "    return torch.exp(loss).item()\n",
    "\n",
    "# Function to calculate prediction confidence\n",
    "def calculate_prediction_confidence(model, tokenizer, text, device):\n",
    "    input_ids = tokenizer(text, return_tensors=\"pt\", padding=True, truncation=True).input_ids.to(device)\n",
    "    with torch.no_grad():\n",
    "        outputs = model(input_ids)\n",
    "        probabilities = torch.softmax(outputs.logits, dim=-1)\n",
    "        return probabilities.max().item()\n",
    "\n",
    "# Function to calculate entropy\n",
    "def calculate_entropy(model, tokenizer, text, device):\n",
    "    input_ids = tokenizer(text, return_tensors=\"pt\", padding=True, truncation=True).input_ids.to(device)\n",
    "    with torch.no_grad():\n",
    "        outputs = model(input_ids)\n",
    "        probabilities = torch.softmax(outputs.logits, dim=-1)\n",
    "        return entropy(probabilities.cpu().numpy().flatten())\n",
    "\n",
    "# Function to calculate feature representation distance\n",
    "def calculate_feature_representation_distance(model, tokenizer, text, centroid, device):\n",
    "    input_ids = tokenizer(text, return_tensors=\"pt\", padding=True, truncation=True).input_ids.to(device)\n",
    "    with torch.no_grad():\n",
    "        #embeddings = model.transformer.wte(input_ids).mean(dim=1).cpu().numpy()\n",
    "        #embeddings = model.model.embed_tokens(input_ids).mean(dim=1).cpu().numpy()\n",
    "        embedding_layer = model.get_input_embeddings()  # Get the embedding layer\n",
    "        embeddings = embedding_layer(input_ids).mean(dim=1).cpu().numpy()\n",
    "    return np.linalg.norm(embeddings - centroid)\n",
    "\n",
    "# Calculate centroid for training set embeddings\n",
    "def calculate_centroid(model, tokenizer, texts, device):\n",
    "    embeddings = []\n",
    "    for text in texts:\n",
    "        input_ids = tokenizer(text, return_tensors=\"pt\", padding=True, truncation=True).input_ids.to(device)\n",
    "        with torch.no_grad():\n",
    "            #embedding = model.transformer.wte(input_ids).mean(dim=1).cpu().numpy()\n",
    "            #embedding = model.model.embed_tokens(input_ids).mean(dim=1).cpu().numpy()\n",
    "            embedding_layer = model.get_input_embeddings()  # Get the embedding layer\n",
    "            embedding = embedding_layer(input_ids).mean(dim=1).cpu().numpy()\n",
    "        embeddings.append(embedding)\n",
    "    return np.mean(embeddings, axis=0)\n",
    "\n",
    "# Calculate centroid for training texts\n",
    "train_centroid = calculate_centroid(generator_model, tokenizer, train_texts, device)\n",
    "test_centroid = calculate_centroid(generator_model, tokenizer, test_texts, device)\n",
    "\n",
    "# Calculate features for training and test texts\n",
    "def calculate_features(model, tokenizer, texts, centroid, device):\n",
    "    perplexities, confidences, entropies, frd_distances = [], [], [], []\n",
    "    for text in texts:\n",
    "        perplexities.append(calculate_perplexity(model, tokenizer, text, device))\n",
    "        confidences.append(calculate_prediction_confidence(model, tokenizer, text, device))\n",
    "        entropies.append(calculate_entropy(model, tokenizer, text, device))\n",
    "        frd_distances.append(calculate_feature_representation_distance(model, tokenizer, text, centroid, device))\n",
    "    return perplexities, confidences, entropies, frd_distances\n",
    "\n",
    "train_features = calculate_features(generator_model, tokenizer, train_texts, train_centroid, device)\n",
    "test_features = calculate_features(generator_model, tokenizer, test_texts, test_centroid, device)\n",
    "\n",
    "# Combine features and labels\n",
    "train_labels = [1] * len(train_texts)  # Members\n",
    "test_labels = [0] * len(test_texts)    # Non-members\n",
    "\n",
    "combined_features = np.vstack((\n",
    "    np.column_stack(train_features),\n",
    "    np.column_stack(test_features)\n",
    "))\n",
    "combined_labels = np.array(train_labels + test_labels)\n",
    "\n",
    "# Normalize features\n",
    "scaler = MinMaxScaler()\n",
    "normalized_features = scaler.fit_transform(combined_features)\n",
    "\n",
    "# Split data for training the attack model\n",
    "X_train, X_test, y_train, y_test = train_test_split(normalized_features, combined_labels, test_size=0.2, random_state=42)\n",
    "\n",
    "# Train LightGBM attack model\n",
    "clf = LGBMClassifier(class_weight=\"balanced\", learning_rate=0.1, n_estimators=100)\n",
    "clf.fit(X_train, y_train)\n",
    "\n",
    "# Evaluate the attack model\n",
    "y_pred = clf.predict(X_test)\n",
    "y_pred_prob = clf.predict_proba(X_test)[:, 1]\n",
    "\n",
    "print(\"Classification Report:\")\n",
    "print(classification_report(y_test, y_pred))\n",
    "\n",
    "roc_auc = roc_auc_score(y_test, y_pred_prob)\n",
    "print(f\"ROC-AUC: {roc_auc:.2f}\")\n",
    "\n",
    "# Plot ROC Curve\n",
    "fpr, tpr, _ = roc_curve(y_test, y_pred_prob)\n",
    "plt.figure()\n",
    "plt.plot(fpr, tpr, color=\"darkorange\", lw=2, label=f\"ROC Curve (area = {roc_auc:.2f})\")\n",
    "plt.plot([0, 1], [0, 1], color=\"navy\", lw=2, linestyle=\"--\")\n",
    "plt.xlabel(\"False Positive Rate\")\n",
    "plt.ylabel(\"True Positive Rate\")\n",
    "plt.title(\"ROC Curve\")\n",
    "plt.legend(loc=\"lower right\")\n",
    "plt.show()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "edbbd424-de6e-48c9-a6a2-525002a7f57a",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Run 1...\n",
      "[LightGBM] [Info] Number of positive: 165, number of negative: 155\n",
      "[LightGBM] [Info] Auto-choosing col-wise multi-threading, the overhead of testing was 0.000572 seconds.\n",
      "You can set `force_col_wise=true` to remove the overhead.\n",
      "[LightGBM] [Info] Total Bins 428\n",
      "[LightGBM] [Info] Number of data points in the train set: 320, number of used features: 4\n",
      "[LightGBM] [Info] [binary:BoostFromScore]: pavg=0.500000 -> initscore=0.000000\n",
      "[LightGBM] [Info] Start training from score 0.000000\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "Precision: 0.4984, Recall: 0.4984, F1-Score: 0.4972, ROC-AUC: 0.5149\n",
      "Run 2...\n",
      "[LightGBM] [Info] Number of positive: 169, number of negative: 151\n",
      "[LightGBM] [Info] Auto-choosing col-wise multi-threading, the overhead of testing was 0.000078 seconds.\n",
      "You can set `force_col_wise=true` to remove the overhead.\n",
      "[LightGBM] [Info] Total Bins 428\n",
      "[LightGBM] [Info] Number of data points in the train set: 320, number of used features: 4\n",
      "[LightGBM] [Info] [binary:BoostFromScore]: pavg=0.500000 -> initscore=0.000000\n",
      "[LightGBM] [Info] Start training from score 0.000000\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "Precision: 0.4430, Recall: 0.4401, F1-Score: 0.4332, ROC-AUC: 0.4187\n",
      "Run 3...\n",
      "[LightGBM] [Info] Number of positive: 162, number of negative: 158\n",
      "[LightGBM] [Info] Auto-choosing col-wise multi-threading, the overhead of testing was 0.000075 seconds.\n",
      "You can set `force_col_wise=true` to remove the overhead.\n",
      "[LightGBM] [Info] Total Bins 428\n",
      "[LightGBM] [Info] Number of data points in the train set: 320, number of used features: 4\n",
      "[LightGBM] [Info] [binary:BoostFromScore]: pavg=0.500000 -> initscore=-0.000000\n",
      "[LightGBM] [Info] Start training from score -0.000000\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "Precision: 0.4688, Recall: 0.4699, F1-Score: 0.4667, ROC-AUC: 0.4580\n",
      "Run 4...\n",
      "[LightGBM] [Info] Number of positive: 160, number of negative: 160\n",
      "[LightGBM] [Info] Auto-choosing col-wise multi-threading, the overhead of testing was 0.000076 seconds.\n",
      "You can set `force_col_wise=true` to remove the overhead.\n",
      "[LightGBM] [Info] Total Bins 427\n",
      "[LightGBM] [Info] Number of data points in the train set: 320, number of used features: 4\n",
      "[LightGBM] [Info] [binary:BoostFromScore]: pavg=0.500000 -> initscore=0.000000\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "Precision: 0.5406, Recall: 0.5375, F1-Score: 0.5286, ROC-AUC: 0.5131\n",
      "Run 5...\n",
      "[LightGBM] [Info] Number of positive: 162, number of negative: 158\n",
      "[LightGBM] [Info] Auto-choosing col-wise multi-threading, the overhead of testing was 0.000077 seconds.\n",
      "You can set `force_col_wise=true` to remove the overhead.\n",
      "[LightGBM] [Info] Total Bins 428\n",
      "[LightGBM] [Info] Number of data points in the train set: 320, number of used features: 4\n",
      "[LightGBM] [Info] [binary:BoostFromScore]: pavg=0.500000 -> initscore=-0.000000\n",
      "[LightGBM] [Info] Start training from score -0.000000\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "Precision: 0.5131, Recall: 0.5132, F1-Score: 0.5124, ROC-AUC: 0.4950\n",
      "Run 6...\n",
      "[LightGBM] [Info] Number of positive: 162, number of negative: 158\n",
      "[LightGBM] [Info] Auto-choosing col-wise multi-threading, the overhead of testing was 0.000076 seconds.\n",
      "You can set `force_col_wise=true` to remove the overhead.\n",
      "[LightGBM] [Info] Total Bins 428\n",
      "[LightGBM] [Info] Number of data points in the train set: 320, number of used features: 4\n",
      "[LightGBM] [Info] [binary:BoostFromScore]: pavg=0.500000 -> initscore=-0.000000\n",
      "[LightGBM] [Info] Start training from score -0.000000\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "Precision: 0.4792, Recall: 0.4799, F1-Score: 0.4720, ROC-AUC: 0.4956\n",
      "Run 7...\n",
      "[LightGBM] [Info] Number of positive: 165, number of negative: 155\n",
      "[LightGBM] [Info] Auto-choosing col-wise multi-threading, the overhead of testing was 0.000077 seconds.\n",
      "You can set `force_col_wise=true` to remove the overhead.\n",
      "[LightGBM] [Info] Total Bins 428\n",
      "[LightGBM] [Info] Number of data points in the train set: 320, number of used features: 4\n",
      "[LightGBM] [Info] [binary:BoostFromScore]: pavg=0.500000 -> initscore=0.000000\n",
      "[LightGBM] [Info] Start training from score 0.000000\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "Precision: 0.5962, Recall: 0.5857, F1-Score: 0.5569, ROC-AUC: 0.5365\n",
      "Run 8...\n",
      "[LightGBM] [Info] Number of positive: 150, number of negative: 170\n",
      "[LightGBM] [Info] Auto-choosing col-wise multi-threading, the overhead of testing was 0.000080 seconds.\n",
      "You can set `force_col_wise=true` to remove the overhead.\n",
      "[LightGBM] [Info] Total Bins 428\n",
      "[LightGBM] [Info] Number of data points in the train set: 320, number of used features: 4\n",
      "[LightGBM] [Info] [binary:BoostFromScore]: pavg=0.500000 -> initscore=0.000000\n",
      "[LightGBM] [Info] Start training from score 0.000000\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "Precision: 0.4933, Recall: 0.4933, F1-Score: 0.4933, ROC-AUC: 0.5767\n",
      "Run 9...\n",
      "[LightGBM] [Info] Number of positive: 160, number of negative: 160\n",
      "[LightGBM] [Info] Auto-choosing col-wise multi-threading, the overhead of testing was 0.000074 seconds.\n",
      "You can set `force_col_wise=true` to remove the overhead.\n",
      "[LightGBM] [Info] Total Bins 428\n",
      "[LightGBM] [Info] Number of data points in the train set: 320, number of used features: 4\n",
      "[LightGBM] [Info] [binary:BoostFromScore]: pavg=0.500000 -> initscore=0.000000\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "Precision: 0.5767, Recall: 0.5750, F1-Score: 0.5726, ROC-AUC: 0.4975\n",
      "Run 10...\n",
      "[LightGBM] [Info] Number of positive: 160, number of negative: 160\n",
      "[LightGBM] [Info] Auto-choosing col-wise multi-threading, the overhead of testing was 0.000085 seconds.\n",
      "You can set `force_col_wise=true` to remove the overhead.\n",
      "[LightGBM] [Info] Total Bins 428\n",
      "[LightGBM] [Info] Number of data points in the train set: 320, number of used features: 4\n",
      "[LightGBM] [Info] [binary:BoostFromScore]: pavg=0.500000 -> initscore=0.000000\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "[LightGBM] [Warning] No further splits with positive gain, best gain: -inf\n",
      "Precision: 0.5635, Recall: 0.5625, F1-Score: 0.5608, ROC-AUC: 0.5769\n",
      "Results saved to lora_dp_high_med_txt_llm32_attack_model_results_new.csv\n"
     ]
    }
   ],
   "source": [
    "import numpy as np\n",
    "import pandas as pd\n",
    "import torch\n",
    "from transformers import AutoTokenizer, AutoModelForCausalLM\n",
    "from sklearn.model_selection import train_test_split\n",
    "from sklearn.metrics import classification_report, roc_auc_score, roc_curve\n",
    "from lightgbm import LGBMClassifier\n",
    "from scipy.stats import entropy\n",
    "from sklearn.preprocessing import MinMaxScaler\n",
    "import matplotlib.pyplot as plt\n",
    "import csv\n",
    "\n",
    "# Set up device\n",
    "device = torch.device(\"cuda:0\" if torch.cuda.is_available() else \"cpu\")\n",
    "\n",
    "# Ensure tokenizer has a pad token\n",
    "if tokenizer.pad_token is None:\n",
    "    tokenizer.pad_token = tokenizer.eos_token\n",
    "\n",
    "# Load datasets\n",
    "train_df = pd.read_csv(\"medical_tc_train.csv\")  # Adjust file name if necessary\n",
    "test_df = pd.read_csv(\"medical_tc_test.csv\")    # Adjust file name if necessary\n",
    "\n",
    "train_texts = train_df[\"medical_abstract\"][:200].tolist()\n",
    "test_texts = test_df[\"medical_abstract\"][:200].tolist()\n",
    "\n",
    "def generate_long_text(model, tokenizer, prompt, max_length=300):    \n",
    "    input_ids = tokenizer(prompt, return_tensors=\"pt\").input_ids.to(device)\n",
    "    output_ids = model.generate(input_ids, max_length=max_length, pad_token_id=tokenizer.eos_token_id)\n",
    "    generated_text = tokenizer.decode(output_ids[0], skip_special_tokens=True)\n",
    "    return generated_text\n",
    "\n",
    "# Function to calculate perplexity\n",
    "def calculate_perplexity(model, tokenizer, text, device):\n",
    "    input_ids = tokenizer(text, return_tensors=\"pt\", padding=True, truncation=True).input_ids.to(device)\n",
    "    with torch.no_grad():\n",
    "        outputs = model(input_ids, labels=input_ids)\n",
    "        loss = outputs.loss\n",
    "    return torch.exp(loss).item()\n",
    "\n",
    "# Function to calculate prediction confidence\n",
    "def calculate_prediction_confidence(model, tokenizer, text, device):\n",
    "    input_ids = tokenizer(text, return_tensors=\"pt\", padding=True, truncation=True).input_ids.to(device)\n",
    "    with torch.no_grad():\n",
    "        outputs = model(input_ids)\n",
    "        probabilities = torch.softmax(outputs.logits, dim=-1)\n",
    "        return probabilities.max().item()\n",
    "\n",
    "# Function to calculate entropy\n",
    "def calculate_entropy(model, tokenizer, text, device):\n",
    "    input_ids = tokenizer(text, return_tensors=\"pt\", padding=True, truncation=True).input_ids.to(device)\n",
    "    with torch.no_grad():\n",
    "        outputs = model(input_ids)\n",
    "        probabilities = torch.softmax(outputs.logits, dim=-1)\n",
    "        return entropy(probabilities.cpu().numpy().flatten())\n",
    "\n",
    "# Function to calculate feature representation distance\n",
    "def calculate_feature_representation_distance(model, tokenizer, text, centroid, device):\n",
    "    input_ids = tokenizer(text, return_tensors=\"pt\", padding=True, truncation=True).input_ids.to(device)\n",
    "    with torch.no_grad():\n",
    "        embeddings = model.model.embed_tokens(input_ids).mean(dim=1).cpu().numpy()\n",
    "    return np.linalg.norm(embeddings - centroid)\n",
    "\n",
    "# Calculate centroid for training set embeddings\n",
    "def calculate_centroid(model, tokenizer, texts, device):\n",
    "    embeddings = []\n",
    "    for text in texts:\n",
    "        input_ids = tokenizer(text, return_tensors=\"pt\", padding=True, truncation=True).input_ids.to(device)\n",
    "        with torch.no_grad():\n",
    "            embedding = model.model.embed_tokens(input_ids).mean(dim=1).cpu().numpy()\n",
    "        embeddings.append(embedding)\n",
    "    return np.mean(embeddings, axis=0)\n",
    "\n",
    "# Calculate centroid for training texts\n",
    "train_centroid = calculate_centroid(generator_model, tokenizer, train_texts, device)\n",
    "test_centroid = calculate_centroid(generator_model, tokenizer, test_texts, device)\n",
    "\n",
    "# Calculate features for training and test texts\n",
    "def calculate_features(model, tokenizer, texts, centroid, device):\n",
    "    perplexities, confidences, entropies, frd_distances = [], [], [], []\n",
    "    for text in texts:\n",
    "        prompt = ' '.join(str(text).split()[:50])\n",
    "        #print(prompt)\n",
    "        text = generate_long_text(model, tokenizer, prompt, max_length=300)\n",
    "        perplexities.append(calculate_perplexity(model, tokenizer, text, device))\n",
    "        confidences.append(calculate_prediction_confidence(model, tokenizer, text, device))\n",
    "        entropies.append(calculate_entropy(model, tokenizer, text, device))\n",
    "        frd_distances.append(calculate_feature_representation_distance(model, tokenizer, text, centroid, device))\n",
    "    return perplexities, confidences, entropies, frd_distances\n",
    "\n",
    "# Open CSV file to store results\n",
    "csv_filename = \"lora_dp_high_med_txt_llm32_attack_model_results_new.csv\"\n",
    "with open(csv_filename, mode=\"w\", newline=\"\") as file:\n",
    "    writer = csv.writer(file)\n",
    "    writer.writerow([\"Run\", \"Precision\", \"Recall\", \"F1-Score\", \"ROC-AUC\"])\n",
    "\n",
    "    for run in range(1, 11):  # Run 10 times\n",
    "        print(f\"Run {run}...\")\n",
    "        train_features = calculate_features(generator_model, tokenizer, train_texts, train_centroid, device)\n",
    "        test_features = calculate_features(generator_model, tokenizer, test_texts, test_centroid, device)\n",
    "    \n",
    "        # Combine features and labels\n",
    "        train_labels = [1] * len(train_texts)  # Members\n",
    "        test_labels = [0] * len(test_texts)    # Non-members\n",
    "    \n",
    "        combined_features = np.vstack((\n",
    "            np.column_stack(train_features),\n",
    "            np.column_stack(test_features)\n",
    "        ))\n",
    "        combined_labels = np.array(train_labels + test_labels)\n",
    "        # Normalize features\n",
    "        scaler = MinMaxScaler()\n",
    "        normalized_features = scaler.fit_transform(combined_features)      \n",
    "        \n",
    "        # Split data for training the attack model\n",
    "        X_train, X_test, y_train, y_test = train_test_split(normalized_features, combined_labels, test_size=0.2, random_state=42 + run)\n",
    "\n",
    "        # Train LightGBM attack model\n",
    "        clf = LGBMClassifier(class_weight=\"balanced\", learning_rate=0.1, n_estimators=100)\n",
    "        clf.fit(X_train, y_train)\n",
    "\n",
    "        # Evaluate the attack model\n",
    "        y_pred = clf.predict(X_test)\n",
    "        y_pred_prob = clf.predict_proba(X_test)[:, 1]\n",
    "\n",
    "        report = classification_report(y_test, y_pred, output_dict=True)\n",
    "        precision = report[\"macro avg\"][\"precision\"]\n",
    "        recall = report[\"macro avg\"][\"recall\"]\n",
    "        f1_score = report[\"macro avg\"][\"f1-score\"]\n",
    "        roc_auc = roc_auc_score(y_test, y_pred_prob)\n",
    "\n",
    "        print(f\"Precision: {precision:.4f}, Recall: {recall:.4f}, F1-Score: {f1_score:.4f}, ROC-AUC: {roc_auc:.4f}\")\n",
    "\n",
    "        # Save to CSV\n",
    "        writer.writerow([run, precision, recall, f1_score, roc_auc])\n",
    "\n",
    "print(f\"Results saved to {csv_filename}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "a3cecedd-f1eb-4b25-92e9-f6b9df48b611",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "LlamaModel is using LlamaSdpaAttention, but `torch.nn.functional.scaled_dot_product_attention` does not support `output_attentions=True`. Falling back to the manual attention implementation, but specifying the manual implementation will be required from Transformers version v5.0.0 onwards. This warning can be removed using the argument `attn_implementation=\"eager\"` when loading the model.\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1500x1000 with 2 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import torch\n",
    "import matplotlib.pyplot as plt\n",
    "import seaborn as sns\n",
    "import numpy as np\n",
    "import pandas as pd\n",
    "def visualize_attention(model, tokenizer, text, layer_idx=-1, head_idx=0, top_n_tokens=150, filename=\"attention_heatmap.jpg\"):\n",
    "    device = torch.device(\"cuda:0\" if torch.cuda.is_available() else \"cpu\")\n",
    "    model.to(device)\n",
    "    model.eval()\n",
    "\n",
    "    inputs = tokenizer(text, return_tensors=\"pt\", truncation=True, max_length=512).to(device)\n",
    "\n",
    "    with torch.no_grad():\n",
    "        outputs = model(**inputs, output_attentions=True)\n",
    "\n",
    "    attentions = outputs.attentions\n",
    "    attention_matrix = attentions[layer_idx][0, head_idx].cpu().numpy()\n",
    "\n",
    "    tokens = tokenizer.convert_ids_to_tokens(inputs[\"input_ids\"][0])\n",
    "\n",
    "    avg_attention = attention_matrix.mean(axis=0)\n",
    "    top_indices = np.argsort(avg_attention)[-top_n_tokens:]\n",
    "    top_tokens = [tokens[i] for i in top_indices]\n",
    "    top_attention_matrix = attention_matrix[np.ix_(top_indices, top_indices)]\n",
    "    df = pd.DataFrame(top_attention_matrix, index=top_tokens, columns=top_tokens)\n",
    "    df.to_csv(\"lora_dp_med_txt_llm32_top_attention_matrix.csv\")\n",
    "    plt.figure(figsize=(15, 10))\n",
    "    # Create the heatmap and store the result (QuadMesh object)\n",
    "    heatmap = sns.heatmap(\n",
    "        top_attention_matrix,\n",
    "        cmap=\"Blues\",\n",
    "        linewidths=0.5,\n",
    "        linecolor=\"gray\",\n",
    "        square=True,\n",
    "        cbar=False,\n",
    "        vmin=0, vmax=1,\n",
    "        xticklabels=top_tokens, yticklabels=top_tokens\n",
    "    )\n",
    "    plt.xticks(rotation=90, fontsize=16, fontweight='bold')\n",
    "    plt.yticks(fontsize=16, fontweight='bold')\n",
    "    plt.xlabel(\"Key Positions\", fontsize=16, fontweight='bold')\n",
    "    plt.ylabel(\"Query Positions\", fontsize=16, fontweight='bold')\n",
    "    plt.title(f\"Top {top_n_tokens} Tokens Attention Weights - Layer {layer_idx+1}, Head {head_idx+1}\")\n",
    "    plt.colorbar(heatmap.collections[0], label=\"Attention Weight\") # Pass the QuadMesh object to colorbar\n",
    "\n",
    "    plt.savefig(filename)\n",
    "    plt.show()\n",
    "text = \"Obstructive sleep apnea following topical oropharyngeal anesthesia in loud snorers. Previous studies support the presence of an upper airway reflex mechanism that contributes to the maintenance of upper airway patency during sleep. We investigated the possibility that interference with this reflex mechanism contributes to the development of obstructive sleep apnea. Eight otherwise asymptomatic snorers (seven male and one female), age 39 +/- 5.3 yr (mean +/- SEM), underwent overnight sleep studies on three successive nights.\"\n",
    "# Example usage\n",
    "visualize_attention(generator_model, tokenizer, text, layer_idx=-1, head_idx=0, top_n_tokens=100, filename=\"fi_lora_dp_high_med_txt_gen_attn_map.jpg\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "576a42a4-3b9c-47c3-a745-05cdb7ac099a",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.7"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
